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Abstract 
The kinetic and mechanistic study of the ligand substitution reactions of a series of trans-
platinum(II) complexes was performed. To this end, three sets of mononuclear trans-
platinum(II) complexes and one set of flexible alkyl-α,ω-diamine linkers dinuclear trans-
platinum(II) complexes were synthesised and characterised by different spectroscopic methods 
and elemental analysis. Substitution of either the coordinated chloride or aqua moeities were 
investigated under pseudo first-order conditions as a function of concentration and temperature. 
Experimental data were corroborated with DFT calculations.   
In the first instance, a comparative study of the kinetic and mechanistic behaviour of ligand 
substitution reactions of some bifunctional analogous cis- and trans-platinum(II) complexes 
with dialkylamine ligands was performed. The reaction of the cis-complexes proceeded in two 
concerted steps whereas those of the trans-complexes followed a single step. The trans-
complexes were found to be approximately 103 more reactive than their corresponding cis-
analogues. The decrease in the rate of ligand substitution in the cis-platinum(II) complexes was 
attributed largely to the steric hindrance due to their structural arrangement. The cis- and the 
trans-complexes were found to form different kinetic products. The cis-complexes were 
observed to undergo complete substitution (dechelation) due to the presence of the strong 
labilising effects of the thiourea-based nucleophiles, unlike the trans-complexes which were 
partially substituted by these nucleophiles. 195Pt NMR spectroscopy was employed to confirm 
the final kinetic products and to demonstrate the stepwise substitution of the respective series 
of complexes with thiourea. 
Ligand substitution reactions of the second set of trans-platinum(II) complexes with mixed 
amine ligands were found to proceed by first-order kinetics in a single step. The reactivity of 
the complexes was largely dependent on the length of the alkyl chain of the alkylamine moiety 
of the complexes. Density functional theory (DFT) calculations showed that an increase in chain 
length by a methylene unit has no direct electronic significance on the metal centre. The 
increase in chain length, however, posed significant steric hindrance on the substitution sites 
due to the flexibility of the alkyl chains and thus governed the overall reaction pattern. The 195Pt 
NMR spectroscopic results established that the mixed amine ligands remain coordinated to the 
metal centre in the final kinetic product. In the third scheme, aqua ligand substitution reactions 
were performed to investigate the comparative substitution behaviour of some mononuclear 
trans-platinum(II) complexes with symmetric and asymmetric amine ligands respectively. The 
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substitution reactions of each of the trans-platinum(II) complexes proceed by first-order 
kinetics in a single step. The reactivity of the complexes was mainly governed by both steric 
and electronic factors. Unlike the trans-platinum(II) complexes with asymmetric amine ligands, 
the ligand system around the complexes with symmetrical amine groups has significant 
electronic effect on the electrophilicity of the metal centre depending on the number of carbon 
atoms around the dialkylamine moieties. The nature of the alkylamine ligand, whether long or 
a branched chain, also play a role on the rate of substitution. The flexible long chain of the 
alkylamine ligand in the asymmetric complexes posed more steric hindrance on the reactive 
centre than the branched chain of the dialkylamine ligand in the symmetric complexes.   
Lastly, we investigated the role of flexible alkyl-α,ω-diamine linkers on the substitution 
behaviour of dinuclear trans-platinum(II) complexes. The ligand substitution reaction of the 
complexes proceeded in three consecutive steps. Each step follows first-order kinetics with the 
respective complex and nucleophile. Both electronic and steric effects drive the overall 
substitution pattern. However, our findings revealed that upon the substitution of the chloro 
moieties by the thiourea-based nucleophiles at the platinum centres, the σ-donor capacity via 
inductive effect of these electron-rich nucleophiles override the steric strain imposed by the 
nucleophiles as well as by the alkanediamine linker on the substitution sites.  Consequently, 
electronic factors governed the overall reaction pattern of these complexes. 195Pt NMR results 
confirmed the simultaneous substitution of all the chloride leaving groups by thiourea-based 
nucleophiles, followed by the subsequent but successive displacement of the ammine groups 
and the flexible alkanediamine linker from the metal centres. In general, the small positive 
enthalpy and the large but negative entropy confirm an associative mode of activation for all 
the studied complexes. 
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Chapter One 
From Obscurity to Prominence: The Prospect of Trans-Platinum Compounds in Anticancer 
Chemotherapy 
 
1.1 Introduction 
Cancer is an enormous global health burden, touching every region and socioeconomic level. 
Today, cancer accounts for about 15% of deaths worldwide – more than HIV/AIDS, 
tuberculosis and malaria combined [1]. Cancer is caused by mutational changes in genes that 
are responsible for cell growth and repair. These changes are mostly because of internal factors 
such as hormones, inherited genetic mutations and immune conditions; and external factors 
such as tobacco, harmful radiation and infectious organisms. Several approaches are employed 
to treat cancer, such as surgery, chemotherapy, radiation therapy, immunotherapy or a 
combined  therapy approach [2]. The choice of treatment depends on the nature of the tumour, 
the stage of the disease and the general state of the patient. However, intrinsic resistance of 
certain cancer cell-lines have limited the effectiveness of the available anticancer treatment 
options [3].  As a result, the number one priority of medicinal inorganic chemists is to develop 
new anticancer agents with improved cytotoxicity [4]. Subsequently, metal-based anticancer 
agents have continued to show some promise.  
Despite the vital role some essential metals play in many biological processes, the intrinsic toxic 
nature of most metals make them to be widely reckoned as uncongenial, beyond a certain 
threshold, in the human body [5]. Their importance in anticancer chemotherapy is hinged on 
the fact that the electrophilic metal sites interact with the nucleophilic groups such as, proteins, 
DNA etc., in the cancer cells. In spite of their relevance, the statistics of clinically approved 
metal-based anticancer agents are veritably low compared to the amount of metal compounds 
which are reported annually. Moreover, the majority of these drugs are platinum compounds. 
Cisplatin, since its serendipitous discovery by Barnet Rosenberg in 1969, is still increasingly 
used worldwide in the treatment of different types of cancers such as testicular, ovarian, head, 
neck, cervical and other cancers [6, 7]. It is generally accepted that the distortion of DNA 
generated upon binding of cisplatin is largely responsible for its antitumor properties [8]. 
Following the example of cisplatin, thousands of platinum-containing compounds have been 
synthesised and evaluated as potential antitumour drugs but only a few compounds reached 
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worldwide clinical applications viz. Carboplatin and Oxaliplatin; while Nedaplatin, Heptaplatin 
and Lobaplatin have been regionally approved in Japan, South Korea and China respectively 
[9].  
Figure 1.1: Cisplatin and its derivatives clinically approved for use globally and regionally 
  respectively [10]. 
 
However, despite the success of cisplatin and carboplatin, side-effects and resistance are their 
main drawbacks [11, 12]. The search for novel platinum compounds that can suppress the side-
effects, overcome the intrinsic and acquired resistance and achieve a broader spectrum of 
cytostatic applications, has been a constant factor among medical inorganic researchers [1]. 
Trans-platinum compounds, which are initially thought to be redundant, have in the recent 
times started to gain some prominence in cancer treatment. This chapter examines the historical 
development of platinum-based anticancer agents and the promising prospect trans-platinum 
complexes have in both the proximate and the remote future. 
 
1.2 Historical Development of Platinum-Based Anticancer Agents: The 
Accidental Discovery of Cisplatin 
The fortuitous revelation of the cytotoxic properties of cisplatin did not only mark a watershed 
in anticancer studies but also was the genesis of the use of coordination compounds in 
anticancer chemotherapy. The synthesis of cis-diamminedichloroplatinum(II), also known as 
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cisplatin, was first reported by Michel Peyrone in 1844 [13]. As it was commonly done at that 
time, it was called Peyrone’s chloride, named after the man who synthesised it, even though, 
its structure was not yet known. It took nearly five decades for its chemical structure to be 
eventually figured out by Alfred Werner [14-17]. Werner was the first to distinguish, through 
structural elucidation, between cisplatin and its trans-isomer transplatin. However, nothing was 
known about the biological importance of cisplatin until Barnett Rosenberg and his colleagues 
in the late 1960s observed, during an electrolytic procedure, that the cell division of Escherichia 
coli was inhibited and filamentous growth took place when an electric current was applied to 
bacteria growth cultured in ammonium chloride solution using platinum electrode [6, 14, 15, 
18].  The inhibition was established to have been caused by the formation of cisplatin and some 
platinum(IV) complexes. Following this discovery, cisplatin, for the first time, was 
administered to a cancer patient in 1971 and by 1978, the drug was finally approved for clinical 
use in the United States of America [15, 19]. Despite the drug activity against several types of 
tumour cells, its severe side effects, intrinsic and acquired resistance, among others, are its 
major limitations. Consequently, extensive research efforts amongst medicinal inorganic 
chemists are targeted at designing and synthesising compounds, whether platinum-based or 
otherwise, that can afford superior cytostatic activity against cancer cells, minimise toxic side 
effects, and overcome cross resistance relative to cisplatin. However, before all these could be 
achieved, the mechanism of action of cisplatin must be well understood and established. 
 
1.3 Mode of Action of Cisplatin 
Research efforts aimed to understand the mode of action of cisplatin have not only helped to 
reveal the mechanism of most platinum-based compounds but also unveiled how they terminate 
tumour cells in the humans. It is predominantly accepted that the central binding target of 
cisplatin is the DNA of the tumour cells [10, 15, 20-23]. The drug could reach its target because 
the chloride ion concentration in the blood plasma, which has been estimated to be 
approximately ~100 mM, helps to suppress the hydrolysis of the complex; consequently the 
structure of the complex is largely unaltered [23, 24]. The chloride coordinated complex gains 
access into the cell either through passive diffusion or active uptake, a process involving copper 
transporter proteins, which is known as the constitutive triple response 1 (CTR1) sites, as an 
integral part [25-27]. Once the neutral cisplatin molecule enters into the cell, it undergoes 
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hydrolysis, because of the low concentration of chloride ions (~4 mM) inside the cell, resulting 
in the loss of one or both chloride ligands to produce a charged complex [28, 29] (Figure 1.2).  
 
 
Figure 1.2: Extracellular and intracellular events that influence cisplatin’s activity. Attention is 
drawn to instances where deactivation/sequestration can occur [30]. 
 
The rate at which cisplatin binds to DNA depends upon this aquation process [29], the charged 
complex produced from this process is more reactive towards biomolecules because aqua 
moieties are substituted faster than chlorides [31]. The cytostatic activity of cisplatin is 
interfered with through the recognition of platinated DNA adducts [32] by the proteins such as 
high-mobility group proteins (HMG)) which proscribed cisplatin from obstructing with DNA 
transcription. Moreover, there are many biomolecules and ions such as chloride ions, hydroxyl 
ions, aqua molecules and other sulfur containing species, such as proteins, peptides and 
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enzymes, inside the cell competing for direct interaction with cisplatin. Some of the drug may 
interact with sulfur donor molecules which are quite abundant in the blood because of the strong 
affinity for the platinum centre has for such molecules [22, 33],  to yield kinetically stable or 
inert platinum-sulfur bonded adducts. The agglomeration of bonded sulfur containing proteins 
and amino acids [34] to the platinum centre usually result in the potential deactivation of the 
drug and this has been established to be essentially responsible for some of the toxic side effects 
[22, 31, 35]. This phenomenon limits the bio-distribution and pharmacokinetics of the drug, 
consequently lowering the formation of the expected platinum-DNA adducts and the 
accumulation of the drug in the cell [15, 36]. Likewise, the strong trans influence of certain 
thio-based compounds, such as thioethers [34] or methionine derivatives [37], to the 
platinum(II) centre elicit the displacement of the amine ligand trans to the chloride or aqua 
nucleofuge by the entering groups before the DNA could bind to the metal site [22, 37]. 
Subsequently, the anticipated mechanism of action of the metal complex is impeded and hence, 
its cytostatic effect. 
 
1.4 Binding of Cisplatin to DNA 
Since the preponderance of evidence has established the fact that DNA bases, such as adenine, 
cytosine, guanine and thymine, are the major targets of cisplatin in cells [38], it is pertinent to 
examine in detail the interaction of cisplatin with DNA. The platinum(II) ion preferentially 
coordinates with nitrogen atoms of the DNA [39]. This is expected since platinum is a soft 
centre [40]. The process of interaction of cisplatin with DNA has been adduced to proceed 
through six stages viz. aquation of the complex; pre-association with the DNA; monofunctional 
adduct formation; closure to a bifunctional adduct; distortion of the DNA and; recognition of 
this distortion [41]. Essentially, the binding of cisplatin to DNA of the cancer cell will normally 
cause programmed cell death (apoptosis) [42-47]. Although, the N1 of adenine and the N3 atom 
of cytosine are suitable positions for platinum binding, the preferred binding site in DNA is the 
N7 atom of guanine [48-55]. It is believed that at physiological pH, the N3 atom of thymine is 
protonated, hence, it is sterically hindered. Besides, the non-planar nitrogen lacks a lone pair 
electron requisite for sigma bond formation to the platinum centre. Nonetheless, the N3 atom 
of thymine becomes a potential binding site with the loss of the hydrogen atom. In Figure 1.3 
a scheme with all the potential binding positions is represented. The strong kinetic preference 
for the N7 atom of guanine, the most favoured position for platinum binding [48, 49, 51], has 
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been attributed to three factors which include: the strong basicity of that position; the hydrogen 
bond interactions between ammine protons of cisplatin with O6 in guanine and; the accessibility 
of the N7 atom of guanine for the platinum complexes [20].  
                       
Figure 1.3: Possible cisplatin binding sites on DNA. N3 are sterically hindered for possible 
binding [56]. 
 
The interaction of cisplatin with DNA leads to the formation of six different types of platinum-
DNA adducts. The most prominent among them in order of their decreasing priorities include 
the following: 1,2-intrastrand d(GpG) cross-links on adjacent guanines; 1,2-intrastrand d(ApG) 
cross-links between an adjacent adenine and guanine, 1,3-intrastrand d(GXG) cross-links 
between alternate guanines separated by one DNA base and 1,4-intrastrand d(GXXG) cross-
links between guanines separated by two DNA bases. In addition to this, a small fraction of 
cisplatin was posited to interact with DNA bases either via interstrand cross-links, involving 
two strands of the DNA double helix, or in monofunctional adducts bonded to a single purine 
and protein DNA cross-link [41, 57, 58]. In the latter, cisplatin is coordinated to a protein 
molecule and a DNA base (Figure 1.4). 
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Figure 1.4: Main adducts formed in the interaction of cisplatin with DNA. (a) 1,2-Intrastrand 
cross-link; (b) 1,3-Intrastrand cross-link; (c) Interstrand cross-link; (d) Protein-DNA 
cross-link [59]. 
 
In essence, these cross-links to the cancer cell and how they lead to cell death are still just 
vaguely understood. However, it is generally accepted that the binding of cisplatin to DNA 
transmutes the DNA conformation resulting in the distortion of its structure. This subsequently 
causes unwinding, bending and flattening of the minor grooves in the DNA helix [60, 61]. The 
alteration results in the suppression of DNA transcription, a step which is very crucial for 
protein synthesis and cell division. Cisplatin will normally attack the telomere, which is a 
regions of recurrent nucleotide sequences at each end of a chromosome inside the DNA, that 
protect the ends of chromosomes from degradation during cell division [62, 63]. The 
deterioration of the telomeric regions of the chromosomes by cisplatin suppresses cell division 
leading to fatal damages in the DNA and subsequently, prohibits replication of the DNA 
resulting in apoptosis. Nevertheless, this process is sometimes circumvented which will usually 
result in the inactivation and resistance to the drug [60]. 
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1.5 Mechanism of Inactivation and Resistance of Cisplatin 
One of the major drawbacks of cisplatin in anticancer chemotherapy is the inherent and acquired 
resistance of the drug [30, 64, 65]. This has limited its success despite its general application to 
different cancer types. Several factors have been posited for cisplatin inactivation and 
resistance. Effectively, a combination of these factors may, to a large extent, be probably 
responsible for the resistance; some of which are briefly highlighted. Firstly, the transformation 
in the properties of the membrane [56], upon which the drug transported and/or effluxed could 
result in low intracellular accumulation of the drug and hence, its resistance. Previous studies 
have suggested that a P-glycoprotein, found in multidrug-resistant cell lines, acts as a pump, 
which limits the accumulation of the drug in the cell [66-69].  Secondly, the presence of thiol-
donor groups in the cell, such as the intracellular peptide glutathione and metallothionine, is 
another cause of cisplatin resistance [70-72]. Since platinum, being a soft centre, has a strong 
affinity for sulfur, the amount of platinum binding to the DNA target will subsequently 
decrease. An increase in the level of glutathione have been observed in some cisplatin-resistant 
cancer cells [73, 74]. Similarly, metallothionien, which is a protein from amino acids [75-78], 
containing twenty cysteines residues involved in metabolizing heavy metals, such as zinc, 
cadmium, and copper, is also believed to be involved in the mechanism of resistance. Elevated 
levels of metallothionien have been reported in some cisplatin-resistant cells [75-78]. Thirdly, 
increased tolerance to platinum-DNA adducts has also been proposed to be culpable for the 
resistance of the drug [79-82] and finally, an increase in DNA repair resulting from nucleotide 
excision repair (NER) may also be instrumental to cisplatin resistance [83-86]. Enhanced DNA 
repair was observed in some cisplatin-resistant cell lines. However, there have been continued 
research efforts with hope to overcome the inactivation and resistance of the drug. 
 
1.6 Other Platinum-Based Complexes of Cis-Configuration 
Following the major limitations to therapeutic efficacy of cisplatin as a result of its severe side 
effects and resistance in certain tumour cells, hundreds of thousands of platinum complexes 
have been synthesised with the aim of improving the clinical limitations of cisplatin [87]. At 
present, most newly developed platinum compounds could not make it to clinical approval, 
even though, many of them are screened for biological activity. In fact, as of 2016, only about 
twenty-two platinum-based cytostatic agents have reached clinical trials [9].  Moreover, the 
preponderance of the synthesised platinum-based compounds is of cis-geometry such as, cis-
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diamine(1,1cyclobutanedicarboxylato)platinum(II) (carboplatin) [32], trans-L-1,2-
diaminocyclohexaneoxalato platinum(II) (oxaliplatin), cis diammineglycolatoplatinum(II), 
(nedaplatin), [cis-diammineglycolatoplatinum(II)] (heptaplatin) and lobaplatin [10, 30, 70]. 
Carboplatin and Oxaliplatin are often referred to as the second and third generations of cisplatin 
derivatives [30, 48]. The former has been reported to be less toxic [48, 88-90] and hence, the 
drug is usually dispensed at higher doses (2000 mg/dose) [56] than standard course of therapy 
(900 mg/ml) [91]. This is due to its very slow aquation process, relative to other drugs currently 
in use [92, 93]. The cyclobutanedicarboxylato ligand is far less labile compared to the chloride 
ligands in cisplatin [94-96]. Carboplatin is reportedly being used as a first-line drug for the 
treatment of ovarian cancer. One advantage of this drug is its remarkably less toxicity towards 
the kidneys and the nervous system [97-100]. The drug is, however, less potent and not as 
versatile in the treatment diverse kinds of cancer as compared to cisplatin [101, 102]. 
Consequently, 1,2-diaminocyclohexaneplatinum(II) (oxaliplatin) which has a bidentate leaving 
group, enhanced water solubility and slower hydrolysis process aiding its cellular uptake level 
[103-105], was developed. The drug was effective for the treatment of colorectal cancer, a type 
of cancer which is resistant to cisplatin and carboplatin [106]. Essentially, despite a large of 
number platinum drugs that are being screened yearly for cytotoxic properties, only cisplatin, 
carboplatin and oxaliplatin have gained worldwide approval. Others such as nedaplatin, the 
carboplatin analogue, has been approved in Japan for the treatment of head, neck, lung and 
oesophageal cancer while lobaplatin has been clinically registered in China [9, 30].  
However, because most of these cytotoxic complexes are mainly of cis-stereochemistry akin to 
cisplatin, they are generally still encumbered with many of the flaws that are associated with 
cisplatin. In fact, some cis-configured platinum(II) compounds were recently discontinued from 
clinical trials because of these limitations that have been highlighted before [9]. Hence, the need 
to design and develop alternative platinum-based anticancer agents that will exhibit superior 
cytotoxicity and less toxicity. The structure and pharmacodynamics of these compounds may, 
however, be much more complex and radically different from those already established for 
cisplatin and its cis-configured derivatives. To achieve the foregoing, there is obviously the 
demand for a paradigm shift in our thinking. 
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1.7 Structure-Activity Relationship (SAR): The Paradigm Shift 
The thinking among medicinal inorganic researchers that informed the earlier structure-activity 
relationship with respect to designing and synthesising alternative platinum-based compounds 
to cisplatin was based on the following:  
Firstly, a cis configuration, with the general formula cis-[PtX2(amine)2] where the X stands for 
the nucleofuge which are normally in a cis-position to each other, is a prerequisite for cytotoxic 
properties of all platinum(II) compounds. All monofunctional binding cationic complexes were 
considered inactive. It is generally believed that the nature of the non-leaving groups influences 
the reactivity of platinum compounds. Since complexes with general formula cis-
[PtCl2(amine)2] of different ligand systems, such as monodentate ligand (ammine, NH3), 
bidentate ligands (diethylenediamine, en) or diaminocyclohexane (dach), as non-leaving 
species, have shown antitumour activity. The activity of these platinum complexes has been 
found to decrease in the following order NH3>RNH2>R2NH>R3N, where R is an alkyl 
substituent [107]. In other words, as the steric demands via the alkyl group substitution of the 
hydrogen atoms on the ammine ligand increases, the cytotoxic properties of the resulting 
platinum complexes decrease. 
Secondly, the nucleofuge, X ligands, such as Cl-, SO4
2- or carboxylate ligands, must be of 
intermediate strength. This is largely because the ligand exchange kinetics of platinum 
compounds are mainly determined by the nature of the leaving groups. This follows the 
rationale that complexes with strong coordinating leaving groups do not have antitumor 
activity. This is due to the fact that the trans effect of the strongly coordinating group will cause 
prompt substitution of the spectator amine ligand. Similarly, it is believed that weakly 
coordinating leaving groups, such as water, do not lead to high cytostatic activity [30, 56].  This 
is because platinum complexes with weakly coordinating ligands react rapidly which makes 
them to be susceptible to forming by-products with other intracellular components.    
Thirdly, the spectator amine ligands are designed to consist of at least one NHR moiety, which 
is necessary for hydrogen-bonding interactions with DNA via the O6 of guanine and to the 5’ 
phosphate group. It is predominantly accepted that the hydrogen-bonding ability of the ligands, 
which will normally elicit steric hindrance around the metal centre, is a crucial factor in 
determining the reactivity of these complexes [20]. The amines can act as hydrogen donors to 
the O6 atom of a guanine and to a 5’ phosphate group in DNA, thus stabilizing platinum-
guanine binding [70]. These interactions are critical for the thermodynamic stability of the 
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resultant platinum-d(pGpG) adduct formed and for the kinetics of the reaction by driving the 
platinum complex to the target, the N7 of guanine.  
Consequently, these factors, especially the first one, became the all-important requirements for 
the structure of platinum complexes expected to exhibit cytostatic activity according to the 
initial structure-activity relationships (SARs). However, Farrell and his co-workers were the 
first to extend the frontier of development of novel anticancer agents which incorporated non-
classical platinum complexes such as trans-platinum and polynuclear platinum complexes 
which have shown remarkable cytostatic potentials even against cisplatin resistant cell 
lines[108, 109]. He suggested that the cytotoxic potential of trans-platinum complexes could 
be greatly enhanced by bulky spectator monodentate amine ligands. Recent reports indicating 
some trans-platinum(II) compounds with superior cytostatic activity relative to most cis-
configured complexes [18] have made synthetic inorganic chemists, nowadays, to jettison the 
earlier held notion that only cis-configured complexes, in which the leaving groups are at cis-
position to each other, can show anticancer activity. 
 
1.8 Unconventional Platinum-Based Anticancer Agents  
The classical structure-activity relationship which has led to the production of the analogues of 
cisplatin, some of which are either now in clinical trials or currently being administered in 
anticancer chemotherapy, is presently being reckoned obsolete. This idea is fundamentally 
flawed because the greater number of the drugs produced from this notion have not transcend 
most of the defects of cisplatin, let alone achieve superior cytotoxicity and wide applicability 
against different cancer types. Hence, the expansive interest among medicinal inorganic 
chemists to explore, in tandem, other unconventional metal-based complexes and alternative 
platinum-based compounds of non-classical structures, in the anticancer research. Most 
importantly, this research effort is focused on those alternative platinum-based anticancer 
agents, particularly the development of trans-platinum(II) complexes in anticancer 
chemotherapy. These complexes can display a distinct mechanism of action in their interaction 
with DNA and possibly could be active against different spectrums of anticancer cells as 
compared to cisplatin and its derivatives. Besides the trans-platinum(II) complexes, other non-
classical platinum-based complexes, such as platinum(IV) complexes, monofunctional 
platinum(II) complexes and multinuclear platinum compounds shall be briefly discussed. 
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1.8.1 Platinum(IV) Complexes 
The cytotoxic potentials of platinum(IV) complexes are not really new as far as anticancer 
research is concerned. When Rosenberg and his co-workers serendipitously discovered the 
biological activity of cisplatin, some platinum(IV) complexes were actually present in the 
mixture of platinum complexes that inhibited the growth of E. coli during the electrolytic 
process using platinum electrodes. However, it is only until recently that interest in their 
deployment as anticancer drugs is becoming more attractive among medicinal inorganic 
researchers. Platinum(IV) complexes have low-spin d6 metal centres which usually assume 
octahedral geometry with six coordinating ligands, unlike platinum(II) complexes that normally 
adopt square-planar geometry because of their low-spin d8 metal centres. The ligand system 
around the platinum(IV) centre mostly consists of two spectator or non-leaving group ligands, 
two leaving groups and two axial ligands.  
The axial ligands are only peculiar to platinum(IV) complexes and normally possess some 
biological importance because some of these ligands can interact with DNA via an intercalative 
mode of binding. The addition of one or two biologically active ligands within the platinum(IV) 
scaffold can generate what is now referred to as “dual-threat” platinum(IV) compounds [30]. 
Examples of some dual-threat platinum(IV) complexes include: ethacraplatin, chalcoplatin, 
mitaplatin, endothall platinum(IV) complex, etc. The biologically active axial ligands in these 
complexes are particularly incorporated in their structures to have the non-DNA targets so as 
to limit cross-resistance with the DNA-targeting platinum(II) species released. In addition to 
this, the inclusion of the axial ligands with the platinum(IV) scaffold enhances the lipophilicity, 
redox stability, solubility and cancer-cell targeting of the drugs. Formation of by-products, other 
than the expected platinum-DNA adducts, are mostly minimised in the platinum(IV) complexes 
because of the kinetically inert nature of its coordination sphere which make them resistant to 
ligand substitution reactions by the biomolecules. It is widely accepted that the extra two axial 
ligands in platinum(IV) complexes enhance their ability to attach to nanoparticles or other 
carrier agents.  
Furthermore, the two non-leaving group and the two leaving group ligands at the platinum(IV) 
centre are mostly similar to those of platinum(II) complexes. The non-leaving groups are 
designed to enhance, inter alia, the resistance profile, the solubility and the lipophilicity of the 
compound. One key aspect of the function of the non-leaving group ligands is that they help to 
determine the nature of the platinum-DNA adduct form from the interaction of the drug with 
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the target biomolecule, the DNA. The leaving group ligands, on the other hand, assist to 
determine the following viz. the toxicity profile, lipophilicity and the solubility of the drug. 
More importantly, the leaving group ligands govern the reaction kinetics of the platinum(IV) 
complexes, just like in other platinum compounds. 
Initially, each of the two non-leaving group and the leaving group ligands in the platinum(IV) 
complexes are patterned like those of cisplatin i.e. they are of cis-geometry. Currently, some 
platinum(IV) compounds are designed to include other conformations, such as those in which 
the leaving and the non-leaving groups are of trans configurations, those in which the non-
leaving group ligand is bidentate and those with mono functional centre i.e. having only one 
leaving group. Moreover, the reactivity of the platinum(IV) complexes with DNA and other 
biomolecules depend on their reduction and substitution rates. The inert nature of the 
platinum(IV) centre makes the chances of direct platination of DNA and other biomolecules in 
that oxidation state nearly impossible because the adducts that are formed through ligand 
substitution will normally occur in weeks. This would have, consequently, made the drug of no 
clinical value given that the platinum drug has a very low retention time in the body.  
However, the simultaneous reduction of platinum(IV) to platinum(II) coupled with the 
substitution of the leaving group ligands, has been considered to be crucial for the cytotoxic 
activity of platinum(IV) compounds. It is widely accepted that the reduction of platinum(IV) to 
platinum(II) through the removal of the two axial ligands, facilitates the binding of the resultant 
divalent complex to bind to DNA which impede transcription and replication and subsequently 
initiate apoptotic processes in the cancer cell. The nature of the axial ligands was initially 
thought to influence the reduction process. Nonetheless, more recent studies have disabused 
researchers of that notion. By and large, platinum(IV) complexes are essentially seen as pro-
drug because they are useful as anticancer agents after the reduction of the platinum centre from 
the oxidation state of IV to give a more active divalent form of the drugs. 
Some remarkable platinum(IV) complexes, such as ormaplatin, iproplatin, LA-12 and 
satraplatin, have recently undergone clinical trials. Tetraplatin, tetrachloro(trans-1,2-
diaminocyclohexane)platinum(IV), commonly referred to as ormaplatin was among the first 
platinum(IV) drugs to enter into clinical screening. The reduction of tetraplatin to a more active 
divalent specie, dichloro(trans-1,2-diaminocyclohexane)platinum(II) which is related to 
Oxaliplatin but for the display of isomerism, is quite fast and instantaneous. The platinum(IV) 
drug has half-lives of 5-15 minutes and 3 seconds In vitro and In vivo respectively. It has been 
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found to be active against some cisplatin-resistant cell lines. However, the drug is still 
encumbered with some toxic behaviour, such as neurotoxicity, which is believed to have risen 
from its rapid reduction to the divalent form resulting from the loss of the two axial chloride 
ligands. 
     
Figure 1.5:  Chemical structures of platinum(IV) agents that have undergone clinical trials [30]. 
 
Iproplatin, cis,trans,cis-dichlorodihydroxobis(isopropylamine)platinum(IV), is a slight 
modified form of ormaplatin where the two axial chloride ligands have been changed to 
hydroxide ligands and the trans-1,2-diaminocyclohexane was modified to diisopropylamine. 
The two hydroxide axial ligands make the reduction in the platinum(IV) complex to be less 
rapid and subsequent deactivation by reducing biomolecules, compared to ormaplatin. The drug 
is well circulated throughout the body as a result of its slower deactivation. The hydroxide 
ligands also enhance the solubility of the drug in the body. Despite these advantages, the general 
conclusion at the final stage of its clinical trials is that the drug lacks the overall effectiveness 
that transcend those already established for cisplatin and carboplatin. 
Satraplatin and LA-12 are quite synonymous except that in the latter the cyclohexylamine is 
substituted with adamantylamine. LA-12, trans,cis,cis-bis(acetato)ammineadamantylamine 
platinum(IV), is currently in the first phase of its clinical trials. Satraplatin, trans,cis,cis-
bis(acetato)amminecyclohexylamineplatinum(IV), on the other hand, was the first platinum-
based drug whose intrinsic lipophilicity and stability makes it appropriate for oral 
administration. Satraplatin undergo reduction by some biological reducing agents, such as 
ascorbate, with a half-life of 50 minutes which is suitable for the platinum(IV) drug to be 
absorbed into the bloodstream. Once the drug enters the bloodstream, it is reduced to six 
different divalent platinum forms.  The one equipped with the most cytotoxic properties of the 
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six divalent platinum species is the ammine(cyclohexylamine)dichloroplatinum(II) arising 
from the removal of the two axial acetate ligands. Satraplatin was found to exhibit superior 
cytostatic activity against some human cisplatin-resistant cancer cell lines and less toxic than 
cisplatin at both In vitro and In vivo studies respectively. Its mechanism of action was, however, 
found to be similar to that of cisplatin involving DNA cross-links, DNA distortion leading to 
the obstruction of transcription and replication of the DNA. It is widely accepted that satraplatin 
is able to overcome cisplatin resistance because of the asymmetrical nature of the DNA adducts 
formed from its interaction with DNA which can circumvent recognition by DNA repair 
proteins such as high-mobility group proteins. Despite a few successes experienced from the 
clinical phase trials by satraplatin, the overall effectiveness and side effects are still in doubt. 
Attempts to combine it with other cytostatic drugs, such as prednisone, has not yielded much 
success either because rather than the expected synergistic effect between the drugs, the overall 
effectiveness of the combined therapy was less than the use of the individual drug alone.                                                                                                      
 
1.8.2 Monofunctional Platinum(II) Complexes 
Monofunctional platinum(II) complexes are a recent category of prospective antineoplastic 
compounds which incorporate only one leaving group ligand in their structures. They consist 
of only one platinum centre. Owing to the one leaving group ligand, they are anticipated to 
interact with the DNA via only one covalent bond. Generally, most other categories of 
platinum-based cytostatic agents can form both monofunctional and bifunctional adducts with 
the DNA. However, the monofunctional platinum(II) complexes via their motif can only form 
monofunctional platinum-DNA adducts. According to the early SARs, all monofunctional 
platinum complexes were reckoned to be lacking cytotoxic properties because certain 
monofunctional platinum(II) complexes, such as [Pt(NH3)3Cl]
+ and [Pt(dien)Cl]+ were found 
to be inactive both In vitro and In vivo [30]. However, research conducted by Engelhard 
Industries, revealed that monofunctional platinum(II) complexes with general formula cis-
[Pt(NH3)2(Am)Cl]
+, where Am is an aromatic N-heterocyclic amine, inhibited tumour cell 
growth In vitro and in certain leukemia cancer cell lines in mouse [30]. Consequently, cis-[Pt-
(NH3)2(9-aminoacridine)Cl] 
+ and cis-[Pt-(NH3)2(chloroquine)Cl]
+, were synthesised and 
observed to interact with DNA via both monofunctional covalent bond formation and 
intercalative mode. However, other studies [110, 111] suggested that there was the possibility 
of the formation of bifunctional adducts via the loss of one of the ammine ligands after the 
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initial covalent bond interaction with the DNA. This suggestion was quickly quashed through 
the NMR analysis of some adducts formed by monofunctional platinum(II) complexes with 
DNA. The NMR spectra clearly showed no evidence of the release of either of the ammine 
ligands for the possibility of bifunctional adduct formation. More recently [112], 
monofunctional platinum(II) complexes, such as pyriplatin, phenanthriplatin, Pt-ACRAMTU 
and derivatives etc. are currently being studied for their anticancer potentials (Figure 1.6). 
 
                                  
Figure 1.6: Chemical structures of some monofunctional platinum(II) complexes [30]. 
  
1.8.3 Non-functional Mononuclear Platinum(II) Compounds 
The non-functional mononuclear platinum(II) complexes, commonly referred to as 
metallointercalators, another class of alternative platinum-based cytostatic agents, are 
beginning to attract significant attention amongst medicinal inorganic chemists. They are 
essentially of the general formula [Pt(IL)(AL)]
2+, where IL is referred to as the intercalating 
ligand and AL is known as the ancillary ligand. These complexes have only one platinum centre 
and do not incorporate any known leaving group ligands in the structural motif. They mainly 
interact with the DNA via a noncovalent intercalative mode of binding. Metallointercalators 
with π-conjugated heterocyclic ligands, such as bipyridine, terpyridine, and phenanthroline, 
employ π−π stacking and dipole−dipole interactions to intercalate between base pairs in double-
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stranded DNA. The π-conjugated heterocyclic ligands allow these platinum(II) compounds to 
unwind, bend, and distort the arrangement within the DNA structure, and it is their structural 
effect on DNA that is believed to mediate their antineoplastic properties. Examples of some 
metallointercator complexes include: [Pt(BDIQQ)]+, PHENRR and the PHENSS series 
etc.(Figure 1.7). 
 
                
Figure 1.7: Chemical structures of non-functional platinum(II) complexes that bind to DNA 
through noncovalent interactions [30]. 
 
1.8.4 Multinuclear Platinum Compounds 
Farrell and his co-workers were the first to extend the frontier of development of novel 
anticancer agents which incorporated non-classical platinum complexes, such as trans-platinum 
and polynuclear platinum complexes. Some of these complexes have showed remarkable 
cytostatic potentials even against cisplatin resistant cell lines. Ever since Farrell et al. developed 
the trinuclear BBR3464 and its dinuclear analogues namely: BBR3571 and BBR3610 (Figure 
1.8), research activities are now being centred around developing more multinuclear 
platinum(II) complexes which can show tremendous potential in cancer chemotherapy [87]. 
The multinuclear platinum complexes are more water soluble and exhibit better DNA 
interactions because of certain features, such as high charge, hydrophilicity and/or flexibility, 
in comparison to cisplatin [30, 87, 113]. The earlier multinuclear compounds that were 
synthesised by Farrell et al. contain trans-[Pt(NH3)2Cl] units with bridging alkanediamine 
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linkers of variable length, designed to facilitate long-distance, flexible intrastrand and 
interstrand cross-links. Such adducts cannot be formed by classical mononuclear platinum(II) 
compounds, such as  cisplatin and transplatin. The dinuclear platinum(II) complexes, such as 
BBR3535, trans-[(PtCl(NH3)2)2μ-(H2N(CH2)4NH2)]Cl2 can form 1,2-, 1,3-, and 1,4-interstand 
cross-links between guanines on opposite strands [30, 114, 115]. The 1,3- and 1,4-cross-links 
with guanines are separated by one and two nucleobase pairs, respectively, whereas the 1,2-
cross-link is formed between guanines of neighbouring nucleobase pairs [30]. These 
unconventional DNA adducts facilitate the dinuclear platinum(II) complex to circumvent 
cisplatin resistance in certain cancer cells, such as ovarian cancer [30, 116]. To improve the 
DNA binding ability of the dinuclear platinum(II) complexes, the trinuclear platinum(II) series, 
such as BBR3464, were synthesised by incorporating a third platinum centre within the 
alkanediamine linker scaffold. Both the di- and tri-nuclear platinum(II) complexes were quite 
successful in their preclinical trials and have, subsequently, undergone different stages of 
clinical developments. However, none of them, including the BBR3464 despite its initial 
success at the phase I and II clinical trials, have not been advanced for full human use.  
 
               
Figure 1.8: Structure of dinuclear complexes: BBR3571 and BBR3610 [117]. 
 
Following the success of these multinuclear complexes with at least one leaving group ligand 
on at least two of the platinum(II) centres, some multinuclear platinum(II) complexes, that are 
based on BBR3464 (Figure 1.9), in which each of the labile chloride ligands on the platinum(II) 
complexes have been replaced by ammine ligands were synthesised. These complexes, such as 
TriplatinNC and TriplatinNC-A (Figure 1.9), react with the DNA noncovalently via 
electrostatic and hydrogen-bonding interactions. The terminal platinum units are believed to 
form distinct amine-phosphate-ammine binding patterns called “phosphate clamps” within the 
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minor groove, which induce B-to-A and B-to-Z conformational changes in canonical DNA 
sequences. These trinuclear complexes can also condense DNA and induce aggregation of small 
transfer RNA molecules because of their high cationic nature. These highly charged complexes 
exhibit micromolar toxicity against cisplatin-sensitive and cisplatin-resistant ovarian cancer 
cells [30, 118]. Their ability to overcome cisplatin resistance was attributed to their high cellular 
accumulation, presumably because of their cationic nature and their unique mode of binding to 
DNA.  
 
 
Figure 1.9: Chemical structures of trinuclear platinum agents. The pendant aliphatic groups of 
TriplatinNC-A are shown in the protonated state, raising the overall charge of the 
complex to 8+ [30]. 
 
 
1.9 Trans-Platinum Complexes: The Veritable Alternative to Cis-
Configured Platinum Complexes 
For well over two decades after the accidental realisation of the antineoplastic properties of 
cisplatin, all platinum(II) complexes of trans stereochemistry were presumably considered 
inconsequential as far as development of new cytostatic agents were concerned [18, 119]. This 
was justifiably so because transplatin, which is the trans isomer of cisplatin, was observed to 
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be biologically inactive [120-127]. Therefore, research efforts to understand its lack of activity 
led to the following widely accepted findings [108, 119, 121, 126, 128-130]: One, the kinetic 
instability of the transplatin makes it susceptible to prompt deactivation by other biomolecules 
before it could reach its target- the DNA; Two, the formation of platinum-DNA adducts with a 
distinct regioselectivity and stereochemistry that is different from those already established for 
cisplatin; and three, transplatin was typically non-toxic. However, the limitations of cisplatin 
and derivatives, such as severe side effects, lack of selectivity, inherent and acquired resistance 
etc., spurred the need amongst medicinal inorganic chemists to seek an alternative platinum-
based drugs with improved selectivity and display a distinct mechanism of action from that of 
cisplatin. Based on these criteria, the anticancer potential of trans platinum complexes was 
revisited since the non-toxic behaviour of transplatin coupled with its regioselectivity and 
distinct binding mode to DNA makes this class of platinum compounds appear promising. 
Farrell and his group were the first to report the anticancer activity of some trans platinum(II) 
complexes of general formula [PtCl2L2] that showed significant cytotoxic properties, where L 
is a planar heterocyclic ligand such as pyridine, thiazole, quinoline etc. [108, 131-136]. They 
believed that incorporating bulky monodentate amine ligands into the structure of transplatin, 
can reduce its kinetic instability and once this is achieved, the distinct DNA binding mode of 
these complexes can then be an additional advantage. He also pioneered some dinuclear 
platinum(II) compounds in which the two chloride leaving group ligands have trans orientation 
[109]. The latter marked the beginning of polynuclear platinum-based complexes in anticancer 
research. Much later, Navarro-Ranninger and his co-workers reported a new class of 
biologically active trans-platinum(II) complexes with asymmetric aliphatic amines, trans-
[PtCl2(L)(L’) [137]. The reports of these active trans platinum complexes made the earlier 
SARs pioneered by Cleare and Hoescheles [138, 139] to be altogether discarded and 
consequently, many prospective trans platinum compounds are being developed including 
those of the platinum(IV) prodrug which on reduction furnishes divalent platinum species with 
trans-geometry. 
This subsection presents an overview of biologically active platinum(II) compounds of trans-
geometry in anticancer research. The historical development of these active trans-platinum(II) 
complexes, some of which were designed and prepared as platinum(IV) prodrugs and/or 
multinuclear platinum(II) complexes, will be examined sequentially in the following subunits.  
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1.9.1 Trans-Platinum(II) Complexes with General Formula trans-[PtCl2(L)(L')] where 
L = N-Donor Aromatic Heterocycle and L' = Ammine, Sulphoxide or a Second 
Molecule of L Ligand) 
Farrell and his group [108, 116, 131, 132, 134-136, 138, 139] were the first to be designed and 
synthesised trans-platinum(II) complexes consisting of three different series of compounds 
which include: Firstly,  L = L' = pyridine (1), N-methylimidazole (2), or thiazole (3); Secondly,  
L = quinoline and L' = RR'SO (R= Me, R' = Me, Bz, or Ph) (4) and; Thirdly, L = quinoline (5) 
or thiazole (6) and L' = NH3 (Figure 1.10). The design of these complexes follows a simple 
replacement of one and/or both ammine ligands in transplatin with bulky planar nitrogen donor 
ligands and/or with aliphatic/aromatic sulphur containing ligands.  
                                     
Figure 1.10: Structures of trans-platinum(II) complexes with symmetric and asymmetric N- and S- 
donor aromatic heterocycles [140]. 
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 Table 1.1: IC50 values for compounds 1, 3. 4, 5 as compared to transplatin and cisplatin 
Values are IC50 (at least three independent experiments) in mM (96 h drug exposure for all cell lines except for L1210 and 
L1210cisR for which the exposure time was 72 h). Values in parentheses are resistance factors (RF = IC50 resistant/IC50 
sensitive parent line). [140] 
 
The resulting trans-platinum(II) complexes produced were of remarkable cytotoxicity similar 
to those of their corresponding cis-analogues and cisplatin. In fact, some derivatives, such as 
trans-[PtCl2(NH3)L] and trans-[PtCl2L2], where L = pyridine, quinoline, isoquinoline, thiazole, 
or benzothiazole exhibited remarkable cytotoxic behaviour in cisplatin- and oxaliplatin-
resistant cell lines. From the results shown in Table 1.1, these trans-platinum(II) complexes 
were found to be nearly hundred times more active than transplatin, and of comparable activity 
to cisplatin, in certain murine and human tumour cell lines. Reports from the National Cancer 
Institute (NCI) panel on human tumour cell line testing studies revealed that these trans-
platinum(II) compounds demonstrated a wide range of antineoplastic activity that is entirely 
different from that of any other anticancer agents. The distinctive cytotoxicity profiles of these 
complexes are not only attributed to their structure but to the way to it binds to DNA in cancer 
cells.  
Furthermore, it is quite interesting to realise that the substitution of one of the ammine ligands 
by quinolone and thiazole is enough to bring about such a phenomenal improvement in the 
cytotoxicity of trans-platinum compounds. Also remarkable is the display of activity, In vivo, 
against the leukaemia cell line by the complex formed from the thiazole substitution. This has 
quashed the presumption that trans complexes cannot show any In vivo anticancer activity. 
Similarly, In vitro studies in cultured breast cancer cells revealed that these trans complexes 
with bulky N-donor heterocyclic amine ligands formed DNA-topoisomerase I cross-links that 
are capable of causing a DNA strand to break and induce apoptosis. These ternary DNA−protein 
1 HX/62 SKOV-
3 
PXN94 41M 41McisR CH1 CH1cisR L1210 L1210cisR 
1 4.5 5.9 7.7 2.2 
 
2.0(0.91) 
 
1.6 1.7(1.1)   
3 4.1 6.2 9.6 2.2 1.6(0.73) 1.3 1.4(1.1)   
4 5.1 4.4 8.2 1.32 1.9(1.4) 0.89 1.0(1.1)   
5        0.51 1.35(2.65) 
transplatin 245 255 222 57 69(1.2) 30 68.5(2.3) 15.7 22.0(1.40) 
cisplatin 12.6 4.4 3.0 0.23 1.4(6.1) 0.1 0.67(6.7) 0.33   9.22(28) 
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cross-links are not observed following cisplatin treatment and thus, characterise the uniqueness 
of these trans-platinum(II) complexes.  
1.9.2 Some Platinum(IV) Complexes with Trans-Geometry 
A bid to achieve orally active platinum drugs has led to the design of some platinum(IV) 
complexes with trans geometry of leaving group ligands. A series of platinum-based 
compounds consisting of platinum(IV) complexes and their corresponding trans-platinum(II) 
analogues were synthesised and investigated for their cytostatic activity In vitro and In vivo 
respectively (Figure 1.11 and Table 1.2 for selected compounds) [32]. Several of the 
platinum(IV) complexes were observed to exhibit a potency comparable to that of cisplatin 
when they were tested against a group of human ovarian carcinoma cell lines (SKOV-3, A2780, 
HX/62, CH1, and 41M) [140]. However, most of their corresponding trans-platinum(II) 
analogues did not show any activity. The antineoplastic efficacy of the platinum complexes 
towards pairs of cisplatin sensitive/resistant human ovarian cancer cell lines (41M/41McisR, 
CH1/CH1cisR, and A2780/A2780cisR) was also investigated to determine the Resistance 
Factor (RF).  
                  
Figure 1.11: Structures of trans-platinum(II) complexes with symmetric and asymmetric N- and S- 
donor aromatic heterocycles [140]. 
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Table 1.2: IC50 mean values (±SD) for compounds 7-12 as compared to transplatin and cisplatin 
Values are IC50 values (at least two experiments) in mM (96 h drug exposure). The numbers in parentheses are 
the resistance factors (RF = IC50 resistant line/IC50 sensitive parent line) [140, 141]. 
 
The cancer cell lines selected were typical of the major mechanisms of resistance to cisplatin. 
41McisR cells have been known to show resistance against cisplatin mainly because of reduced 
drug accumulation. Still in the same vein, CH1cisR cells display resistance to cisplatin through 
enhanced DNA repair/tolerance while A2780cisR cells, on the other hand, show resistant to 
cisplatin via a combination of decreased accumulation, enhanced DNA repair/tolerance, and 
elevated glutathione levels [142, 143]. Most of the trans-platinum(IV) complexes exhibited 
potency that completely overcome the cisplatin resistance of 41McisR and CH1cisR (RF of ca. 
1.5), but were able to overcome that of A2780cisR, only to a certain extent (Table 1.2). 
Fourteen trans-platinum(IV) complexes, possessing axial hydroxide ligands, displayed 
remarkable In vivo antitumour activity against the subcutaneous murine ADJ/PC6 
plasmacytoma model. Nevertheless, the trans-platinum(IV) complex, having axial 
ethylcarbamate ligands, did not show any activity against murine cell line.  
Surprisingly, all the trans-platinum(II) and trans-platinum(IV) complexes possessing dichloro 
and tetrachloro ligands were found to be inactive. Three of the trans-platinum(IV) complexes 
7-9, (see Figure 1.11) maintain some potency against a cisplatin resistant variant of the 
ADJ/PC6 plasmacytoma and several others exhibited antitumour activity against 
subcutaneously grown advanced-stage human ovarian carcinoma xenografts. Interestingly, 
complex 7 which is known as JM335, has been reported to be the first trans-platinum complex 
 HX/62 SKOV-
3 
4IM 4IMcisR CH1 CH1cisR A2780 A2780cisR 
     7 4.4±0.5 6±0.9 1.3±0.13   
    
1.4±0.12 
  (1.1) 
1.1±0.33 
 
2.1±0.2 
  (1.9) 
0.42±0.07 3.0±0.26 
  (7.1) 
     8     3.4    3.9     1.3     1.4 
   (1.1) 
    1.1     1.7 
   (1.5) 
    0.61     2.5 
   (4.2) 
     9     1.2    2.5     0.84      1.3 
   (1.5) 
    0.44     0.62 
   (1.4) 
    0.49     1.6 
   (3.3) 
    10     1.8    4.7     1.1     0.9 
   (0.8) 
    0.74     1.62 
   (2.2) 
    0.21     4.2 
   (20) 
    11   14.2  10.3     4.6    4.4 
   (1) 
    3.7     5.4 
   (1.4) 
    1.9     6.4 
   (3.3) 
    12   10.2   8.2     1.3    1.3 
   (1) 
    1.1     1.9 
   (1.7) 
    1.1     4.2 
    (4) 
transplatin  245±45 255±77  57±18  70±13 
  (1.2) 
 30±38 68.5±11 
   (2.3) 
  32±8 260±46 
  (8.1) 
cisplatin 12.6±2.9 
 
4.4±3.1 
 
0.26±0.078 1.2±0.4 
  (4.7) 
0.11±0.02 0.71±0.2 
   (0.4) 
0.33±0.1 5.2±1.3 
 (15.7) 
  
25 
 
showing significant In vivo antitumour activity towards models of acquired cisplatin resistance 
[144]. 
1.9.3 Trans-Platinum(II) Complexes with Asymmetric Aliphatic Amine Ligands of the 
General Formula  trans-[PtCl2(L)(L')]  
Transplatin derivatives with aliphatic amines, such as trans-[PtCl2(isopropylamine)(L’)] 
(L’=dimethylamine, isopropylamine, or propylamine) denote another category of trans-
platinum(II) complexes that have shown remarkable cytotoxic properties [137, 145, 146]. These 
complexes (Figure 1.12) were found to have comparable activity in cisplatin sensitive cells to 
that of cisplatin and significantly higher than that of cisplatin in several cisplatin resistant cancer 
cells (Table 1.3). Compound 13 was observed to circumvent cisplatin resistance in cell lines, 
such as HL60 human leukemic cells and Pam 212-ras murine keratinocytes, which are ras-
related resistance through its ability to form interstrand cross-links within a short time as 
compared to cisplatin [137]. Similarly, the complex was found to exhibit superior cytotoxicity 
against the multifactorial cisplatin resistance and other ras-related resistance. However, 
detailed In vivo studies have not been done on these promising trans-platinum(II) cytostatic 
agents.  
                     
Figure 1.12: Structures of trans-platinum(II) complexes with asymmetric aliphatic amine ligands 
[140]. 
  
26 
 
 
              Table 1.3: IC50 Mean Values (±SD) for Compounds 18-23 (Figure 1.12) 
 
 
 
 
 
 
 
 
 
 
 
   Values are IC50 Values in mM (24 h incubation time). The numbers in parentheses are resistance factors (RF = IC50 resistant line/IC50 sensitive parent line 
[137,147]. 
 
 
 
 HL-60 JURKAT HeLa VERO PAM212 PAM212-ras A2780 A2780cisR CH1 CH1cisR 
13 17±2 5±0.3 
  
32±3   
   (1.9) 
47±4 
 
56±2 
 
6±0.5     
15 20±2 5±0.4 43±3 
  
52±4 
   
50±3 32±1     
16       1.7 9.3(5.5) 4.2 15.1(3.6) 
 
17       2.1 15.5(7.4) 5.5 18.0(3.3) 
 
Transplatin 50±3 22±0.7 
   
89±4 148±6 
    
123±5 164±8 >200 >200 >200 >200 
cisplatin 25±1 7±0.3 
 
38±1 50±3 
   
114±3 156±6 2.2 38(17.3) 6.0 23.0(3.8) 
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1.9.4 Trans-Platinum(II) Complexes with Mixed Amine Ligands of the General Formula  
trans-[PtCl2(L)(L')] Containing Non-planar and Planar N-donor Amine Ligands 
Trans-Platinum(II) complexes with asymmetric amine ligands were observed to have problems, 
especially in aqueous medium despite their effective antineoplastic activities [140]. Hence, 
water soluble platinum complexes which are able to interact rapidly with DNA and form DNA 
adducts different from those formed by cisplatin and transplatin, were designed and synthesised. 
These cationic trans-platinum(II) complexes consist of non-planar and planar amine ligands 
[148] (Figure 1.13). The ligand systems, L and L’, around the platinum centre consist of 
piperazine, L and  a variation of the L’ ligands from non-planar, cyclic and non-cyclic, to planar 
N-donor amine ligands. The choice of piperazine as a fixed ligand in this class of trans-
platinum(II) complexes was informed by the following: Firstly, the positive charge on the non-
coordinating nitrogen would enhance solubility in aqueous medium and facilitate rapid 
interaction with the polyanionic DNA; Secondly, piperazine is a nonplanar cyclic amine ligand 
that is flexible and has a hydrogen bond donor that can react with the DNA to possibly form 
new types of lesions and; Thirdly, it is bulky enough to influence the substitution of the chloride 
ligands [149].  
Table 1.4: IC50 Mean Values (±SD) for Compounds 18-23 
IC50 values in mM (24 h incubation time).The numbers in parentheses are the resistance factor (RF = IC50 
resistant/IC50 sensitive parent line) [150, 151]. 
 
 A2780 A2780cisR CH1 CH1cisR 41M     41McisR 
18  5 ± 1 44 ± 4 (8.8) 12 ± 3 34 ± 4 
(2.8) 
52 ± 5 155 ± 12 
(3.0) 
19 16 ± 2 28 ± 2 (1.8) 
 
17 ± 2 
  
19 ± 3 
(1.1) 
  
32 ± 5 48 ± 3 (1.5) 
20 14 ± 1 30 ± 2 (2.1) 10 ± 1 50 ± 3 
(5.0) 
38 ± 3 122 ± 8 
(3.2) 
21 18 ± 2 64 ± 5 (3.6) 22 ± 3 85 ± 7 
(3.9) 
37 ± 4 118 ± 9 
(3.2) 
22 10 ± 3 24 ± 3 (2.4) 16 ± 2 43 ± 3 
(2.6) 
45 ± 3 147 ± 10 
(3.3) 
23 17 ± 3 43 ± 3 (2.5) 26 ± 2 53 ± 3 
(2.0) 
43 ± 3 153 ± 10 
(3.6) 
24   5 ± 0.7 20 ± 2 (4.0) 15 ± 2 94 ± 6 
(6.0) 
27 ± 2 150 ± 8 
(5.5) 
26   7 ± 1 80 ± 5 (11) 22 ± 3 154 ± 8 
(7.0) 
37 ± 4 118 ± 9 
(3.2) 
Transplatin >200 >200 >200 >200 >200 >200 
cisplatin 2.2 ± 0.6 38 ± 3 (17.3) 6 ± 1 23 ± 3 
(3.8) 
26 ± 2 107 ± 8 
(4.1) 
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One of the most active complexes among this category of trans-platinum(II) compounds is 
Compound 19, illustrated in Figure 1.13. The complex has the ability to overcome cisplatin-
resistance resulting from reduced accumulation of the drug and enhanced DNA repair/damage 
tolerance (Table 1.4). Besides trans-platinum compounds having piperazine ligand, other 
compounds containing a piperidine and/or a 4-Me-pyridine were also synthesised viz. trans- 
[PtCl2(piperidine)(L’)] (L’ = ammine or 4-Me-pyridine) and trans-[PtCl2(NH3)(4-Me-
pyridine)] compounds 24, 25, and 26 (Figure 1.13). These compounds were observed to show 
potential for superior cytotoxic activities against human ovarian carcinoma (OV-1063) and 
colon carcinoma (C-26) cancer cells [148]. Moreover, compounds 24 and 26 circumvent, to 
some extent, cisplatin resistance of A2780cisR cells but are highly cross-resistant to cisplatin 
in the case of CH1cisR and 41McisR cells respectively (Table 1.4) [150].  
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Figure 1.13: Structures of trans-platinum(II) complexes with mixed planar and non-planar amine 
ligands [140, 148-150]. 
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1.9.5 Trans-Platinum(II) Complexes with Iminoether Ligands General Formula trans-
[PtCl2{HN=C(OR)R’}2] or trans-[PtCl2(NH3){HN=C(OR)R’}]  
In order to improve on the solubility of the foregoing trans-platinum(II) compounds, the acetate 
ligands were introduced into the structure as the leaving group instead of the chloride ligands. 
Surprisingly, these complexes are similar to carboplatin except for the fact that they are of trans 
geometry. The trans-platinum(II) complexes with iminoether ligands maintained the 
cytotoxicity profile of the parent chloro complexes despite the slight modification of their 
structures to overcome solubility problems. Some of these complexes have one or two 
iminoether ligands and are of the general formula trans-[PtCl2{HN=C(OR)R’}2] or trans-
[PtCl2(NH3){HN=C(OR)R’}] (compounds 27-29 in Figure 1.14). The iminoether ligand can 
exist in two different conformations- E and Z, because of the non-symmetrical nature of the 
groups around the imine (C=N) bond. Consequently, the platinum(II) complexes with 
iminoether ligands do not just exist in their traditional cis and trans isomers but also exhibit 
extended isomerism at the coordinated ligand sites. Iminoethers exhibit some of the 
characteristics of both the aromatic N-donor heterocycles, such as pyridine, and the aliphatic 
amines. In other words, they exist as the intermediate between the N-donor aliphatic and 
aromatic amines because like the aromatic N-donor heterocycles, iminoether ligands are planar 
resulting from the sp2 hybridization of the nitrogen atom and like aliphatic amines, they have 
one hydrogen atom linked to the nitrogen, which in most cases, is susceptible to hydrogen-bond 
formation. Detailed mechanistic studies showed that, similar to transplatin, the trans- 
[PtCl2(HN=C(OMe)Me)(NH3)] series formed monofunctional adducts that developed into 
interstrand cross-links between adjacent guanine and cytosine nucleobases [152, 153]. The 
trans-platinum(II) complexes with iminoether ligands formed lesions which are thought to be 
flexible as a result of the imine bond, thereby inducing structural effects on DNA different from 
the more rigid lesion formed by transplatin [152]. 
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Table 1.5: IC50 Mean Values (±SD) for Compounds 27, 28 and 29 (Figure 1.14) 
IC50 values in M (96 h incubation time). The numbers in parentheses are the resistance factor (RF = IC50 resistant/IC50 sensitive parent line) [140, 152]. 
 
 A2780 A2780cisR 4IM 4IMcisR SKOV-3 HCT-116 KM12 A549 MDA MCF7 
27 1.5±0.2 10.8±1.8 
     (7.2) 
3.3±1.2   
   (1.9) 
6.2±1.9 
 
19±4 
 
4.5±1.8 6±2.4 2.1±1.0 11.5±3.1 3.5±1.4 
28 1.3±0.3 7.0±1.3 
  (5.4) 
3.4±1 
  
8.5±1.1 
  (2.5) 
120±24 20±4.5 55±8 14±2 61±1 1.5±0.2 
29 2.8±0.7 10.6±2 
  (3.8) 
5.6±1.2 7.8±0.5 
  (1.4) 
43±12 12.6±3 18.9±5 4.9±1 36±5 12.3±3 
Transplatin 14±4 118.2±11 
  (8.4) 
36±5 61.2±8 
   (1.7) 
170±25 35±5 355±36 360±24 140±21 45±7 
cisplatin 0.2±0.05 3.2±0.8 
  (16) 
0.6±0.01 2.7±0.3 
  (4.5) 
4±0.9 1.9±0.3 8±1.5 1.3±0.2 2.5±0.3 1.2±0.2 
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One of the first trans-platinum(II) complexes with iminoether ligands that was investigated in 
full for its cytotoxicity profile is trans-EE-[PtCl2(HN=C(OMe)Me)2] complex, compound 27. 
The complex demonstrated a growth inhibitory effectiveness similar to those of cisplatin when 
it was tested against colon, lung, ovary and breast cancer cell lines (Table 1.5).  
Furthermore, the complex displayed no cross-resistance with cisplatin in ovarian cancer cells 
and substantial In vivo activity in P388 murine leukemia cancer cells [154, 155]. The cellular 
uptake and extent of platinum-DNA binding were found to be remarkably better for trans-
platinum(II) complexes with iminoether ligands than that of cisplatin, which indicates that DNA 
was the central intracellular target [155]. Consequently, compound 27 was to overcome the 
cisplatin-resistance of A2780/cp8 cells, a resistance that is due to the low accumulation of 
cisplatin and a greater amount of glutathione in the cell line. The trans-Pt(II) complexes with 
iminoether ligands form stable monofunctional adducts with double helix DNA [154, 156], 
which direct the DNA toward the minor groove [157]. The monofunctional platinum-DNA 
adducts formed were not recognised by repair proteins, such as HMGB proteins, and thus were 
readily removed by nucleotide excision repair (NER). However, conversion of the 
monofunctional adducts into DNA−protein cross-links generated lesions that were able to 
circumvent NER, impede DNA polymerases, or lead to apoptosis. SAR investigations 
established that trans-platinum(II) derivatives with only one iminoether ligand were less toxic 
than those with two of these ligands [152]. Regarding the additional isomerism that occurs 
within the trans-[PtCl2(HN=C(OCH3)CH3)(NH3)] series, the E conformation, compound 29 
showed greater inhibitory potency against cancer cells than the Z conformation, compound 28. 
These analogues contain only iminoether ligands compared to compound 27. However, the 
complexes, are less cytotoxic than compound 27. This suggests that the iminoether ligand 
configuration is a major determinant of cytotoxic activity. Additionally, the inhibitory potency 
is reduced for compound 28 in relation to compound 29. Essentially, compounds 28 and 29 
partially bypass the cisplatin resistance dependent upon multifactorial mechanisms, such as 
A2780cisR cells, RF of 5.4 and 3.8, respectively.  
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Figure 1.14: Structures of trans-platinum(II) complexes with iminoether-ligands [140, 152-153].  
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The complexes also overcome resistance due to low accumulation, such as in 41McisR cells, 
RF of 2.5 and 1.4, respectively. Their activity profiles are different from that already established 
for cisplatin. Compounds 27, 28 and 29 all exhibit an In vivo antitumor activity comparable to 
that of cisplatin towards murine leukemic and solid metastasising tumours, as well as towards 
human xenografts [153, 158, 159]. 
Furthermore, in order to efficiently investigate the effect of different conformations of the 
iminoether ligand on the trans-platinum(II) activity, trans-platinum(II) complexes bearing 
cyclic iminoether ligands mimicking the E and Z configuration were synthesised, compounds 
30-33 [160]. Complexes 30 and 32 with cyclic ligands mimicked the Z conformation while 31 
and 33 mimicked the E conformation. With the cyclic ligands the complexities that are 
associated with the E/Z isomerization encountered in acyclic iminoether compounds were 
readily bypassed. Moreover, compounds 32 and 33 showed better cytotoxic profiles than their 
corresponding isomers, compounds 28 and 29. Nonetheless, they all displayed similar activity 
profiles, effect of ligand configuration, and activity towards cisplatin resistant cells [152]. 
In a bid to extend the structure-activity relationship of the trans-platinum(II) complexes with 
iminoether ligands, two compounds, trans-[PtCl2{HN=C(CH3)2], 34 which has two 
acetonimines and (trans-[PtCl2(NH3){HN=C(CH3)2], 35 which has one acetonimine and one 
ammine were synthesised and studied (Figure 1.14) [161]. Acetonimines are like iminoethers 
because they have sp2-hybridization of the nitrogen atom, akin to pyridine, with a proton still 
bound to nitrogen like in secondary aliphatic amines, and a planar shape with the steric bulk 
localised only on one side of the donor atom. Compounds 34 and 35, in a panel of human tumour 
cell lines of different sources, both demonstrated remarkable cytotoxic activity, mean IC50 = 
10.6, and 26 μM, respectively and bypassed the cisplatin resistance of ovarian cell sublines, 
A2780cisR and 41McisR, RF of approximately 1.8, hence, showing that the imino- group can 
also determine the activity of the trans geometry. 
. 
1.10 Aim of this Study 
Platinum-based anticancer agents are among the most widely accepted metal-based [162-168] 
chemotherapeutics with cisplatin, despite its profound drawbacks [169-176], such as severe 
toxicity, lack of selectivity, inherent and acquired resistance, and transient retention in the 
bloodstream, still the most clinically, universally used agent [169, 170, 177-188]. Several 
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research efforts have been targeted towards developing alternative platinum-based cytostatic 
agents that will not only eliminate some of the challenges that are associated with cisplatin but 
also improve on its cytotoxicity. Most of the synthesised cis-configured complexes, which 
comprised of mainly the second-generation platinum-based drugs, such as carboplatin, 
oxaliplatin etc., are yet to be globally accepted and moreover, many of them are still 
encumbered with some of the limitations that are plaguing the continued use of cisplatin [48, 
93, 178, 189-193]. Burgeoning interests among medicinal inorganic chemists, in recent years, 
have been to develop platinum-based anticancer agents with pharmacodynamics that are 
relatively complex and radically different from those already established for cis-configured 
platinum(II) based complexes. Among compounds that are currently being considered, 
platinum(II) complexes with trans-stereochemistry are starting to gain a lot of research 
attentions [194, 195]. 
The initial thought amongst many medicinal inorganic researchers that cis-configuration is a 
prerequisite for cytotoxicity because of the dearth of activity of the non-toxic transplatin, the 
trans-isomer of cisplatin, has been discarded with recent developments. This non-toxic nature 
of transplatin motivated research efforts to understand the dearth of activity of transplatin and 
these efforts brought about two major findings [18, 119, 125, 194]. First, kinetic instability 
which bring about prompt deactivation of the complex and second, the formation of DNA 
adducts characterised by a regioselectivity and a stereochemistry that are radically different 
from those of cisplatin and its derivatives. The second finding was reckoned to be a remarkable 
breakthrough since it offers an alternative mode of action to those already established for 
cisplatin. However, for this to be achieved, the first problem on kinetic instability must be 
resolved. Farrell et al. [135] and much later Ranninger et al.[196], were able to overcome this 
challenge when they incorporated bulky amine ligands into the structure of transplatin which 
elicit some symmetrical and asymmetrical trans-configured platinum(II) complexes with 
significantly high cytotoxicity, better than cisplatin both in vitro and in vivo and with relatively 
less toxicity. Following this success, many other trans-platinum(II) complexes have been 
synthesised including the polynuclear trans-platinum(II) complexes which were introduced by 
Farrell.  
Furthermore, most of these platinum compounds with trans stereochemistry have showed 
promising prospect as alternative anticancer drugs. However, the mechanism of action of these 
compounds are still not quite understood. Moreover, the literature is inundated annually with 
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kinetic and mechanistic studies of cis-configured platinum(II) complexes, all in an effort to 
better understand their mechanism of action as well as facilitate the design and synthesis of 
complexes with superior cytotoxic properties. Since trans-platinum compounds offer an 
alternative prospect in metal-based anticancer research, efforts to provide detailed kinetic and 
mechanistic studies of this class of alternative platinum-based compounds will be important not 
only to enhance a better understanding of their mechanism of action but also in the design and 
synthesis of trans-compounds with superior cytotoxicity and comparably low toxicity. To our 
knowledge, no such detailed kinetic and mechanistic study of trans-platinum-based compounds 
are currently available in literature. 
Hence, the central aim of this research is to provide a detailed kinetic and mechanistic study of 
some mononuclear and dinuclear trans-platinum(II) complexes. In this study, mononuclear and 
dinuclear trans-platinum(II) complexes were investigated with neutral thiourea-based 
nucleophiles, such as thiourea (TU), 1-methyl-2-thiourea (MTU), 1,3-dimethyl-2-thiourea 
(DMTU), 1,1,3,3-tetramethyl-2-thiourea (TMTU). The choice of thiourea-based nucleophiles 
varies according to their steric demands. Sulfur donor thiourea-based nucleophiles represent a 
typical example of the interaction of the sulfur containing biomolecules, such as proteins, 
peptides and enzymes, in the body with platinum-based drugs [197-199]. Platinum being a soft 
centre [200] has a very strong affinity for sulfur [201-203] containing molecules which are quite 
abundant in the human body. More so, the interaction of platinum-based anticancer drugs with 
biomolecules has been established to be responsible for the high toxic behaviour of these drugs 
[204-207]. Furthermore, computational modelling through density functional theory at the level 
B3LYP with LANL2DZ basis set using the Gaussian 09 programme suite [208] is incorporated 
in this study to a facilitate theoretical interpretation of the kinetic and mechanistic behaviour of 
the investigated trans-platinum(II) complexes. 
To this end, the specific objectives of this study include: 
1. To investigate the kinetic and mechanistic behaviour of analogous cis and trans-
dialkylamine diaquaplatinum(II) complexes of the general form, [PtX2L2]. This is aimed 
to ascertain how bifunctional trans-platinum(II) complexes will substitute kinetically in 
comparison to their corresponding cis isomers. This is presented in Chapter Three. 
 
2. To extend the understanding of ligand substitution kinetics of mononuclear trans-
platinum(II) complexes further mixed amine ligands with varying the chain lengths of 
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the alkylamine ligand with be used. The studied trans-platinum compounds are of the 
general form, [Pt(NH3)LX2]. This is covered in Chapter Four. 
 
 
3. To carry out a comparative study of the substitution behaviour of some bifunctional 
mononuclear trans-platinum(II) complexes with symmetric and asymmetric 
dialkylamine and alkylamine ligands respectively. This work is reported in Chapter 
Five. 
 
4. To gain an in-depth understanding through a kinetic and mechanistic investigation of 
the role of flexible alkyl-α,ω-diamine linkers on the substitution behaviour of some 
dinuclear trans-platinum(II) complexes. The chloride leaving groups are trans to each 
other on the platinum centre. Mechanistic behaviour of these dinuclear trans-
platinum(II) compounds were compared to those of their corresponding mononuclear 
counterparts. This work is presented in Chapter Six.  
. 
 
 
 
 
 
 
 
 
 
 
  
38 
 
References 
[1] R. Siegel, A. Jemal, American Cancer Society. Cancer Facts & Figures, (2015) 25-55. 
[2] S.J. McPhee, M.A. Papadakis, M.W. Rabow, Current Medical Diagnosis & Treatment, 
McGraw-Hill Medical New York:, (2010) 1-100. 
[3] V. Panda, P. Khambat, S. Patil, International Journal of Clinical Medicine, 2 (2011) 512-
517. 
[4] I. Kostova, Current Medicinal Chemistry, 13 (2006) 1085-1107. 
[5] I. Kostova, Recent Patents on Anti-Cancer Drug Discovery, 1 (2006) 1-22. 
[6] E. Alessio, Bioinorganic Medicinal Chemistry, John Wiley & Sons, (2011) 5-20. 
[7] C. Andreini, I. Bertini, G. Cavallaro, G.L. Holliday, J.M. Thornton, JBIC Journal of 
Biological Inorganic Chemistry, 13 (2008) 1205-1218. 
[8] I. Bratsos, T. Gianferrara, E. Alessio, C.G. Hartinger, M.A. Jakupec, B.K. Keppler, 
Bioinorganic Medicinal Chemistry, (2011) 151-174. 
[9] J.P. Parker, Z. Ude, C.J. Marmion, Metallomics, 8 (2016) 43-60. 
[10] M. Fanelli, M. Formica, V. Fusi, L. Giorgi, M. Micheloni, P. Paoli, Coordination 
Chemistry Reviews, 310 (2016) 41-79. 
[11] L. Ronconi, P.J. Sadler, Coordination Chemistry Reviews, 251 (2007) 1633-1648. 
[12] M.A. Jakupec, M. Galanski, V.B. Arion, C.G. Hartinger, B.K. Keppler, Dalton 
transactions, (2008) 183-194. 
[13] M. Peyrone, European Journal of Organic Chemistry, 51 (1844) 1-29. 
[14] R.A. Alderden, M.D. Hall, T.W. Hambley, Journal of Chemical Education, 83 (2006) 
721-728. 
[15] S. Dasari, P.B. Tchounwou, European Journal of Pharmacology, 740 (2014) 364-378. 
[16] A. Werner, Zeitschr. Anorg. Chem, 3 (1893) 267-270. 
[17] A. Werner, Zeitschrift für Anorganische und Allgemeine Chemie, 3 (1893) 267-330. 
[18] J.J. Wilson, S.J. Lippard, Chemical Reviews, 114 (2013) 4470-4495. 
[19] L. Kelland, Nature Reviews Cancer, 7 (2007) 550-573. 
[20] J. Reedijk, Proceedings of the National Academy of Sciences, 100 (2003) 3611-3616. 
[21] P.S. Sengupta, R. Sinha, G. De, Transition Metal Chemistry, 26 (2001) 638-643. 
[22] M. Zaki, F. Arjmand, S. Tabassum, Inorganica Chimica Acta, 444 (2016) 1-22. 
[23] E.R. Jamieson, S.J. Lippard, Chemical Reviews, 99 (1999) 2467-2498. 
[24] C.J. Jones, J.R. Thornback, Medicinal Applications of Coordination Chemistry, Royal 
Society of Chemistry, (2007) 94-100. 
[25] J.-X. Liang, H.-J. Zhong, G. Yang, K. Vellaisamy, D.-L. Ma, C.-H. Leung, Journal of 
Inorganic Biochemistry, 177 (2017) 276-286. 
[26] S. Medici, M. Peana, V.M. Nurchi, J.I. Lachowicz, G. Crisponi, M.A. Zoroddu, 
Coordination Chemistry Reviews, 284 (2015) 329-350. 
  
39 
 
[27] B.J. Reedijk, Platinum Metals Review, 52 (2008) 2-11. 
[28] T.G. Appleton, A.J. Bailey, K.J. Barnham, J.R. Hall, Inorganic Chemistry, 31 (1992) 
3077-3082. 
[29] L. Cubo, A.G. Quiroga, J. Zhang, D.S. Thomas, A. Carnero, C. Navarro-Ranninger, S.J. 
Berners-Price, Dalton Transactions, (2009) 3457-3466. 
[30] T.C. Johnstone, K. Suntharalingam, S.J. Lippard, Chemical Reviews, 116 (2016) 3436-
3486. 
[31] S.E. Miller, D.A. House, Inorganica Chimica Acta, 187 (1991) 125-132. 
[32] M. Gielen, E.R. Tiekink, Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: 
The Use of Metals in Medicine, John Wiley & Sons, (2005) 5-25. 
[33] J.-M. Teuben, J. Reedijk, JBIC Journal of Biological Inorganic Chemistry, 5 (2000) 463-
468. 
[34] S.E. Crider, R.J. Holbrook, K.J. Franz, Metallomics, 2 (2010) 74-83. 
[35] A. Pasini, C. Fiore, Inorganica Chimica Acta, 285 (1999) 249-253. 
[36] J. Vinje, E. Sletten, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current 
Medicinal Chemistry-Anti-Cancer Agents), 7 (2007) 35-54. 
[37] X. Wang, Z. Guo, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current 
Medicinal Chemistry-Anti-Cancer Agents), 7 (2007) 19-34. 
[38] S. Manohar, N. Leung, Journal of Nephrology, (2017) 1-11. 
[39] S. Sheth, D. Mukherjea, L.P. Rybak, V. Ramkumar, Frontiers in Cellular Neuroscience, 
11 (2017) 330-341. 
[40] A. Chattopadhyay, A. Dey, P. Karmakar, S. Ray, D. Nandi, A.K. Ghosh, Progress in 
Reaction Kinetics and Mechanism, 43 (2018) 274-285. 
[41] T.W. Hambley, Journal of the Chemical Society, Dalton Transactions, (2001) 2711-
2718. 
[42] F.-L. Li, J.-P. Liu, R.-X. Bao, G. Yan, X. Feng, Y.-P. Xu, Y.-P. Sun, W. Yan, Z.-Q. 
Ling, Y. Xiong, Nature Communications, 9 (2018) 501-508. 
[43] M. Liu, Z. Han, Q.-X. Zhu, J. Tan, W.-J. Liu, Y.-F. Wang, W. Chen, Y.-L. Zou, Y.-S. 
Cai, X. Tian, Cancer gene therapy, 25 (2018) 1-12. 
[44] F. Peng, H. Zhang, Y. Du, P. Tan, Molecular Medicine Reports, 17 (2018) 4767-4776. 
[45] M. Rada, S. Nallanthighal, J. Cha, K. Ryan, J. Sage, C. Eldred, M. Ullo, S. Orsulic, D.-J. 
Cheon, Oncogene, (2018) 1-20. 
[46] C.-Y. Sun, Y. Zhu, X.-F. Li, X.-Q. Wang, L.-P. Tang, Z.-Q. Su, C.-Y. Li, G.-J. Zheng, B. 
Feng, Frontiers in Pharmacology, 9 (2018) 90-110. 
[47] M. Yang, X. Yang, D. Yin, Q. Tang, L. Wang, C. Huang, P. Li, S. Li, Neoplasma, 65 
(2018) 42-48. 
[48] I.A. Riddell, S.J. Lippard, Metallo-Drugs: Development and Action of Anticancer 
Agents: Development and Action of Anticancer Agents, 18 (2018) 1-8. 
[49] V. Jha, H. Ling, Journal of Molecular Biology, 430 (2018) 1577-1589. 
[50] T. Fang, Z. Ye, J. Wu, H. Wang, Chemical Communications, (2018) 5-21. 
  
40 
 
[51] C.R.R. Rocha, M.M. Silva, A. Quinet, J.B. Cabral-Neto, C.F.M. Menck, Clinics, 73 
(2018) 767-785. 
[52] L. He, Z. Meng, D. Xu, F. Shao, Scientific Reports, 8 (2018) 767. 
[53] A. Saha, A. Pal, R. Goswami, Journal of Chemical and Pharmaceutical Sciences, 11 
(2018) 8-19. 
[54] F.A. Suliman, D.M. Khodeer, A. Ibrahiem, E.T. Mehanna, M.K. El-Kherbetawy, H.M. 
Mohammad, S.A. Zaitone, Y.M. Moustafa, International Immunopharmacology, 61 (2018) 8-
19. 
[55] A. Boot, M.N. Huang, A.W. Ng, S.-C. Ho, J.Q. Lim, Y. Kawakami, K. Chayama, B.T. 
Teh, H. Nakagawa, S.G. Rozen, Genome Research, (2018) 20-23. 
[56] J. Reedijk, European Journal of Inorganic Chemistry, 2009 (2009) 1303-1312. 
[57] A.M.J. Fichtinger-Schepman, A.T. van Oosterom, P.H. Lohman, F. Berends, Cancer 
Research, 47 (1987) 3000-3004. 
[58] E. Reed, Y. Ostchega, S.M. Steinberg, S.H. Yuspa, R.C. Young, R.F. Ozols, M.C. 
Poirier, Cancer Research, 50 (1990) 2256-2260. 
[59] E.P. López, Applications in Cancer Chemotherapy Doctoral Thesis. Institute of 
Chemistry, Faculty of Mathematics & Natural Sciences, Leiden University, (2005) 1-10. 
[60] V. Brabec, O. Hrabina, J. Kasparkova, Coordination Chemistry Reviews, (2017) 311-
321. 
[61] S. Dutta, C. Rivetti, N.R. Gassman, C.G. Young, B.T. Jones, K. Scarpinato, M. Guthold, 
Journal of Molecular Recognition, (2018) 2718-2731. 
[62] L. Saker, S. Ali, C. Masserot, G. Kellermann, J. Poupon, M.-P. Teulade-Fichou, E. 
Ségal-Bendirdjian, S. Bombard, International Journal of Molecular Sciences, 19 (2018) 1951-
1965. 
[63] R. Charif, C. Granotier-Beckers, H.C. Bertrand, J. Poupon, E. Ségal-Bendirdjian, M.-P. 
Teulade-Fichou, F.D. Boussin, S. Bombard, Chemical Research in Toxicology, 30 (2017) 
1629-1640. 
[64] N. Aztopal, D. Karakas, B. Cevatemre, F. Ari, C. Icsel, M.G. Daidone, E. Ulukaya, 
Bioorganic & Medicinal Chemistry, 25 (2017) 269-276. 
[65] S. Komeda, H. Yoneyama, M. Uemura, A. Muramatsu, N. Okamoto, H. Konishi, H. 
Takahashi, A. Takagi, W. Fukuda, T. Imanaka, Inorganic Chemistry, 56 (2017) 802-811. 
[66] S.T. Pan, Z.L. Li, Z.X. He, J.X. Qiu, S.F. Zhou, Clinical and Experimental 
Pharmacology and Physiology, 43 (2016) 723-737. 
[67] G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, S. Sarkar, 
Cancers, 6 (2014) 1769-1792. 
[68] P. Samuel, R.C. Pink, S.A. Brooks, D.R. Carter, Expert Review of Anticancer Therapy, 
16 (2016) 57-70. 
[69] K. Luo, X. Gu, J. Liu, G. Zeng, L. Peng, H. Huang, M. Jiang, P. Yang, M. Li, Y. Yang, 
Experimental Cell Research, 347 (2016) 105-113. 
[70] S. Dilruba, G.V. Kalayda, Cancer Chemotherapy and Pharmacology, 77 (2016) 1103-
1124. 
  
41 
 
[71] J. Hrabeta, V. Adam, T. Eckschlager, E. Frei, M. Stiborova, R. Kizek, Anti-Cancer 
Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer 
Agents), 16 (2016) 686-698. 
[72] D.L. Wong, M.J. Stillman, Metallomics, 10 (2018) 713-721. 
[73] R.P. Perez, T.C. Hamilton, R.F. Ozols, Pharmacology & Therapeutics, 48 (1990) 19-27. 
[74] P. Andrews, S. Howell, Cancer cells (Cold Spring Harbor, NY: 1989), 2 (1990) 35-43. 
[75] E. Tuzel, K. Yorukoglu, E. Ozkara, Z. Kirkali, Central European Journal of Urology, 68 
(2015) 45-68. 
[76] T. Kimura, T. Kambe, International Journal of Molecular Sciences, 17 (2016) 335-357. 
[77] J.-H. Lee, J.-W. Chae, J.K. Kim, H.J. Kim, J.Y. Chung, Y.-H. Kim, Journal of Controlled 
Release, 215 (2015) 82-90. 
[78] B. Kawahara, S. Ramadoss, G. Chaudhuri, C. Janzen, S. Sen, P.K. Mascharak, Journal of 
Inorganic Biochemistry, (2018). 
[79] A.K. Srivastava, C. Han, R. Zhao, T. Cui, Y. Dai, C. Mao, W. Zhao, X. Zhang, J. Yu, Q.-
E. Wang, Proceedings of the National Academy of Sciences, (2015) 201421365. 
[80] E. Reed, T.L. Larkins, C.H. Chau, W.D. Figg, DNA Repair: ERCC1, Nucleotide 
Excision Repair, and Platinum Resistance, in:  Handbook of Anticancer Pharmacokinetics and 
Pharmacodynamics, Springer, 2014, pp. 333-349. 
[81] M. Zimmermann, S.-S. Wang, H. Zhang, T.-y. Lin, M. Malfatti, K. Haack, T. Ognibene, 
H. Yang, S. Airhart, K.W. Turteltaub, Molecular Cancer Therapeutics, 16 (2017) 376-387. 
[82] S. Wang, H. Zhang, T.M. Scharadin, M. Zimmermann, B. Hu, A.W. Pan, R. Vinall, T.-y. 
Lin, G. Cimino, P. Chain, PloS one, 11 (2016) e0146256. 
[83] L. Yang, A.-M. Ritchie, D.W. Melton, Oncotarget, 8 (2017) 55241-55260. 
[84] A. Sawant, A.M. Floyd, M. Dangeti, W. Lei, R.W. Sobol, S.M. Patrick, DNA repair, 51 
(2017) 46-59. 
[85] S.G. Awuah, I.A. Riddell, S.J. Lippard, Proceedings of the National Academy of 
Sciences, 114 (2017) 950-955. 
[86] R. Sabarinathan, L. Mularoni, J. Deu-Pons, A. Gonzalez-Perez, N. López-Bigas, Nature, 
532 (2016) 264. 
[87] P.O. Ongoma, D. Jaganyi, Transition Metal Chemistry, 39 (2014) 407-420. 
[88] M.A. Blum Murphy, W. Qiao, N. Mewada, R. Wadhwa, E. Elimova, T. Takashi, L. Ho, 
A. Phan, J. Baker, J. Ajani, American Journal of Clinical Oncology, 41 (2018) 321-325. 
[89] R.-D. Hofheinz, D. Arnold, E. Fokas, M. Kaufmann, T. Hothorn, G. Folprecht, R. 
Fietkau, W. Hohenberger, M. Ghadimi, T. Liersch, Annals of Oncology, (2018) 111-142. 
[90] T. Okuyama, S. Sameshima, E. Takeshita, R. Yoshioka, Y. Yamagata, Y. Ono, N. 
Tagaya, T. Noie, M. Oya, World Journal of Surgical Oncology, 16 (2018) 101-127. 
[91] B. Lippert, Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, John 
Wiley & Sons, (1999) 5-30. 
[92] N. Lamichhane, G.K. Dewkar, G. Sundaresan, L. Wang, P. Jose, M. Otabashi, J.-L. 
Morelle, N. Farrell, J. Zweit, Journal of Nuclear Medicine, 58 (2017) 1997-2003. 
  
42 
 
[93] F. Ponte, I. Ritacco, G. Mazzone, N. Russo, E. Sicilia, Inorganica Chimica Acta, 470 
(2018) 325-330. 
[94] C. Fong, Molecular Mechanisms of Cytotoxic Side Effects of Platinum Anti-Cancer 
Drugs–a Molecular Orbital Study (2014). 
[95] L. Oliveira, J. Caquito Jr, M. Rocha, Biophysical Chemistry, 241 (2018) 8-14. 
[96] Y. Mochida, H. Cabral, K. Kataoka, Expert Opinion on Drug Delivery, 14 (2017) 1423-
1438. 
[97] R.L. Coleman, M.F. Brady, T.J. Herzog, P. Sabbatini, D.K. Armstrong, J.L. Walker, B.-
G. Kim, K. Fujiwara, K.S. Tewari, D.M. O'Malley, The Lancet Oncology, 18 (2017) 779-791. 
[98] D.M. O’Malley, K.N. Moore, I. Vergote, L.P. Martin, L. Gilbert, A.G. Martin, K. Malek, 
M.J. Birrer, U.A. Matulonis, Hypertension, 3 (2017) 21-34. 
[99] Q. Miow, T. Tan, J. Ye, J. Lau, T. Yokomizo, J. Thiery, S. Mori, Oncogene, 34 (2015) 
1899. 
[100] J.K. Chan, M.F. Brady, R.T. Penson, H. Huang, M.J. Birrer, J.L. Walker, P.A. 
DiSilvestro, S.C. Rubin, L.P. Martin, S.A. Davidson, New England Journal of Medicine, 374 
(2016) 738-748. 
[101] A.E. Teschendorff, S.-H. Lee, A. Jones, H. Fiegl, M. Kalwa, W. Wagner, K. Chindera, 
I. Evans, L. Dubeau, A. Orjalo, Genome Medicine, 7 (2015) 105-156. 
[102] B. Thibault, L. Genre, C. Broca, M. Barbier, C. Zanna, G. Vuagniaux, J.-P. Delord, B. 
Couderc, in, AACR, (2015). 
[103] K. Barkat, M. Ahmad, M.U. Minhas, I. Khalid, Journal of Applied Polymer Science, 
134 (2017) 45310-45315. 
[104] A. Narmani, M. Kamali, B. Amini, A. Salimi, Y. Panahi, Process Biochemistry, 69 
(2018) 178-187. 
[105] P. Sundaramoorthy, T. Ramasamy, S.K. Mishra, K.-Y. Jeong, C.S. Yong, J.O. Kim, 
H.M. Kim, Acta Biomaterialia, 42 (2016) 220-231. 
[106] K. Rajpoot, S.K. Jain, Artificial Cells, Nanomedicine, and Biotechnology, 46 (2018) 
1236-1247. 
[107] A. Sigel, H. Sigel, Metal Ions in Biological Systems: Volume 32: Interactions of Metal 
Ions with Nucleotides: Nucleic Acids, and Their Constituents, CRC Press, (1996). 
[108] N. Farrell, Journal of Medicinal Chemistry, 32 (1989) 2240-2241. 
[109] N.H. Farrell, Miles P.; McCormack, John J.; DeAlmeida, Sergio G., in: W.I.P. 
Organisation (Ed.) The Patent Cooperation Treaty, United States of America, (1988) 1-23. 
[110] L.S. Hollis, W.I. Sundquist, J.N. Burstyn, W.J. Heiger-Bernays, S.F. Bellon, K.J. 
Ahmed, A.R. Amundsen, E.W. Stern, S.J. Lippard, Cancer Research, 51 (1991) 1866-1875. 
[111] S.F. Bellon, S.J. Lippard, Biophysical Chemistry, 35 (1990) 179-188. 
[112] C. Bauer, T. Peleg‐Shulman, D. Gibson, A.H.J. Wang, European Journal of 
Biochemistry, 256 (1998) 253-260. 
[113] P.A. Wangoli, G. Kinunda, New Journal of Chemistry, 42 (2018) 214-227. 
[114] D. Yang, S.S. van Boom, J. Reedijk, J.H. van Boom, N. Farrell, A.H.-J. Wang, Nature 
Structural and Molecular Biology, 2 (1995) 575-591. 
  
43 
 
[115] Y. Zou, B. Van Houten, N. Farrell, Biochemistry, 33 (1994) 5404-5410. 
[116] N. Farrell, Y. Qu, M.P. Hacker, Journal of Medicinal Chemistry, 33 (1990) 2179-2184. 
[117] C. Billecke, I. Malik, A. Movsisyan, S. Sulghani, A. Sharif, T. Mikkelsen, N.P. Farrell, 
O. Bögler, Molecular & Cellular Proteomics, 5 (2006) 35-42. 
[118] A.L. Harris, X. Yang, A. Hegmans, L. Povirk, J.J. Ryan, L. Kelland, N.P. Farrell, 
Inorganic Chemistry, 44 (2005) 9598-9600. 
[119] W.B. Dirersa, International Journal of Chemical and Pharmaceutical Analysis, 2 (2014) 
40-47. 
[120] N.P. Barry, P.J. Sadler, Pure and Applied Chemistry, 86 (2014) 1897-1910. 
[121] J. Geng, M. Aioub, M.A. El-Sayed, B.A. Barry, The Journal of Physical Chemistry B, 
121 (2017) 8975-8983. 
[122] D. Corinti, C. Coletti, N. Re, S. Piccirillo, M. Giampà, M.E. Crestoni, S. Fornarini, RSC 
Advances, 7 (2017) 15877-15884. 
[123] O. Vrana, V. Novohradsky, Z. Medrikova, J. Burdikova, O. Stuchlikova, J. Kasparkova, 
V. Brabec, Chemistry–A European Journal, 22 (2016) 2728-2735. 
[124] D.Y. Lando, C.-L. Chang, A.S. Fridman, I.E. Grigoryan, E.N. Galyuk, Y.-W. Hsueh, 
C.-K. Hu, Journal of inorganic biochemistry, 137 (2014) 85-93. 
[125] V. Brabec, O. Vrana, O. Novakova, J. Kasparkova, Chemical Communications, 52 
(2016) 4096-4098. 
[126] J.L. Kolanowski, L.J. Dawson, L. Mitchell, Z. Lim, M.E. Graziotto, W.K. Filipek, T.W. 
Hambley, E.J. New, Sensors and Actuators B: Chemical, 255 (2018) 2721-2724. 
[127] E. Wachter, A. Zamora, D.K. Heidary, J. Ruiz, E.C. Glazer, Chemical Communications, 
52 (2016) 10121-10124. 
[128] U. Kalinowska-Lis, J. Ochocki, K. Matlawska-Wasowska, Coordination Chemistry 
Reviews, 252 (2008) 1328-1345. 
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Chapter Two 
Kinetics and Mechanisms of Substitution Reactions of d8 Square-Planar Complexes : Theory and 
Instrumental Details  
 
2.1 Preamble 
Square planar is a molecular geometry in which constituent atoms or group of atoms 
surrounding a central atom form the corners of a square in the same plane with the central atom 
[1]. The geometry is mostly adopted by transition metal complexes of a d8 low spin 
configuration. Most common examples of metal ions that exhibit such configuration include: 
Au(III), Ni(II), Pd(II), Pt(II), Ir(I) and Rh(I).  Ligand substitution reactions of these metal ions 
play a fundamental role in most biological and chemical processes. For example, Ni(II) and 
Pd(II) complexes are employed in homogeneous catalysis while Au(III), Pt(II) etc. are useful 
in anticancer chemotherapy [2]. In anticancer therapy, drugs such as cisplatin are designed to 
inhibit tumour growth by substituting the chloride ligand with a guanosine base of DNA [3]. 
This process has been established to involve the formation of bonds as well as the breaking of 
bonds.  
The breaking and formation of covalent bonds during the interaction of electron-rich and 
electron-poor centres [4-6], often referred to as nucleophile–electrophile interaction, is one of 
the basic processes in chemistry. The nucleophile–electrophile interaction is the rationale that 
underpins the mechanism of reacting species. This process sometimes involves the substitution 
of an ion, an atom or a group of atoms from the functional site of the electrophile by the 
incoming nucleophile, a phenomenon known as ligand substitution reactions. Ligand 
substitution reaction occur when a ligand in a coordination sphere of a functional centre is 
replaced by another atom, a group of atoms or an ion resulting in a temporary change in the 
coordination number because of the breaking of bonds (with the leaving group) and the 
formation of new bonds (with the incoming species) [7]. Substitution reactions can be 
considered from two important perspectives: the electron rearrangement at the functional centre 
resulting from bond breaking and making processes; and the kinetics of the bond breaking and 
formation processes [8].  
The kinetics and mechanisms of d8 low spin metal complexes have been attracting a lot of 
attention from researchers in recent years [9]. Specifically, among the d8 metal ions listed 
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above, substitution reactions of platinum(II) complexes are the most extensively studied and 
well-established in medicinal inorganic research, essentially because of its redox stability and 
relatively slow reactivity [9-11]. Consequently, a great number of platinum complexes of 
specific design have been synthesised and investigated for their kinetic and mechanistic 
behaviour and preponderance of these studies are reported in literature annually [7, 12-15]. 
Moreover, the information obtained on platinum(II) complexes can be extrapolated to 
understand the behaviour of other d8-metal complexes since the mechanism of substitution 
behaviour of platinum(II) is similar to other square planar d8-metal complexes, most especially 
those of Pd(II) complexes. However, Pd(II) complexes are ca.105 more reactive than their 
corresponding platinum(II) complexes [9, 16]. In this chapter, kinetics, mechanisms as well as 
factoring influencing the substitution reactions of platinum(II) complexes will be examined. 
 
2.2 Mechanisms of Reactions at a d8 Square-Planar Metal Centre 
The mechanism of a reaction can be defined as the pathway by which reactants are transformed 
into products [17]. It sometimes involves the formation of intermediate species, usually in the 
first step, which are subsequently consumed in the other steps. In coordination chemistry, 
nucleophile-electrophile interactions form the basis of reaction mechanisms. The metal site of 
the complexes is the electrophilic centre while the incoming ligands are the nucleophilic agents 
[17, 18]. In general, the mechanism of ligand substitution reactions at a d8 square planar metal 
centre can be fundamentally classified into three namely: Associative, Dissociative and 
Interchange. 
 
2.2.1 Associative Mechanism (A) 
This mechanism involves the formation of a single intermediate through two transition states 
in which bond formation takes priority over bond breaking (Figure 2.1). In other words, the 
rate determining step is the one involving the formation of a bond between the metal centre and 
the incoming nucleophile. The associative mechanism type is the most common mechanism for 
coordinatively unsaturated metal complexes, such as square-planar complexes, a typical 
example of these are the platinum(II) complexes [19]. The reaction proceeds mostly via a five-
coordinate transition state with an intermediate with a trigonal bipyramidal structure. 
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Figure 2.1:  Energy profile and equation of ligand substitution reaction for an associative 
mechanism [20]. 
 
A case in point is when the entering group, Y, and the nucleofuge (leaving group), X, are 
equivalent in terms of their chemical composition, the energy of the transition states of the bond 
formation and breaking processes will be equivalent (Figure 2.2). In a non-coordinating solvent 
and when the concentration of Y is in excess, the rate of substitution will largely be determined 
by the character of the incoming nucleophile. The incoming group, Y is involved in both the 
initial and the final stages of the transition state but the spatial arrangement of the complex is 
maintained [12, 21]. 
 
Figure 2.2: A typical associative mode of ligand substitution at a square planar metal centre [22].  
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In a typical associative mechanism, all the participating ligand species, such as the chelate 
ligand, the leaving group and the incoming nucleophile can influence the activation energy and 
the stability of the reaction. This will, subsequently, impact the rate of the substitution reaction 
of the complex. Consequently, most ligand substitution reactions are carried out by varying the 
nature of the ligands [23]. 
During substitution, the electrophilic d8 square-planar platinum(II) metal centre usually 
undergoes an associative mechanism involving a five-coordinate, trigonal bipyramidal 
transition state which has eighteen electrons in the valence shell [24]. This is made possible 
because of the empty 6pz orbitals in the platinum(II) centre that can readily accommodate the 
extra electrons from the incoming nucleophiles [12, 15, 17]. Moreover, square-planar 
complexes are normally less crowded, hence, the incoming ligand can access the metal site both 
from above and below the plane, and still retain its geometry as shown in Figure 2.2. 
 
2.2.2 Dissociative Mechanism (D) 
This mechanism is normally displayed in metal complexes with an octahedral geometry. Most 
of the first-row transition metal series in the periodic table exhibit this mechanism during a 
substitution process because they have attained their saturated coordination number of six. 
Typically, the nucleofuge (the leaving group ligand) is lost in the first step, producing an 
intermediate with a reduced coordination number. The bond between the leaving group and the 
metal breaks completely before the nucleophile (incoming group) can attach itself to the metal 
centre. The intermediate formed during the bond breaking process usually have a lower 
coordination number. This allows the intermediate to selectively choose the potential ligands 
in the surrounding medium before it reacts with the incoming group [15]. The reaction rate of 
the electrophile with the incoming group is dependent on the character of the nucleofuge 
(leaving group) and is independent of the concentration and the nature of the incoming group. 
The nucleofuge moves from the coordination shell, which favours the solvent attack as the 
solvent is present in large access, hence, the product is formed while the leaving group is still 
in proximity.  A typical energy profile and equation of dissociative mode of substitution at a 
square planar metal centre is shown below in Figure 2.3. For square planar platinum(II) 
complexes, non-stereo specific products are formed through dissociative mechanism. During 
dissociative mechanism, the complex forms a T-shaped three coordinate intermediate, which 
undergoes intermolecular transformation of ‘cis-like’ configuration to form a ‘trans-like’ 
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configuration. The mechanism is rare for square-planar platinum(II) complexes because an 
increase of electron density at the platinum(II) centre generally prevents the approach of the 
nucleophiles and stabilisation of the coordinatively unsaturated 14-electron intermediate. 
However, a dissociative mechanism will be dominant for substitution at a square-planar metal 
centre under the following three conditions, viz. in the presence of very bulky ligands, good 
leaving groups and strongly coordinating solvent [15, 25, 26]. With regards to bulky ligands, it 
essentially forestalls the nucleophile from approaching the metal centre. 
 
Figure 2.3: Energy profile and equation of a typical ligand substitution reaction for a dissociative 
mechanism type [20]. 
 
Similarly, if the bond breaking between the metal centre and the leaving group dominates upon 
the approach of the nucleophile, a dissociative mechanism will be favoured. This is usually the 
case in the presence of strongly coordinating solvent because the solvent is in excess, it can 
easily facilitate the knock-off of the nucleofuge which results in the formation of the 
intermediate with a reduced coordination number. Unlike octahedral complexes, square-planar 
complexes essentially favour an associative mode of substitution, especially platinum(II) 
complexes. However, dissociative mechanisms have been reported in some square-planar 
complexes [25, 26]. 
  
2.2.3 Interchange Mechanism  
One major feature of the interchange mechanism is the absence of an intermediate (Figure 2.4); 
both the nucleofuge and the nucleophile are involved in the formation of a specie known as the 
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activated complex [20]. In this mechanism, for the single activated complex to be formed, 
formation between the metal centre and the incoming nucleophile, and bond breaking between 
the metal and the leaving group occur in concert. There is an interplay of two possible scenarios 
in an interchange mechanism.  
 
Figure 2.4: Energy profile and equation of a typical ligand substitution reaction for an interchange 
mechanism type [20]. 
 
Firstly, if the rate of reaction depends on the nature of the incoming nucleophile, since the rate 
limiting step involves bond formation between the incoming nucleophile and the metal centre 
in the transition state, then the phenomenon is known as an associatively activated interchange 
mechanism (Ia). In this case, the bond-breaking process is less important even though the two 
steps exist in concert leading to the formation of the single activated complex. Secondly, if on 
the other hand, the breaking away of the nucleofuge from the inner coordination sphere is 
initiated as the nucleophile begins to approach the inner coordination sphere (the reactive 
centre) from the outer coordination sphere, in which case, bond-breaking dominates over bond-
formation in the transition state, this is called a dissociatively activated interchange mechanism 
(Id). This mechanism, in most cases, is initiated by the surrounding solvent molecules since they 
are present in the reaction medium in excess relative to the concentration of the nucleofuge, 
even before the nucleophile is introduced into the reaction medium. Thus, the possibility of 
solvent molecules attaching itself to the reactive metal centre is very high, hence, there is no 
discrimination between the nucleophile and the solvent molecules.    
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2.3 Kinetic Measurements 
2.3.1 Determination of Rate Constants for Ligand Substitution Reactions 
It has been well-established in kinetic experiments that the rate of any reaction is dependent on 
the concentration of the reactants, operating temperature, pressure etc. The reaction rate and its 
corresponding rate constant can be determined by monitoring the concentration of one of the 
reactant or product species as a function of time. This is evaluated by following the time 
dependence of a variable which correlate with concentration and/or absorbance. For diluted 
solutions, the absorbance and concentration are directly proportional according to the Beer-
Lambert law [27]. Kinetic measurements of ligand substitution reactions of platinum(II) 
complexes are often performed by monitoring the change in absorbance at suitable wavelengths 
as a function of time [15]. Ideally, since all chemical reactions are reversible, these substitution 
reactions essentially do not go to completion but rather towards equilibrium and can be written 
as 
                       
where   A = metal complex (ML3X),     B = Incoming nucleophile Y,     
X = nucleofuge (leaving group),  
k2 = second-order rate constant for the attack of the incoming nucleophile  
k-2= second-order rate constant of the reverse reaction 
 
From the foregoing, the forward reaction is second-order while that of the reverse reaction is 
first-order [27]. The overall reaction, for both forward and backward processes, will display a 
mixed-order behaviour which often complicates the study. However, ligand substitution 
reactions for the forward reaction can be simplified by performing the study under pseudo first-
order conditions [27] in which the concentration of the incoming nucleophile is at least in a ten-
fold excess of that of the metal complex ([B]0 >>>[A]0) and the rate of formation of product C 
or the rate of disappearance of reactant A or B can be written as: 
  −
𝑑[𝐴]
𝑑𝑡
=  −
𝑑[𝐵]
𝑑𝑡
=  
𝑑[𝐶]
𝑑𝑡
=  𝑘2[𝐴]𝑡[𝐵]𝑡 −  𝑘−2[𝐶]𝑡                            (2.2) 
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 the mass balances at any time, t, can be expressed as:   
                                     [𝐴]𝑡 = [𝐴]0 − [𝐶]𝑡  𝑎𝑛𝑑 [𝐵]𝑡 = [𝐵]0 − [𝐶]𝑡                      (2.3) 
   At equilibrium, it can be written as: 
   [𝐴]𝑒 = [𝐴]0 − [𝐶]𝑒  𝑎𝑛𝑑  [𝐵]𝑒 = [𝐵]0 − [𝐶]𝑒                     (2.4) 
 Also, at equilibrium, the rates of the forward and the reverse reactions are equal, hence, 
                     −
𝑑[𝐴]
𝑑𝑡̅̅ ̅
= 𝑘2[𝐴]𝑒[𝐵]𝑒 − 𝑘−2[𝐶]𝑒 = 0                              (2.6) 
Therefore,             𝑘2[𝐴]𝑒[𝐵]𝑒 = 𝑘−2[𝐶]𝑒                        (2.7) 
Rearranging equation 2.4 and substituting it into equation 2.7, we have: 
    𝑘2[𝐴]𝑒[𝐵]𝑒 =  𝑘−2([𝐴]0 − [𝐴]𝑒)             (2.8) 
Expanding the equation,  we get:       𝑘−2[𝐴]0 = 𝑘2[𝐴]𝑒[𝐵]𝑒 +  𝑘−2[𝐴]𝑒               (2.9) 
Rearranging equation 2.3 and substituting it into equation 2.2 gives: 
   −
𝑑[𝐴]
𝑑𝑡
=  𝑘2[𝐴]𝑡[𝐵]𝑡 −  𝑘−2([𝐴]0 −  [𝐴]𝑡)            (2.10) 
Thus,         𝑘2[𝐴]𝑡[𝐵]𝑡 −  𝑘−2[𝐴]0 = 𝑘−2[𝐴]𝑡             (2.11) 
Combining equations 2.9 and 2.11, we obtain:  
  −
𝑑[𝐴]
𝑑𝑡
=  𝑘2[𝐴]𝑡[𝐵]𝑡 − 𝑘2[𝐴]𝑒[𝐵]𝑒 − 𝑘−2[𝐴]𝑒 + 𝑘−2[𝐴]𝑡            (2.12) 
Under pseudo first-order conditions when [B]0 >>>[A]0, equation 2.12 becomes 
  −
𝑑[𝐴]
𝑑𝑡
=  𝑘2[𝐴]𝑡[𝐵]0 − 𝑘2[𝐴]𝑒[𝐵]0 −  𝑘−2[𝐴]𝑒 + 𝑘−2[𝐴]𝑡           (2.13) 
Re-writing equation 2.13 gives  
   −
𝑑[𝐴]
𝑑𝑡
= (𝑘2[𝐵]0 +  𝑘−2)([𝐴]𝑡 −  [𝐴]𝑒)                            (2.14) 
Rearranging 2.14 and finding the integral of the resulting equation give: 
   ∫
𝑑[𝐴]
([𝐴]𝑡− [𝐴]𝑒)
[𝐴]𝑡
[𝐴]0
 =  −(𝑘2[𝐵]0 +  𝑘−2) ∫ 𝑑𝑡
𝑡
0
         (2.15) 
   ln (
[𝐴]𝑡− [𝐴]𝑒
[𝐴]0− [𝐴]𝑒
) =  −(𝑘2[𝐵]0 +  𝑘−2)𝑡          (2.16) 
 When 𝑘𝑜𝑏𝑠 =  𝑘2[𝐵]0 +  𝑘−2 , equation 2.16 will become: 
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   ln (
[𝐴]𝑡− [𝐴]𝑒
[𝐴]0− [𝐴]𝑒
) =  −𝑘𝑜𝑏𝑠 𝑡          (2.17) 
    Where kobs = observed first-order or observed pseudo first-order rate constant 
[B]0 = is the initial concentration of the nucleophile = [NU]. 
 
Hence, a linear graph is obtained from the plot of kobs against [NU] with a slope of k2 and an 
intercept of k-2. The equilibrium constant, K is evaluated from k2/k-2. K depicts the 
thermodynamic equilibrium position of the reaction [28, 29]. Figure 2.5 shows a typical plot 
obtained for the substitution reaction of tPt with neutral thiourea-based nucleophiles (where 
tPt is diaqua transplatin). 
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Figure 2.5: Pseudo first-order rate constants plotted as a function of the concentration of the 
entering nucleophiles for the substitution reaction of the diaqua tPt complex by 
thiourea (TU), dimethythiourea (DMTU), and tetramethylthiourea (TMTU) in water at 
298 K. 
 
The k2 is dependent upon the character and concentration of the incoming nucleophile (Figure 
2.5) [13, 15]. A plot which passes through zero implies that the forward reaction is irreversible 
and goes to completion. However, if there is a significantly positive intercept, this may be 
attributed to the reverse reaction or a parallel solvolysis reaction [13, 15, 24]. Some kinetic 
studies are performed in coordinating solvents [7], such as water, methanol etc., which are 
normally present in excess. In a situation where the contribution from the reverse reaction is 
negligible, then the k-2 term can be ascribed as a measure of the solvolysis pathway [12, 13, 17]. 
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In such cases, the k-2 pathway involves two sequential associative steps, viz. the rate-
determining step in which a solvent-metal complex bond is formed followed by the rapid 
substitution of the coordinated solvent molecule by the incoming nucleophile (Figure 2.6). This 
solvent associated pathway has been reported for the substitution kinetics of several square 
planar complexes [12, 18, 30-33]. This solvolysis pathway follows first-order kinetics and is 
hence independent of the concentration of the incoming nucleophile. The second pathway 
involves the direct nucleophilic attack by the incoming ligand, Y and so the k2 is sensitive to 
the nature of the incoming nucleophile. 
    𝑘𝑜𝑏𝑠 =  𝑘2[NU]       (2.18) 
  
Notably, all the kinetics of substitution reactions reported in chapter three to chapter six have 
the k-2 term to be negligible, hence, under pseudo first-order conditions the values of k2 can be 
calculated directly from Equation 2.18. 
                        
Figure 2.6:  A proposed dual reaction pathway for an associative substitution mechanism at the 
platinum(II) centre, where solv = solvent [22]. 
 
2.3.2 Activation Parameters  
The evaluation of rate constants as a function of temperature are ordinarily employed to 
determine the reactions’ activation parameters [12, 18, 33]. These parameters are pivotal in 
order to identify the mechanism of the reaction. Through the Transition State Theory, the 
enthalpy of activation (∆H#) and the entropy of activation (∆S#) are derived. In practice, to 
measure ∆H# and ∆S#, the observed second-order rate constant is measured at different 
temperatures. The third activation parameter, volume of activation, ∆V# is measured by varying 
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the pressure of the reaction medium. The activation parameters together with the second-order 
rate constants obtained can thus be used to postulate the mechanism of any reaction.  
  
2.3.2.1 Determination of Enthalpy of Activation, (∆H#) and Entropy of Activation, 
(∆S#) 
Both ∆H# and ∆S# of the reactions are normally obtained from the temperature dependence 
studies of their rate constants based on the transition state theory [24, 34]. According to this 
theory, it is assumed that many reactions between A (metal centre) and B (incoming 
nucleophile) proceed via a pre-equilibrium mechanism between the reactants and the transition-
state species (activated complex, AB#) before it is converted to the product C [26]. The 
mechanism is presented in equation 2.19. 
     (2.19) 
The rate law for the reaction above can be expressed as: 
  −
𝑑[𝐴]
𝑑𝑡
=  𝑘1[𝐴𝐵]
#      (2.20) 
At equilibrium, 
  K# = 
𝑘1
𝑘−1
=  
[𝐴𝐵}𝑒
#
[𝐴]𝑒[𝐵]𝑒
      (2.21) 
By rearranging, you get:  
  [𝐴𝐵}𝑒
# =  𝐾#[𝐴]𝑒[𝐵]𝑒      (2.22) 
Substituting equation 2.22 into equation 2.20 
  −
𝑑[𝐴]
𝑑𝑡
=  
𝐾𝑏𝑇
ℎ
𝐾#[𝐴]𝑒[𝐵]𝑒     (2.23) 
However,   −
𝑑[𝐴]
𝑑𝑡
=  𝑘2[𝐴]𝑡[𝐵]𝑡     (2.24) 
Comparing equations 2.23 and 2.24  
 ∴    𝑘2 =  
𝐾𝑏𝑇
ℎ
𝐾#       (2.25) 
Where  𝑘𝑏 = Boltzmann’s constant (1.38 x 10
−23J/K)  
h = Planck’s constant (6.626 x 10−34 J s) [27] 
 
60 
 
Expressing the pre-equilibrium constant, we have: 
  ∆𝐺# =  −𝑅𝑇 𝐼𝑛 𝐾#      (2.26) 
 
 ∆𝐺# = 𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 𝐺𝑖𝑏𝑏′𝑠 𝑓𝑟𝑒𝑒 𝑒𝑛𝑒𝑟𝑔𝑦 
  
But    ∆𝐺# =  ∆𝐻# −  T∆𝑆#          (2.27) 
 
By combining equations 2.25 and 2.26 gives: 
 
  𝐼𝑛 𝐾# =  −
∆𝐻#
𝑅𝑇
+  
∆𝑆#
𝑅
      (2.28) 
 
Substituting equations 2.28 into 2.25 gives the Eyring equation: 
 
  𝑘2 =  
𝐾𝑏𝑇
ℎ
𝑒−
∆𝐻#
𝑅𝑇 . 𝑒
∆𝑆#
𝑅       (2.29) 
 
Rearranging and taking the natural logarithm of both sides gives: 
 
  ln (
𝑘2
𝑇
) =  −
∆𝐻#
𝑅
.
1
𝑇
+ (ln
𝑘𝑏
ℎ
+ 
∆𝑆#
𝑅
)     (2.30) 
 
 
  ln (
𝑘2
𝑇
) =  −
∆𝐻#
𝑅
.
1
𝑇
+ (23.8 +  
∆𝑆#
𝑅
)    (2.31) 
 
 
The activation enthalpy, ∆𝐻# and entropy, ∆𝑆# values can be derived from a plot of ln(k2/T) 
versus 1/T which gives a linear graph with a negative slope (Figure 2.7). The activation 
enthalpy value can be calculated from this slope while the entropy of activation can be 
determined from the intercept on the vertical axis.  
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Figure 2.7: Plot of ln(k2/T) against 1/T for the reaction of diaqua tPt with the thiourea 
nucleophiles in water at various temperatures ranging from 293 to 313 K. 
 
 
The graph is literally referred to as the Eyring plot [35]. The magnitude of the two activation 
parameters can be employed to describe the mechanism of any substitution reaction. For an 
associative activated mechanism, the value of ∆𝐻# tend to be relatively small whereas that of 
∆𝑆# tends to be significantly negative. However, in a dissociative activated mechanism, the 
∆𝐻# value is normally large while that of ∆𝑆# will be positive [15, 36]. Oftentimes, when these 
activation parameters are used to predict the mechanism of a reaction, such inference are 
ordinarily made from the kinetic data derived from the substitution reaction of the metal 
complex with different nucleophiles. The drawback in using this method is that the activation 
entropy, ∆𝑆# is normally obtained from the intercept on the vertical axis of the graph by 
extrapolating the graph to indeterminable temperatures. Consequently, the attendant errors that 
accompany the determined ∆𝑆#values are customarily three times higher than that of ∆𝐻# [36]. 
Accordingly, it is more reliable to use the volume of activation, (∆𝑉#) in assigning a reaction 
mechanism. This is because ∆𝑉# is often calculated by measuring the bimolecular rate 
constants, k2 as the pressures of the reaction media are being varied. However, in order to make 
a meaningful description on the mode of activation, the sign and the magnitude of both the 
activation enthalpy and entropy are imperative.   
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2.3.2.2 Volume of Activation (∆𝑽#)  
The activation volume, ∆𝑉# is a more reliable parameter for describing the underlying 
mechanism of any reaction as compared to the use of enthalpy and entropy of activation alone. 
The volume of activation denotes the change in partial volume as the reaction proceeds from 
reactants to the transition state, in such a way that the volume profile of the reaction mixture 
can be analysed in terms of the changes in the overall volume of the reactants [37-39]. ∆𝑉#is 
derived from different observed rate constants, kobs, and determined at different applied 
pressures. Pressure dependence studies of the rate constants result in the volume of activation 
as outlined in the thermodynamic equation below. 
    ∆𝑉 =  (
𝛿∆𝐺
𝛿𝑃
)
𝑇
                         (2.32 ) 
But ∆𝐺# =  −𝑅𝑇 𝐼𝑛 𝐾# and by combining this with equation 2.32, it can be rewritten as 
 
              (
𝛿 ln 𝐾#
𝛿𝑃
)
𝑇
=  −
∆𝑉#
𝑅𝑇
      (2.33) 
  Where ∆𝑉#= the volume of activation and is equal to the difference between the 
partial molar volumes. 
Combining equations 2.25 and 2.33 gives: 
      𝛿 (
ln 𝑘2
𝛿𝑃
)
𝑇
 = −
∆𝑉#
𝑅𝑇
         (2.34) 
From equation 2.34, it can be deduced that if rate constant, k2 increases with increasing 
pressure, ∆𝑉# is negative. If on the other hand, ∆𝑉# has a positive value, this implies that there 
is a decrease in the second-order rate constant k2 as the pressure of the reacting mixtures 
increasing. 
Rearranging equation 2.34 and integrating both sides within the limits gives: 
 ∫ ln 𝑘2 =  −
∆𝑉#
𝑅𝑇
∫ 𝛿𝑃
𝑃
0
𝑘2
(𝑘2)0
      (2.35) 
 
 ln 𝑘2 =  ln(𝑘2)0 −  
∆𝑉#
𝑅𝑇
𝑃      (2.36) 
ln(𝑘2)0 = the rate constant at zero pressure  
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A linear graph with a negative slope of  
∆𝑉#
𝑅𝑇
 is derived from the plot of ln k2 verses P. The 
volume of activation, (∆𝑉#) is a combination of both an intrinsic contribution (∆𝑉𝑖𝑛𝑡
# ) due to 
changes in internuclear distances within the reactants to form the transition state and an 
electrostrictive contribution (∆𝑉𝑒𝑙𝑒𝑐
# ). For ligand substitution reactions involving charged 
species, the experimentally obtained ∆𝑉#is dominated by ∆𝑉𝑒𝑙𝑒𝑐
#  due to changes in charge that 
occur during the reaction. However, this is not case for solvent exchange reactions due to the 
absence of electrostrictive changes ∆𝑉# ≈ ∆𝑉𝑖𝑛𝑡
#  , the activation step for bond formation [27, 
37, 40]. Moreover, a positive value of ∆𝑉# implies a dissociative mechanism while a negative 
value indicates an associative mechanism. The errors associated with the volume of activation 
are relatively small compared to the entropy of activation because the activation volumes are 
determined from the slope of the graph. Therefore, a high pressure between 100 - 200 MPa is 
required to have a significant effect on the reaction rates.  
  
2.4 Instruments Employed in Kinetics Studies 
The performance of kinetic measurements often involve monitoring the dependence of a certain 
physical quantity, such as concentration, pressure, pH, conductivity, absorbance, density etc., 
as a function of time [27]. The concentration of the products or the reactants in the reaction are 
commonly a function of the physical parameter being measured. The values obtained from the 
kinetic measurement is then fitted into a suitable equation to determine the rate constant [12]. 
Different techniques, such as nuclear magnetic resonance (NMR), UV/Visible 
spectrophotometry and pulsed methods are used to investigate the rate of reactions [27, 28, 41]. 
The choice of instrument employed to monitor the reaction kinetics depends on the nature and 
rapidity of the reaction [42]. Irrespective of the technique employed, the measured physical 
property must be proportional to the concentration as a function of time after mixing. The 
reactants must be mixed within the shortest time possible depending on the reaction time scale. 
Physical conditions, such as temperature, pressure etc., must be accurately controlled. A 
chemical reaction is broadly considered as fast if it can attain half of the initial concentration of 
the reactant that is being monitored within 10 seconds [43]. Experimental determination of the 
rate constant of very fast reactions, such as proton transfer, enzymes and non-covalent complex 
formation [15] which are outside the limit of the classical laboratory time-scale are studied 
using specialised instruments. The time-scale for fast reactions varies between 1 minute to 10-
14 seconds [36]. Sometimes, fast reactions are investigated by bringing their rates into the 
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classical laboratory time-range by tuning the reaction conditions, such as temperature, 
concentration or the solvent. This method is only reliable if the half-life of the reaction is greater 
than 1 hour. Basically, the two main methods often used to study fast reactions include flow 
methods and pulse methods [44, 45].  
However, significantly slow reactions are usually studied using classical methods, such as 
UV/Visible spectrophotometry, which involves first mixing of the reagents first and then 
determining the decrease in the concentration of the reactant(s) or the increase in the 
concentration of the product(s) as a function of time. The mixing time for the starting reacting 
species and taken measurement should be negligible so that it does not impact on the actual rate 
of the reaction. Although there are several methods available for kinetic studies [15, 27, 42, 44, 
45], the UV/Visible spectrophotometry and the stopped-flow techniques are employed in this 
research project.  
  
2.4.1 UV/Visible Spectrophotometry  
Oftentimes, a slow substitution reaction, that is a reaction that lasts beyond 16 minutes, is 
followed using a UV/Visible spectrophotometer. UV/Visible spectrophotometry is a technique 
[17] which is sensitive enough to detect sample concentrations in the range 10-4 to 10-6 M [35]. 
The instrument consists of two light sources, one in the visible (tungsten lamp, for detection 
ranging from 800 to 350 nm) and the other in ultraviolet (deuterium lamp, for detection ranging 
from 350-200 nm), a monochromator, reference and sample compartments, temperature control 
unit, detector, the data processer and the output-readout system [46]. The detector that is 
commonly employed is a photomultiplier tube. In a UV/Visible spectrophotometer, radiation 
from the light source passes through a monochromator, then the light is dispersed by the grating 
prisms and the monochromator allows light of a single wavelength to pass through. The light 
with a single wavelength with intensity, I0, passes through the sample cell called a cuvette with 
length, l where the sample absorbs some light. Contemporary spectrophotometers are based on 
a double-beam design where it manages the light alternatively to pass through the sample cell 
and the reference cell using a chopper which is a motor that rotates a mirror into and out of the 
light path [46, 47]. The basic set-up of the UV/Visible spectrophotometer is presented in Figure 
2.8.  
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Figure 2.8:  Schematic diagram of a double beam UV/Visible Spectrophotometer [7].   
  
The extent of interaction of the sample with transmittance or absorbance is determined by 
measuring both the intensity of the incident transmittance or absorbance, I0 (without the sample) 
and the transmitted intensity, I (with the sample). The light transmitted from the sample is 
expressed as follows: 
   𝑇 =  
𝐼0
𝐼
       (2.37) 
 where I0 = the intensity of the incident light obtained from the solvent reference cell,
           I = the intensity of the transmitted light from the power source after passing 
through the sample cell 
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Absorbance can be expressed as  
  𝐴 =  − log 𝑇       (2.38) 
In ligand substitution kinetics, absorbance values are used instead of transmittance because 
there is a linear relationship between absorbance and two important parameters, the 
concentration of the reacting species and the path length of the cuvette, as stated by Beer-
Lambert’s law (equation 2.38). 
  𝐴 =  𝜀𝐶𝑙        (2.39) 
𝜀 = 𝑚𝑜𝑙𝑎𝑟 𝑎𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑣𝑖𝑡𝑦 (
M
cm
) , 𝐶 = 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (M)  
𝑙 = 𝑝𝑎𝑡ℎ 𝑙𝑒𝑛𝑔𝑡ℎ (𝑐𝑚) 
  
For any simple first-order process, 
       (2.40) 
The absorption at any time t, (At) is given as: 
 𝐴𝑡 =  𝜀𝑋[𝑋] + 𝜀𝑌[𝑌]       (2.41) 
where, At = the absorbance at any time, t, εX and εY = molar absorptivity of X and Y species 
respectively. 
If the reaction proceeds to completion, the absorption is given by: 
 𝐴∞ =  𝜀𝑋[𝑋]0 +  𝜀𝑌[𝑌]0       (2.42) 
 
where 𝐴∞ = absorbance upon completion of reaction, [𝑋]0 𝑎𝑛𝑑 [𝑌]0 = initial   
concentration of X and Y species respectively 
 
The kinetic analysis relating the optical absorbance to the first-order rate constant (equation 
2.38) can be obtained from the integrated rate-law given in equation 2.43. The absorbance-time 
resolved data in kinetic reactions are used directly to calculate the observed rate constants using 
equation 2.43. 
67 
 
  ln
[𝑋]0
[𝑋]𝑡
=  ln (
𝐴0 − 𝐴∞
𝐴𝑡− 𝐴∞
) =  𝑘𝑜𝑏𝑠𝑡     (2.43) 
 
In this study, relatively slow substitution reactions were performed on a Cary 100 Bio 
UV/Visible spectrophotometer with a cell compartment thermostated by a Varian Peltier 
temperature controller having an accuracy of ± 0.05 °C. UV/Visible scans were recorded at 
predetermined time intervals over the wavelength range of 200 to 800 nm immediately after 
mixing the reacting species. The obtained kinetic data were graphically analysed using the 
Origin 9.1® software suite [48] to give the kinetic trace with the time taken for the reaction to 
go to completion. The time obtained from the kinetic trace gave the observed first-order rate 
constant, kobs. It is pertinent to mention that the UV/Visible absorption spectroscopy is also used 
to carry out spectrophotometric titrations, especially in pKa determination experiments. The pKa 
values of the coordinated aqua ligand is an important thermodynamic set of data used to 
estimate the electrophilicity of the metal centre [49-55]. 
 
2.4.2 Flow Techniques 
Flow techniques are normally employed to investigate reactions that take place in milliseconds 
time scale. The mixing time in flow methods varies roughly from 1 millisecond to 10 seconds. 
These methods are used to monitor quite fast reactions with half-lives of about 10-2 seconds 
[42, 47]. Generally, flow techniques allow two reactant solutions to be rapidly mixed under 
pressure in a reaction mixing chamber. The changes in the concentrations of the reactants or 
products are then measured at various time intervals at different positions of the tube. The flow 
methods can be either continuous-flow or stopped-flow techniques. The design of the flow 
instrument is often associated with monitoring of reaction progress by UV/Visible 
spectrophotometry techniques in which equation 2.43 is used to calculate the observed rate 
constants. 
 
2.4.3 Continuous Flow Method 
A simple continuous-flow method, shown schematically in Figure 2.9. Continuous flow is 
applied when studying rapidly fast reactions, reactions within one second [36, 56]. In the 
continuous-flow method, two reacting solutions (A and B, Figure 2.9) are driven into the 
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mixing chamber by the pistons and the resulting solution then flows into the observation tube. 
This solution is then spectroscopically detected at a specific distance (d) from the mixer where 
a steady state is attained. One of the limitations of this technique is that it requires a large 
amount of reacting solutions. The use of the stopped-flow technique provides an alternative to 
overcome this limitation [27, 40].   
                         
Figure 2.9: Schematic diagram of a continuous flow kinetic system [22].  
 
2.4.4 Stopped-Flow Method  
The stopped-flow method (Figure 2.10) is commonly used as a tool in the investigation of 
mechanisms of molecular kinetic processes in the time range from milliseconds to hundreds of 
seconds. Throughout this research project, an Applied Photophysics SX.20 stopped-flow 
reaction analyser coupled to an online data acquisition system was employed to study the 
moderately fast reactions. The temperature of the instrument was controlled to within ± 0.1 °C.  
For experiments requiring the stopped flow technique, small volumes of solutions are rapidly 
driven from syringes by a compressed gas-driven piston (800 kPa) into a high efficiency mixer 
to initiate a fast reaction at a set temperature. The new reaction mixture is rapidly moved into 
an observation cell while the previous contents of the cell are flushed out. The volume of the 
respective reactants that is fed into the mixing chamber is limited by the stop syringe which 
provides the “stopped-flow”. The composition of the reaction mixture is then 
spectrophotometrically followed at a pre-set wavelength whereby the amount of light 
transmitted through the mixed solution undergo changes as the reaction proceeds in the 
stationary mixed solution. A photomultiplier unit converts the transmitted light into an electric 
current and a signal is fed to the computer over a suitable time range. The kinetic traces acquired 
under pseudo first-order conditions are then fitted to exponential functions to evaluate the 
observed pseudo first-order rate constant. Some examples of the stopped flow kinetic traces are 
shown in Figures 3.3, 4.3, 5.3 and 6.3 in Chapters Three, Four, Five and Six respectively. In 
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general, the stopped-flow technique is the most widely accepted technique for studying very 
fast reactions which have a half-life range of ca. 100 to 103 seconds [27, 40].  
                        
Figure 2.10 Diagrammatic representation of the stopped-flow [35].  
 
2.5 Factors Influencing the Reactivity at a d8 Square-Planar Platinum(II) 
Centre  
2.5.1 The Influence of Incoming Nucleophiles 
Several kinetic investigations have established that the associative mechanism of ligand 
substitution reactions in platinum(II) complexes depends on the nucleophilicity of the different 
incoming groups [12, 13, 15, 33, 35, 46]. The idea of nucleophilicity gives a quantitative 
measure of the ability of a Lewis base to act as an incoming group and to influence a reaction 
rate in a nucleophilic substitution process. The extent of nucleophilicity is established by 
determining the relative rate of the reaction of different nucleophilic groups with a standard 
substrate. In inorganic reaction mechanisms, the substitution reactions of trans-[Pt(py)2Cl2] in 
methanol solution is normally employed as the standard and the nucleophilicity factor is often 
expressed for Pt(II) complexes in terms of nPt index given by equation 2.44 [57].   
   𝑛𝑃𝑡 = log
𝑘2
𝑘−2
       (2.44) 
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where k2 = the rate constant for the reaction of the incoming nucleophile, k-2 = the rate constant for 
solvent attack (methanol) 
 
Several studies on the platinum(II) complexes have reported the order of nucleophilic 
reactivity as follows [58, 59]: 
 𝑅3𝑃˃ 𝑇𝑈 >  𝑆𝐶𝑁
− >  𝑁3
−  >  𝑁𝑂2
− >  𝐵𝑟− > 𝑃𝑦 > 𝐴𝑛𝑖𝑙𝑖𝑛𝑒 ~ 𝑁𝐻3 ~ 𝐶𝑙
−  > 𝐻2𝑂 >  𝑂𝐻
− 
The nucleophilicity index, nPt obtained is applicable to other Pt(II) systems according to the 
expression given in equation 2.45 [60, 61]. 
 log 𝑘2 = 𝑆(𝑛𝑃𝑡) +  log 𝑘−2         (2.45) 
The equation above indicates that for a specific substrate except for complexes with π acceptor 
ligands, there is linear free energy relationship between log k2 for a certain nucleophile and 
nucleophilicity index, nPt value (Figure 2.11). The substrates with π-acceptor ligands are 
exceptions because they can form metal-ligand π-bonding at the transition state thereby 
lowering the energy of the transition state. This also depends on the π-donor ability of the metal 
complex which makes some nucleophilic species to be more reactive towards some better π-
donor metal complexes or less reactive to certain complexes. The slope S of the plots in Figure 
2.11, is the nucleophilic discrimination factor and the intercept log k-2 , is the intrinsic factor. 
The former is dependent on the nature of the complex and is a relative measure of its ability to 
discriminate between the various incoming nucleophiles. 
 
Figure 2.11: Plots of log k2 against nPt  for the determination of the nucleophilic discrimination 
factor, S of Pt(II) complexes [30]  where: NNC = [Pt(N−N−C)Cl] (N−N−CH = 6-
phenyl-2,2’-bipyridine), NCN = [Pt(N−C−N)Cl] (N−CH−N = 1,3-di(2-
pyridyl)benzene), and NNN = [Pt(N−N−N)Cl]Cl (N−N−N = 2,2’:6’,2’-terpyridine). 
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A large value of S implies that the complex is very sensitive to changes in the nature of the 
nucleophilic reagent. The magnitude of k-2 is a function of the "intrinsic" reactivity of the 
platinum complex with the poorest nucleophilic reagent whose effect can be measured in any 
solution [61]. With such a poor nucleophile, the complex is expected to drive the reaction to 
the activated complex of the reaction. If on the other hand, the value of k-2 is small, the tendency 
of the complex to react is minor and will rely more on the nucleophile. It is pertinent to recall 
that nucleophilicity is a kinetic term which, in most cases, correlated with the polarizability of 
the incoming ligand, basicity and the nature of the substituent on the ligand. 
 
2.5.1.1 Polarizability of the Nucleophile 
It is widely accepted that polarizable molecules and ions, such as thiourea, iodide ion and 
unsaturated systems are more nucleophilic than their basicities can afford [62]. For neutral 
nucleophiles, size dictates the nucleophilicity and this is because larger elements have a bigger, 
more diffuse and more polarizable electron density. This electron density enhances the 
formation of a more effective orbital overlap in the transition state of bimolecular nucleophilic 
substitution reactions, which results in a transition state that is of lower energy and a 
nucleophilic substitution that take place at a faster rate. This is also corroborated by the hard 
and soft acid-base theory. “Hard” nucleophiles preferentially favours “hard” metal centres 
whereas “soft” nucleophiles prefer “soft” substrates or metal centres [15]. The term soft 
nucleophiles refer to the relatively polarizable nucleophiles while hard nucleophiles allude to 
relatively non-polarizable. Like soft bases, soft nucleophiles have high HOMO energy thereby 
making them to be effective as nucleophiles [5, 63, 64]. In solution, polarizable nucleophiles 
are superior to non-polarizable nucleophiles because they can respond easily to the demand for 
charge reorganisation. For ionic nucleophiles, the polarizability of the nucleophilicity follows 
the order 𝐼− >  𝐵𝑟−  >  𝐶𝑙− >  𝐹−. This polarizability order explains the trend in reactivities 
of the ionic nucleophiles as reported in a number of kinetics studies [65, 66]. 
 
2.5.1.2 Basicity of the Nucleophile 
Basicity has a vital role in determining the nucleophilic reactivity toward Pt(II) complexes [62, 
65, 67]. As already observed in the cases of Pd(II) complexes [68], the reactivity of platinum(II) 
complexes is linearly related to the basicity of the incoming nucleophiles [69, 70]. Pitteri et al. 
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[70] observed that for a reversible substitution reaction, there is a relatively large dependence 
of reactivity upon the basicity of the nucleophile in the reverse process as compared to the 
forward reaction. The observation indicates that the formation of the transition state involves a 
structure containing a well-formed Pt–X and a weak Pt–Nu, where X and Nu are leaving group 
and the incoming nucleophile respectively. In general, the relationship between basicity of the 
nucleophiles and the rate constant of a given substitution reaction can be described by equation 
2.46. 
  log 𝑘2 = 𝛼(𝑝𝐾𝑎) +  𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡      (2.46) 
A straight line graph is obtained from the plot of log k2 versus pKa with the slope of α, which 
denotes the ability of the Pt(II) centre to screen the incoming ligands of different basicity [60, 
61]. The positive slopes imply an increase in the electron density around the reactive metal 
centre which is typical of an associative mode of substitution behaviour. The negative slope is 
an indication of the solvolytic reverse reaction [71, 72]. 
  
2.5.2 The Character of Non-participating Groups in the Complex 
2.5.2.1 Trans Effect 
The idea of the trans effect was introduced by Chernyaev in 1926 to elucidate on the empirical 
observation that the rate of substitution of a ligand in a square planar or octahedral metal 
complex depends on the group trans to it much more so than groups in cis positions [18]. 
Following this discovery, the kinetics of many other systems have been rationalised using the 
trans effect [51, 73]. The trans effect can be best described as the effect of a coordinated ligand 
upon the rate of substitution of ligands opposite to it. The ligand trans to the leaving group can 
influence the reaction rate by several orders of magnitude between105-106 [74]. 
Generally, the substitution rate of the leaving group by the incoming group is faster if the trans 
ligand is a strong σ donor or a good π-acceptor [75]. However, relatively hard pure σ- donors, 
such as NH3, H2O and OH
- have a weak trans-directing effect. This clear contradiction appears 
to imply that there is another factor responsible to trans directing of substitution and this is the 
trans influence. Trans influence is the degree to which a ligand weakens the bond that is trans 
to itself. This is completely a thermodynamic effect and manifests itself as changes in bond 
lengths, force constants and vibrational frequencies [76]. For instance, for a series of trans-
metal complexes if a trans ligand T is changed, the M- X bond length is very sensitive to the 
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electronegativity of T (where T, M and X stands for trans ligand, metal centre and leaving 
group respectively). If the electronegativity of the ligand that is trans to the leaving group, X 
decreases, the distance M- X increases. This increase in length results from a weakened bond 
in the ground state and leads to the increase in the reactivity of the association process. 
Basically, the structural trans influence follows the order:  
 𝐻− > 𝑅3𝑃 ˃ 𝑆𝐶𝑁
− >  𝐼− >  𝐶𝐻3~ 𝑂𝑙𝑒𝑓𝑖𝑛𝑠 ~ 𝐶𝑂 ~ 𝐶𝑁
− > 𝐵𝑟− > 𝐶𝑙−  >  𝑁𝐻3 >  𝑂𝐻
− 
 
2.5.2.2 σ-Donation Trans Effect 
Based on the polarization theory, the trans effect is considered to be predominantly electrostatic 
in origin and transmitted through σ-bonds, also known as σ-trans effect [76]. In the ground state 
and in square planar complexes, such as Pt(II), strong σ-donor ligands donate electrons very 
efficiently to the metal via σ-bonds. The efficient sigma donor capability can be attributed to 
their good overlap with the metal orbital which results in an interaction thereby lowering the 
overall energy (Figure 2.12). In other words, if the trans ligand is a strong σ-donor, the metal’s 
p-orbital bonds more preferentially with it than the ligand trans to it. This results into elongation 
and weakening of the M-X bond while strengthening the M-T bond (Figure 2.13). In 
substitution reactions, the weak bond will break easily thereby leading to the increase in the 
substitution rate. 
 
 
Figure 2.12:  Sketch showing the effect of a σ-donor trans ligands on energies of ground state and 
transition state of a square-planar platinum(II) complex. TS = transition state [77-79]. 
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The σ-trans effect order which is approximately the order of decreasing polarizability of the 
ligands is [12, 15]: 
𝐻− > 𝑅3𝑃 ˃ 𝑆𝐶𝑁
− >  𝐼− >  𝐶𝐻3 >  𝐶𝑂 >  𝐶𝑁
− > 𝐵𝑟− > 𝐶𝑙−  >  𝑁𝐻3 >  𝑂𝐻
− 
Since the polarizability of the metal ion is important, this theory readily accounts for the 
observation that the trans effect is greatest in the most polarizable or softest platinum(II) 
complexes than those of Pd(II). 
 
Figure 2.13: Sigma-bonding effect [60]. (a) Strong sigma-donor ligand T , the sigma-bond strength 
of M-T is much greater than that of M-X , (b) weak sigma-donor trans ligand gets 
poorer overlap with the metal orbital 
 
Particularly, as electrons are donated from the filled ligand orbital to the vacant metal orbital, 
this kind of interaction will diminish the total (positive) natural bonding order (NBO charge) of 
the platinum(II) centre due to an increase in electron density in the xy plane. An increase in the 
rate of substitution reaction in platinum(II) complexes as a result of the trans σ-donation effect 
was reported in previous studies [80, 81]. 
 
2.5.2.3 π-Back-Donation Trans Effect 
In the π-trans effect theory for d8 square-planar complexes, such as platinum(II) [75] the 
trigonal bipyramidal intermediate can be stabilised by removing the electron density from π-
orbitals of the incoming group Y (via metal d orbitals) to π-acceptor orbitals of the trans ligand 
T (Figure 2.14) [82]. This electronic communication through π-bonding is only possible if the 
three ligands and the metal centre all lie in the same plane in the transition state thereby 
enhancing effective delocalization of the extra charge from the metal. Pi-back bonding also 
favours low energy of the transition state resulting in a low activation energy for the substitution 
reaction (Figure 2.15) [83]. Calculation of the overlap of the valence orbitals of several ligands 
with the platinum 6pπ orbital presupposes a pi-trans effect order of increasing nucleophilicity 
[12, 15, 18, 36, 83]: 
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 𝐶2𝐻2 ≈ 𝐶𝑂 > 𝐶𝑁
− > 𝑁𝑂2
− >  𝑆𝐶𝑁− >  𝐼− > 𝐵𝑟− > 𝐶𝑙−  >  𝑁𝐻3 >  𝑂𝐻
− 
The overall trans effect trend combines both σ- and π-trans effects as follows [ibid.]: 
𝐶2𝐻2 ≈ 𝐶𝑂 > 𝐶𝑁
− > 𝑅3𝑃 > 𝐻
− > 𝐶𝐻3 ≈ 𝑆𝐶𝑁2𝐻4> 𝐼
− > 𝐵𝑟− > 𝐶𝑙−  >  𝑃𝑦, 𝑁𝐻3 >  𝑂𝐻
− >  𝐻2𝑂 
 
 
Figure 2.14: Schematic diagram of the π-bonding mechanism for the trans-effect [18]. 
 
 
Figure 2.15: Trans effect on activation energy [19]. 
 
π-Acceptor groups, unlike σ-donor groups, increase the total NBO charge of the platinum(II) 
atom by decreasing the electron density in the xz plane through π-back-donation. It also 
enhances a nucleophilic attack in the xz plane thereby stabilising the corresponding penta-
coordinated transition state [84]. Systematic adjustment of the position of π-acceptor groups 
(cis/trans) affects the electronic communication in the system, thus, has an effect on the 
reactivity of the platinum(II) centre with cis π-back bonding found to be stronger than trans π-
back bonding [85]. Until recently, it was widely acknowledged that an increase in π-surface and 
hence π-acceptor properties in a system enhances the nucleophilic substitution process of 
platinum(II) complexes [66, 86-88]. However, in a recent study [66], it was observed that an 
increased π-surface of isoquinoline does not accelerate the rate of substitution reactions but 
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rather it decelerates the reactivity by a magnitude of three mainly because the isoquinoline is a 
net σ-donor.  
2.5.2.4 Cis Effect 
The ligand that is cis to the nucleofuge exerts a veritably small electronic effect. This effect 
becomes prominent only when the nucleophile is poor in terms of its donor capacity. This effect, 
however, becomes significant when the cis ligands are big which preclude the incoming 
nucleophile from accessing the axial position of the metal centre [89, 90] and sometimes, bring 
about a mechanistic change from an associative to a dissociative mechanism. This is made 
possible because, in associative ligand substitution reactions, a trigonal-bipyramidal transition 
state is greatly strained by cis blocking but not nearly so crowded by trans blocking. Reports in 
literature reveals that cis blocking causes the relative drop in the rate of reaction by a factor of 
thousands compared to trans blocking [91]. Besides the cis steric hindrance, the cis σ- donor 
effect also increases the electron density at the metal centre and slows down the reactivity of 
the platinum(II) complex [92]. Unlike the cis σ- donor effect, the cis π-effect reduces electron 
density at the platinum(II) centre thereby accelerating its reactivity. 
 
2.5.3 Role of the Leaving Group 
The role of the leaving group on the rate of the substitution reaction is dependent on the 
following: nature of the reaction centre, nature of incoming nucleophiles and the nature of the 
trans ligand [38]. Hence, it will be inappropriate to make a clear-cut general trend. For 
complexes in which leaving group effects occur, it is presumed that bond breakage of the five-
coordinate intermediate produced during an associative mode of substitution may considerably 
contribute towards the observed kinetic variables and may even be the rate-determining step 
under rigorous conditions, such as strongly bonded leaving groups [76]. A set of reactions 
which have been employed to investigate the role of the leaving group effect on the substitution 
kinetics of square planar complexes is given in equation 2.47 below [7]. 
  
In the study above, the strongly complexing dien ligand has rendered the three other 
coordination positions and the incoming ligand (NU) that most often used is pyridine (py). The 
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reaction rates obtained in aqueous solution are given in Table 2.1 and the rate constant for the 
displacement of X decreases in the order [76]: 
 𝑁𝑂3
− >  𝐻2𝑂 > 𝐶𝑙
− > 𝐵𝑟− >  𝐼− >  𝑁3
− >  𝑆𝐶𝑁− >  𝑁𝑂2 >  𝐶𝑁
−    
 
Table 2.1:  The role of the leaving group on reaction rate of platinum(II) complexes in water at 
 298 K [ibid.]. 
                                  
 
A considerable difference in the relative rates of different leaving groups observed reveals that 
a substantial perturbation of the Pt-X bond in the transition state does not lead to a dissociation 
process but only requires the Pt-X bond breaking a significant contribution comparable to that 
of Pt-py bond forming. Needless to say, the leaving groups high in the trans-effect series are 
substituted at a slower rate. This is in good agreement with the combined σ- and π-trans-effect 
theory which presupposes that good trans-effect groups will be strongly bonded to the metal. 
An opposite case scenario, that a poor trans labiliser is readily replaced need not be true. The 
hydroxyl ion, for instance, is a very poor trans labiliser, it is, however, very difficult to 
substitute. The same is true for the ammine ligand [12, 18, 93]. Basically, groups which best 
stabilise a negative charge are the best leaving groups, example of such are the weakest bases 
they are very stable anions and are, thus, the best leaving groups. 
 
2.5.4 Effect of Solvent 
Serving as the reaction medium in which the reaction occurs, the solvent may, in some cases, 
compete with the incoming nucleophile and rapidly substitute the nucleofuge thereby rendering 
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the reaction rate to be independent of the concentration of incoming nucleophile. This has been 
reported for substitution reactions of platinum(II) complexes proceeding through the solvent 
pathway [32, 67]. The effect of the solvent used in substitution kinetics of square-planar 
complexes in the overall reaction rate depends on the coordination capability of the solvent [7, 
12]. This effect has been experimentally studied for the chloride exchange reaction for trans-
Pt(py)2Cl2 as shown in equation 2.48, Table 2.2. 
 
 
 
Table 2.2:    Chloride Exchange Reaction: The Effect of Solvent at 298 K [94].
 
 
The results obtained indicate that the reactions in strongly coordinating solvents often proceed 
through a solvolysis pathway. The concentration of the chloride ligand influences the solvolysis 
pathway. However, for the weakly or non-coordinating solvents, the opposite is true. The rates 
of the reaction in coordinating solvents, such as DMSO etc., showed a direct dependence on 
the nucleophilicity of the solvent, (𝑘𝑠 ≫ 𝑘𝐶𝑙[𝐶𝑙
−]). This is also because the soft platinum(II) 
site preferentially coordinate to the large sulfur atom in DMSO. For poorly coordinating (or 
non-coordinating) solvents, such as CCl4, larger reaction rates have been reported by Romeo et 
al., when the chloride ion acts as the nucleophile (𝑘𝐶𝑙[𝐶𝑙
−] > 𝑘𝑠) [18, 26, 95]. The Lewis acidity 
of the solvent and reactivity often predicted via linear free energy relationships between 
different parameters is believed to be a function of the solvation of the incoming nucleophile. 
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2.5.5 Effect of Steric Hindrance 
In an associative mechanism, the transition state of ligand substitution reactions is more 
crowded than the ground state because there is a total of five groups around the reactive centre. 
Consequently, the steric bulk and the size of the incoming nucleophile can play a dominant role 
to determine the rate of the substitution process. Moreover, the effect of steric hindrance on the 
reaction rate can be either because of the steric demand in the inert ligand or in the incoming 
nucleophile. Likewise, an increase in the steric demand of the inert ligands often retard the rate 
of substitution. Steric hindrance not only slows down the associative attack of a bulky 
nucleophile but also sometimes have a remarkable effect on the nature of the substitution 
mechanism. This presupposes that steric effects are more dominant than electronic effects [14]. 
Studies have shown that steric barriers due to methyl and ethyl substituents on the tridentate 
(Rndien) ligands retard the substitution rate of [Pd(Rndien)Cl]
+ complexes by a factor of 5 on 
increasing the size of the substituent, R, as compared to the complex that is less sterically 
hindered (Table 2.3).  
 
Table 2.3: Rate constants and activation parameters for the substitution of chloride ions by iodine 
ions in [Pd(Rndien)Cl]+ in water at 298 K (n = 0. 3-5) [94]. 
 
A similar trend is expected to be followed by the complexes with a platinum(II) centre, even 
though, this has not yet been studied extensively. The successive experimental chapters of this 
thesis clearly demonstrate that increasing the steric bulk of the spectator ligands and of the 
incoming nucleophiles, such as neutral thiourea-based nucleophiles, respectively decreases the 
substitution rate in all the investigated trans-platinum(II) complexes. However, no alteration in 
mechanism due to steric hindrance is reported in this study. 
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Chapter Three 
A Kinetic and Mechanistic Study of Analogous Bifunctional Dialkylamine Platinum(II) Complexes 
 
Abstract 
This study was aimed at investigating the comparative substitution behaviour of analogous cis/trans-
Pt(II) complexes with dialkylamine inert ligands. The rate of substitution of aqua ligands by three 
nucleophiles: thiourea (TU), 1,3-dimethylthiourea (DMTU) and  
1,1,3,3-tetramethylthiourea (TMTU), for the complexes: [cis-Pt(OH2)2(NH3)2](ClO4)2 (cPt),  
[cis-Pt(OH2)2(NH2CH3)2](ClO4)2 (cPtM), [cis-Pt(OH2)2{NH2CH(CH3)2}2](ClO4)2 (cPtR),  
[trans-Pt(OH2)2(NH3)2](ClO4)2 (tPt), [trans-Pt(OH2)2(NH2CH3)2](ClO4)2 (tPtM) and  
[trans-Pt(OH2)2{NH2CH(CH3)2}2](ClO4)2 (tPtR) was investigated under pseudo first-order 
conditions as a function of concentration and temperature by stopped-flow and UV/Visible 
spectrophotometry. The reactions of the cis-complexes proceeded in two concerted steps whereas 
those of the trans-complexes followed a single step. The cis-complexes followed second-order 
kinetics with respect to each complex and nucleophile whilst the trans-analogues proceeded by first-
order kinetics. The pseudo first-order rate constants, kobs obeyed the rate law:  
kobs = k2[nucleophile]. The trans-complexes were observed to be approximately 10
3 more reactive 
than their corresponding cis-analogues. The electronic and the steric hindrance due to the geometries 
of the complexes control the overall reaction pattern. The order of reactivity of the complexes is tPt 
> tPtM > tPtR > cPt > cPtM > cPtR. The reactivity of the nucleophiles with the complexes decreases 
with an increase in steric demand in the order: TU > DMTU > TMTU. The trans-dialkylamine 
complexes formed distinctly different kinetic products relative to their  
cis-analogues. 195Pt NMR spectroscopic results confirmed the final kinetic products of each of the 
cis- and trans-complexes. The negative entropy of activation (ΔS≠) values in all the complexes 
investigated assert an associative substitution mechanism, with the mechanism being more 
pronounced in the cis-complexes than in their trans-analogues. 
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3.1 Introduction 
The fortuitous revelation of cis-diamminedichloroplatinum(II), cisplatin, as an anticancer agent has 
galvanised interest in medicinal inorganic chemistry research in the last five decades with many more 
platinum-based chemotherapeutics being developed [1, 2]. The finding ab initio, that the trans-isomer 
of cisplatin lacked any biological activity influenced the early structure–activity relationships that a 
cis geometry of the two leaving groups is crucial for the biological activity of platinum-based 
anticancer agents [2-7]. Consequently, all trans-platinum complexes were presumably thought to be 
impotent as antitumour drugs. 
 
However, it has been suggested that the cytotoxic potential of trans-platinum complexes could be 
greatly enhanced by bulky spectator monodentate amine ligands. Farrell et al. have reported that some 
trans complexes with general formula [PtCl2L2] showed significant cytotoxities when L is a planar 
heterocyclic ligand such as pyridine or thiazole [3]. Similarly, Navarro-Ranninger et al. have reported 
a new class of biologically active trans-platinum(II) complexes with asymmetric aliphatic amines, 
trans-[PtCl2(L)(L′)] [8]. These discoveries have revolutionized the development of new platinum-
based anticancer agents because these trans-platinum compounds exhibited significantly high 
cytotoxicities, both in vitro and in vivo, against cisplatin resistant tumour cell lines. Hence, their 
pharmacodynamics may, however, be much more complex and completely different relative to that 
already established for cis configured platinum(II) complexes [7]. Efforts to further understand the 
mechanism of action of cis-configured platinum(II) complexes have been ubiquitous. 
 
Moreover, the kinetic and mechanistic study of substitution of platinum(II) complexes with cis 
configurations has been well established.  Both Jaganyi et al. [9-12] and van Eldik et al. [13] have 
reported that the substitution behaviours of platinum(II) complexes of cis configuration with thiol-
based nucleophiles undergo dechelation to give two or more thiourea-substituted platinum(II) 
complexes in a two or more step process. Nonetheless, the substitution kinetics and mechanism of 
platinum(II) complexes in which the chloride leaving groups are trans to each other on the platinum 
centre is still relatively unknown.  
 
Song et al. [14] recently reported that there is a possibility of transformation in transplatin to cisplatin 
under UVA irradiation. Their findings are based on the fact that transplatin, which was observed to 
be veritably non-toxic in the dark to all cell lines, was found to be of comparable toxicity with 
cisplatin under UVA irradiation. The authors attribute this observation, among other things, to the 
transformation of transplatin to cisplatin under UVA light. However, Brabec and co-workers [15] 
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have demonstrated through NMR spectroscopy that the loss of chloride ligands of transplatin upon 
irradiation resulted in the formation of bifunctional adducts and subsequently led to the remarkable 
increase of its toxicity level in cancer cells. They debunked the claim that transplatin is transformed 
to cisplatin under UVA irradiation by using three independent methods after which they concluded 
that transplatin upon UVA irradiation does not rearrange to its cis isomer. 
 
In order to further the understanding of the mechanistic behaviours of these platinum(II) complexes, 
analogous cis and trans-dialkylamine dichloroplatinum(II) complexes of the general form, [PtX2L2], 
were investigated (see Figure 3.1). Our central aim is to ascertain how bifunctional trans-platinum(II) 
complexes will substitute kinetically relative to their cis isomers by using bio-relevant thiourea-based 
nucleophiles such as, thiourea (TU), 1,3-dimethyl-2-thiourea (DMTU) and 1,1,3,3-tetramethyl-2-
thiourea (TMTU).  
 
     
           cPt                cPtM               cPtR 
    
             tPt                   tPtM                 tPtR 
 
Figure 3.1: Structures of the studied cis-platinum(II) complexes and their trans-analogues. The charges and 
counterions on the complexes have been omitted for the sake of clarity. 
 
3.2 Experimental 
3.2.1 Chemicals and Reagents 
Methylamine hydrochloride (ma), isopropylamine (ipram) (99.5%), K2PtCl4 (98%), cis-
[Pt(NH3)2Cl2] (99.9%), trans-[Pt(NH3)2Cl2], KOH, AgClO4 (97%), NaClO4
.H2O (98%), HCl (32%) 
and HClO4 (70%) were purchased from Sigma-Aldrich and were used without further purification. 
The nucleophiles: thiourea (TU, 99%)), 1,3-dimethyl-2-thiourea (DMTU, 99%) and 1,1,3,3-
tetramethyl-2-thiourea (TMTU, 98%) used for the kinetic determinations were also obtained from 
Sigma-Aldrich. All preparations of aqueous solutions were done using ultrapure water. 
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3.2.2 Synthesis of Complexes 
3.2.2.1 General Procedure for the Synthesis of cis-Pt(amine)2Cl2  
The chlorido complexes cis-[Pt(ma)2Cl2](cPtM) and cis-[Pt(ipram)2Cl2] (cPtR) were synthesised 
according to literature procedures reported by Messori et al. [2] and Pantoja et al. [16] with slight 
modifications. K2PtCl4 (500 mg, 1.2 mmol) was dissolved in water (5 mL) and treated with  
KI (1 g, 6 mmol) at room temperature to produce a dark brown solution of K2PtI4 after 15 minutes of 
stirring.  
 
The iodo derivative of cis-[Pt(ma)2Cl2] (cPtM) was first prepared by slowly adding four equivalents 
of methylamine hydrochloride (4.8 mmol) to the dark brown solution of K2PtI4. The mixture was 
subsequently treated with four equivalents of KOH (269 mg, 4.8 mmol) in the dark at room 
temperature. After the addition was completed, the reaction mixture was stirred in the dark at room 
temperature for five hours to give a yellow precipitate, cis-[Pt(ma)2I2]. The precipitate was obtained 
by filtration, washed thoroughly with warm water, diethyl ether and air dried. 
 
To prepare the iodo derivative of cis-[Pt(ipram)2Cl2] (cPtR), four equivalents of isopropyl amine 
(4.80 mmol) was added slowly to the dark brown solution of K2PtI4. The resulting mixture was stirred 
five hours at room temperature to produce a yellow precipitate, cis-[Pt(ipram)2I2], which was filtered, 
washed intensively with warm water, diethyl ether and allowed to dry by air. 
 
The iodo complexes were converted to their chlorido analogues by suspending the iodo complexes, 
viz. cis-[Pt(ma)2I2] (441 mg, 0.864 mmol) /cis-[Pt(ipram)2I2] (585 mg, 1.03 mmol), in 10 mL of water 
and treated with 1.9 equivalent AgClO4. The mixture was stirred overnight in the dark. A yellow 
precipitate of AgI was removed by filtration through a 0.45µm nylon membrane and to the filtrate, 
four equivalents of KCl was added and stirred at 40 °C for six hours. The resulting precipitate was 
left overnight at 4 °C. The yellow solids, cis-[Pt(ma)2Cl2] and cis-[Pt(ipram)2Cl2 respectively, were 
filtered, washed with water and air dried. 
 
cis-[Pt(ma)2Cl2] (cPtM) Yield: 85 mg (30%). 1H NMR (500 MHz, DMSO-d6),  
δ(ppm): 2.26 (t, 6H); 4.88 (s, 4H). 195Pt NMR (107 MHz, DMSO-d6), δ(ppm): -2214.4. TOF MS/ES+ 
(Accurate mass), m/z: (M + Na)+: 350.97 (C2H10N2NaPtCl2, species).  
Anal. Calc. for C2H10N2PtCl2: N, 8.54; C, 7.32; H, 3.07. Found: N, 8.60; C, 6.99; H, 2.76. 
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cis-[Pt(ipram)2Cl2] (cPtR) Yield: 296 mg (75%). 1H NMR (500 MHz, DMSO-d6),  
δ(ppm): 1.22 (d, 12H); 3.11 (sept., 2H); 4.75 (s, 4H). 195Pt NMR (107 MHz, DMSO-d6), δ(ppm): -
2218.5. TOF MS/ES+ (Accurate mass), m/z: (M + Na)+: 407.03 (C6H18N2NaPtCl2, species).  
Anal. Calc. for C6H18N2PtCl2: N, 7.29; C, 18.76; H, 4.72. Found: N, 7.50; C, 18.54; H, 4.45. 
 
3.2.2.2 Synthesis of trans-[Pt(ma)2Cl2] 
trans-[Pt(ma)2Cl2] was obtained following the synthetic procedure outlined by Messori et al.[2] with 
a few modifications.  A suspension of cis-[Pt(ma)2I2] (220 mg, 0.432 mmol) in water was treated with 
5 equivalents of methylamine hydrochloride (2.16 mmol). The resulting mixture was stirred at room 
temperature for 12 hours to give a colourless solution. The resulting solution was concentrated at 70 
°C until a bright orange precipitate was detected and then left to stand overnight at 4 °C. The orange 
solid, trans-[Pt(ma)2I2] was filtered, washed with warm water and air dried.  
 
trans-[Pt(ma)2I2] (177 mg, 0.346 mmol) was suspended in 10 mL of water and treated with  
1.9 equivalents AgClO4. The mixture was stirred overnight in the dark. AgI was removed by filtration 
through a 0.45 µm nylon membrane and to the filtrate, a four equivalent of KCl was added and stirred 
at 40 °C for six hours to give a yellow precipitate of trans-[Pt(ma)2Cl2]. The solution was left to stand 
overnight at 4 °C. The product was filtered, washed thoroughly with warm water and air dried.  
 
trans-[Pt(ma)2Cl2] (tPtM) Yield: 12.8 mg (9%). 1H NMR (500 MHz, DMSO-d6),  
δ(ppm): 2.33 (t, 6H); 4.24 (s, 4H). 195Pt NMR (107 MHz, DMSO-d6), δ(ppm): -2195.  
TOF MS/ES+, m/z: (M + Na)+: 350.96 (C2H10N2NaPtCl2, species). Anal. Calc. for C2H10N2PtCl2:  
N, 8.54; C, 7.32; H, 3.07. Found: N, 8.61; C, 6.97; H, 2.60. 
 
3.2.2.3 Synthesis of trans-[Pt(ipram)2Cl2] 
The trans-[Pt(ipram)2Cl2] was synthesised following the method reported by  
Navarro-Ranninger et al. [17]. To a suspension of cis-[Pt(ipram)2Cl2 (200 mg, 0.521 mmol), 4 
equivalents of isopropylamine was added. The resulting mixture was heated at 70 °C and stirred until 
a colourless solution was obtained which was then heated at reflux for 30 minutes. The solution was 
left to cool to room temperature and concentrated HCl (0.364 mL) was added and subsequently heated 
at reflux for 8 hours. The yellow solution obtained was cooled in an ice bath and left to stand at 4 °C 
overnight. The product was obtained by filtration and thoroughly washed with water and dried in air. 
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trans-[Pt(ipram)2Cl2] (tPtR) Yield: 80 mg (40%). 1H NMR (500 MHz, DMSO-d6),      
δ(ppm): 1.19 (d, 12H); 3.03 (sept., 2H); 4.20 (s, 4H). 195Pt NMR (107 MHz, DMSO-d6), δ(ppm): -
2205. TOF MS/ES+, m/z: (M + Na)+: 407 (C6H18N2PtCl2, species). Anal. Calc. for C6H18N2PtCl2: N, 
7.29; C, 18.76; H, 4.72. Found: N, 7.53; C, 18.51; H, 4.36. 
 
3.3 Instrumentation and Physical Measurements 
1H, 13C and 195Pt NMR spectroscopic analyses were carried out on a Bruker Avance III 500 MHz. All 
1H and 13C NMR chemical shifts were referenced to Si(CH3)4 while 
195Pt NMR chemical shifts were 
externally referenced to K2[PtCl6]. 
195Pt NMR has been established as an effective method for the 
determination of the coordination details at the metal centre since its chemical shifts are largely 
influenced, among other things, by the nature of the coordinated donor atoms [18]. A Waters Micro-
mass LCT Premier spectrometer was employed for mass determination of the complexes. Elemental 
analyses of synthesised complexes were recorded on Thermo Scientific Flash 2000. The pH of the 
aqueous solutions of the complexes was recorded using a Jenway 4330 Conductivity/pH meter fitted 
with a Micro 4.5 diameter glass electrode which was calibrated at 25 °C using buffer solutions of pH 
4.0, 7.0 and 10.0 purchased from Merck. A Varian Cary 100 Bio UV/Visible spectrophotometer 
thermostatted by a Varian Peltier temperature controller was used to obtain the UV/Visible absorption 
spectra for the determination of pKa values and kinetic studies of slow reactions. Kinetic 
measurements of moderately fast reactions were monitored on an Applied Photophysics SX20 
stopped-flow analyser coupled to an online data acquisition system. The temperature of the 
instrument was kept within ±0.05 °C for all the measurements. Analyses of the pH and time-
dependent kinetic spectral data were performed using the Origin 9.1® software suite. 
 
3.4 Preparation of Platinum(II) Aqua Complexes and Determination of their 
pKa Values 
The aqueous solutions of the complexes cPt, tPt, cPtM, tPtM, cPtR and tPtR were prepared 
according to literature [9,11]. A suitable amount of AgClO4 was added to each of the corresponding 
chloro complexes at a molar ratio of 1: 1.98. Both the chloro complex and the AgClO4 were dissolved 
in 0.01M HClO4 and the mixture was vigorously stirred in the dark at 45 °C for 24 hours. The AgCl 
precipitate obtained was filtered off through a 0.45 µm nylon membrane. The filtrate was diluted to 
300 mL with 0.01 M HClO4.  
 
Spectrophotometric pH titrations were performed using NaOH as a base in the pH range of 2-10 at 
25 °C. To avoid absorbance corrections resulting from dilution, a large amount (300 mL) of the 
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complexes were used for the titrations. Adjustments in pH were made by a stepwise addition of 
crushed NaOH pellets in the pH range 1–3, while a pasteur pipette was used for dropwise additions 
of NaOH solutions of different concentrations (1.0, 0.5, 0.1 and 0.01 M) or same concentrations of 
HClO4 acid (for reversibility of the pH) were added to the solution in the pH range of 4–10 until the 
desired pH was attained prior to withdrawal of a 1.0 mL aliquot from the solution for pH measurement 
and 2.0 mL aliquots for spectrophotometric monitoring. The 1.0 mL aliquot after each pH 
measurement was discarded to avoid in situ contamination of the complex solution by chloride ions 
leaching from the pH electrode. 
 
3.5 Computational Estimations 
Density functional Theoretical (DFT) estimations of the complexes cPt, tPt, cPtM, tPtM, cPtR and 
tPtR were performed at the DFT level B3LYP [19] with the LANL2DZ basis set [20] using the 
Gaussian ′09 programme suite. B3LYP relates to the hybrid functional Becke’s three-parameter 
formulation, which has been proven to be superior to conventional functionals. The LANL2DZ is 
double-zeta basis set containing effective core potential (ECP) representations of electrons near the 
nuclei for transition metal complexes [21]. The theoretical calculations of the complexes were 
executed in water taking into account the effects of the solvent by employing conductor polarisable 
continuum model (CPCM) formalism [22, 23]. The complexes were optimized in their aqua form as 
cations of +2 charge, and the singlet states were used because of low electronic spin of platinum(II) 
complexes. 
 
3.6 Results and Discussion 
3.6.1 pKa Determination of the Diaqua Complexes 
To obtain information on the acidity of the coordinated water moeities and the reactivity of all the 
aqua complexes, their pKa values were determined. To this end, a spectrophotometric pH titration 
with NaOH as a base in the pH range 2–10 was carried out. The pH dependence of the aqua complex 
was observed by UV/Visible spectrophotometry. The pKa values of the coordinated aqua ligands were 
obtained by plotting the absorbance at a specific wavelength as a function of pH. The typical spectral 
changes recorded during the pH titration with NaOH are presented in Figure 3.2 for the trans-aqua 
complexes tPtR. The overall process can be presented by Scheme 3.1.  
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Figure 3.2: UV/Visible spectra of the diaqua tPtR complex recorded as a function of pH in the range 2-
10 at 298 K. Inset: Titration curve at 230 nm. 
 
 
 
 
Scheme 3.1: Proposed stepwise deprotonation for the pH dependence of the trans-platinum(II) complexes. The 
charge on the complexes were omitted for clarity  
 
The spectral data was analysed using Origin 9.1®  [24] to obtain the resulting pKa values for the aqua 
moieties by fitting the data to a double sigmoidal function which gave the best statistical fit and 
afforded two pKa values which are indicative of the fact that there are three coloured species for each 
of the aqua complexes present in solution as a function of pH. The data obtained for the deprotonation 
of the aqua moieties from the complexes are summarised in Table 3.1. 
 
Table 3.1: Summary of pKa values for the deprotonation steps of aqua moieties from the analogous cis- and         
 trans-platinum(II) complexes. 
       cPt       tPt      cPtM     tPtM      cPtR      tPtR 
pKa1 4.99 ± 0.01 4.24 ± 0.05 5.40 ± 0.29 4.56 ± 0.06 6.61 ± 0.62 5.92 ± 0.07 
pKa2 7.26 ± 0.01 6.91 ± 0.04 7.52 ± 0.12 7.05 ± 0.03 7.62 ± 0.12 7.28 ± 0.16 
 
A closer inspection of the data in Table 3.1 shows that the pKa1 and pKa2 values for the deprotonation 
of the first and second coordinated water molecules for all the trans-complexes are significantly lower 
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than those of their corresponding cis-analogues. The trans-aqua complexes are clearly more acidic 
than their corresponding cis-counterparts. The deprotonation of the first coordinated water ligand 
increase in the order tPt (pKa1 4.24) < tPtM (pKa1 4.56) < cPt (pKa1 4.99) < cPtM (pKa1 5.40) < tPtR 
(pKa1 5.92) < cPtR (pKa1 6.61). A similar trend is observed for the deprotonation of the second aqua 
molecule, albeit at higher pH values relative to the first. The higher acidity of the trans complexes as 
compared to the analogous cis complexes has been previously reported in a related study involving 
analogous cis- and trans-complexes using NMR spectroscopy [25, 26]. Since pKa values are 
associated with the electrophilicity of the metal centre [27], it can be inferred, therefore, that the 
geometry of the complexes bears significant influence on the electrophilicity of the metal centre in 
the investigated complexes.  The DFT-calculated NBO charges for the corresponding cis/trans-
analogues in Table 3.2 underpin the observed experimental data. 
 
Table 3.2: A summary of the DFT calculated data for the investigated analogous cis- and trans-platinum(II) 
complexes at B3LYP/LANL2DZ level of theory. 
 
All the trans-configured platinum(II) complexes have a slightly lower charge on the platinum centre 
as compared to each of their corresponding cis-isomers. The difference in NBO charge on the 
platinum centre between analogous cis/trans-platinum(II) complexes can be attributed to the 
remarkable difference in charge distribution as expressed as the dipole moment between the two 
configurations [28, 29]. The cis-configuration enhances charge separation within a molecule 
compared to the trans-configuration. Hence, whereas the charge separation in the trans-platinum(II) 
                                                    
                                             
 
 
   
Parameters cPt tPt       cPtM tPtM    cPtR tPtR 
Bond 
Length/Distance 
(Å) 
      
cis/trans-Pt–OH2 2.106 2.058       2.116 2.063    2.120 2.066 
a 2.482 2.575       2.535 2.984    2.455 3.116 
b 3.458 3.460       3.415 3.446    3.435 3.465 
NBO Charge       
Pt2+ 0.774 0.808       0.754 0.791    0.736 0.758 
Dipole Moment 0.425 0.002       2.420 0.002    6.404 0.002 
94 
 
complexes are negligible, those of their analogues cis-platinum(II) complexes are quite significant. 
Furthermore, the dipole moment is expectedly the same, and veritably zero, for all the trans-
complexes. There is, however, a significant increase in the dipole moments in all the cis-complexes 
as the steric bulk of the amine spectator ligands increases from ammine to isopropylamine. This can 
be ascribed to the increase in the inductive negative charge in the cis-complexes resulting from the 
increase in the sigma donor abilities of the amine moieties [30, 31]. 
  
Additionally, contrary to what was previously reported by Cubo et al. [26], the nature of the aliphatic 
amine moieties has a significant effect on the pKa values of all the studied complexes. For instance, 
in the trans-complexes, the pKa value of transplatin, tPt, is 0.32 and 1.68 pH units lower than that of 
tPtM and tPtR respectively. This is corroborated by the remarkable difference in the DFT-calculated 
NBO charges on the platinum centres with tPt being more electrophilic than the other two trans-
complexes having bulkier amine ligands. Similarly, this trend is also observed in the cis-complexes. 
Cisplatin, cPt is 0.41 and 1.62 pH units lower than the bulkier cis-complexes, cPtM and cPtR 
respectively. This phenomenon is quite consistent with the electrophilicity of the platinum centres 
based on their NBO charges. 
 
The pKa values of the second aqua ligands are higher than the first one i.e. pKa1 < pKa2. This has been 
previously observed [1, 9, 25-27, 32, 33] and has been attributed to the general reduction in the overall 
charge from +2 to +1 on the platinum centre resulting from the formation of the first hydroxo species. 
Another reason posited for this observation is the possibility of hydrogen bonding between the 
aqua/hydroxo groups resulting from the first deprotonation step. However, this possibility is much 
more prominent in the cis-configured complexes compared to their trans-counterparts because of the 
proximity of the aqua/hydroxo groups in the cis-complexes due to their geometry.  
 
3.6.2 Kinetic Analysis 
The kinetics of the substitution of the coordinated water ligands in the analogous cis- and trans-
dialkylamine platinum(II) complexes were investigated spectrophotometrically by monitoring the 
changes in absorbance at suitable wavelengths as a function of time at 298 K. The proposed reaction 
pathways for the reaction of the analogous cis- and trans-platinum(II) complexes with the neutral 
nucleophiles are presented in Schemes 3.2 and 3.3. The reactions with the diaqua complexes were 
performed at pH 2 in order to ensure that all the complexes cPt, cPtM, cPtR, tPt, tPtM and tPtR are 
present in their diaqua form based on the reported pKa values in Table 3.1. 
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Scheme 3.2: Proposed pathway for the reaction of the trans-platinum(II) complexes with the thiourea-
based nucleophiles. 
             
 
 
Scheme 3.3:  Proposed pathway for the reaction of the cis-platinum(II) complexes with the thiourea-based 
nucleophiles. 
 
The substitution reactions of all the studied cis-platinum(II) complexes proceeded in two concerted 
reaction steps whereas those of the trans-platinum(II) followed a single reaction step. All the reaction 
steps in both the cis- and the trans-platinum(II) complexes showed a clear dependence on the 
concentration of the nucleophile. Kinetic traces for the cis-platinum(II) complexes all gave an 
excellent fit to a double exponential function which is indicative of a two-step process whereas those 
of the trans-platinum(II) complexes fitted perfectly to a single exponential, typical for one-step 
reaction. 
  
The so-obtained pseudo-first-order rate constants, kobs1 and kobs2 for the cis-complexes and kobs for the 
trans-complexes, computed from the kinetic traces were plotted against the concentration of the 
entering nucleophiles (Figure 3.3). A linear dependence, without any intercept, on the nucleophile 
concentration was observed for all the studied reactions. The linear fits pass through the origin which 
is indicative of the fact that the possibility of parallel or reverse reactions are negligible or absent. 
The dependence of the observed pseudo-first-order rate constants on the concentration of the entering 
nucleophile obeyed the rate law presented in equation 3.1, where k2 represent the second-order rate 
constants for the substitution reactions of the analogous cis- and trans-dialkylamine platinum(II) 
complexes. 
     kobs = k2[Nu]                               (3.1) 
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Figure 3.3:  Pseudo first-order rate constants plotted as a function of the concentration of the entering 
nucleophiles for the substitution reaction of the diaqua tPtR complex by TU, DMTU, and TMTU 
at pH = 2.0 (0.09 M NaClO4 + 0.01 M HClO4) and 298 K 
 
The comparative second-order rate constants for the substitution processes of the corresponding 
analogous cis- and trans-dialkylamine platinum(II) complexes are summarised in Table 3.3. In the 
case of the cis-platinum(II) complexes, the substitutions turned out to be rather slow in which the first 
and the second steps occurred in concert. The reactions with the bulkiest nucleophile, TMTU, was 
too slow to be followed to completion for all the cis-configured platinum(II) complexes. The second-
order rate constant, k2 1st, for the first step of the reactions of the cis-platinum(II) complexes with the 
thiourea-based nucleophiles was assigned to the substitution of both labile aqua ligands, whereas the 
second step was ascribed to the displacement of the monodentate amine moieties consequent upon 
the strong trans effect of the coordinated thioureas. However, in the trans-platinum(II) complexes, 
the single step observed was assigned to the simultaneous removal of the two aqua ligands.  
 
3.6.3 NMR Studies 
Substitution of the chloride ligands in all the studied complexes with on an excess thiourea (TU) was 
investigated by 195Pt NMR spectroscopy. A typical 195Pt NMR spectra for the substitution of cPtR 
and tPtR with TU respectively are presented in Figures 3.4 and 3.5. In both cases,  
at t = 0, a signal due to the starting complexes [cis-Pt{NH2CH(CH3)2}Cl2] and  
[trans-Pt{NH2CH(CH3)2}Cl2] were observed at  –2218.5 ppm and   –2206 ppm respectively. In the 
case of the cis-configured complex, there is the formation of an intermediate species at –3382 ppm 
which is assigned to the substitution of the two chloro ligands [cis-Pt{NH2CH(CH3)2}(TU)2]
2+, 
followed by the eventual substitution of the two amine moieties via a strong trans effect of the TU to 
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give the final product after 24 hours at –4092 ppm assigned to [Pt(TU)4]2+. Notably, the final products 
of all the cis-configured complexes were obtained at –4092 ppm. However, in the case of the [trans-
Pt{NH2CH(CH3)2}Cl2], the signal of the final product was found at -3209 ppm within 20 minutes and 
remained the same after 24 hours. The signal of the final product of the tPtR was ascribed to [trans-
Pt{NH2CH(CH3)2}(TU)2]. The final products of all the trans-platinum(II) complexes, however, 
appear between -3170 ppm and -3210 ppm.  
                t = 24 h  
  t = 10 h 
     t = 0.0 h 
Figure 3.4: 195Pt NMR spectra of the reaction mixture of cPtR-Cl with six mole equivalents of TU, 
showing pure cPtR-Cl (δ = –2218.5 ppm) before the reaction, the intermediate species (δ = –
3382 ppm) formed during course of the reaction, [cis-Pt{NH2CH(CH3)2}2(TU)2]2+ and the 
final degradation product (δ = –4092 ppm) corresponding to [Pt(TU)4]2+ . 
 
 
              t = 0.5 h 
    
 
t = 0.2 h 
       
 t = 0.0 h 
Figure 3.5: 195Pt NMR spectra of the reaction mixture of tPtR-Cl with six mole equivalents of TU, 
showing pure tPtR-Cl (δ = –2206 ppm) before the reaction, and the final stable biadduct 
product (δ = –3209 ppm) ascribed to [trans-Pt{NH2CH(CH3)2}2(TU)2]2+. 
 
Based on the NMR results, it is reasonably concluded, therefore, that the cis- and the trans-
platinum(II) complexes do not form the same kinetic product with TU. The presence of the strong 
labilising thiourea nucleophiles at the platinum(II) centre forces the substitution of the amine ligands 
attached to the metal centre in all the cis-configured platinum(II) complexes. This result is consistent 
with what have been previously reported by other researchers in related studies [9, 13, 31-33]. The 
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substitution of the amine groups was not observed in any of the trans-configured platinum(II) 
complexes. Unlike the notion posited by Song et al. [14], our current findings are congruous with the 
earlier findings of Brabec et al. [15]. 
It has been well-established that the pKa values of the coordinated aqua ligand is an experimental 
indicator of the electron density around the metal centre [27, 34]. Hence, the lower the pKa value the 
more electrophilic and in most cases, the more reactive a metal complex is. In this study, both the 
experimental and the theoretical findings perfectly aligned. All the trans-complexes are more 
electrophilic than their corresponding cis-counterparts based on their respective pKa values and this 
phenomenon is underpinned by the DFT-calculated charges on the platinum centres for both the cis- 
and the trans-dialkylamine platinum(II) complexes respectively. The general trend of the second 
order rate constants for the substitution of aqua ligands by the entering nucleophiles is as follows: tPt 
> tPtM > tPtR > cPt > cPtM > cPtR. Each of the trans-platinum(II) complexes is ca. 103 times more 
reactive than its corresponding cis-platinum(II) analogues. This trend agrees very well with the 
electrophilicity of their respective platinum centre based on the experimentally determined pKa values 
and the DFT-calculated NBO charges.  
 
Moreover, a thorough look at the DFT-calculated data in Table 3.2 shows that the average bond 
length between the platinum centre and the aqua ligands is higher in all the cis-configured 
platinum(II) complexes compared to their corresponding trans-complexes. This implies that the 
substitution of the aqua moieties by the entering nucleophiles are ordinarily expected to occur faster 
in the cis-complexes than those of their corresponding trans-counterparts because their aqua ligands 
should have been more labile in the ground state. Hence, the second order rate constants of the cis-
complexes in the first step should have been greater than those of their corresponding trans-
analogues. This is not unexpected because of the trans effect between H2O and NH3 with the ammine 
ligand having a greater trans effect than the aqua ligand. This, however, was not the case based on 
the second-order rate constants obtained, which is summarised in Table 3.3. 
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Table 3.3: Second-order rate constants for the reaction of the investigated analogous diaqua cis- and 
trans-platinum(II) complexes with thiourea nucleophiles at pH = 2.0 (0.9 M NaClO4 + 0.01 
M HClO4) and 298 K 
Complex Nucleophiles k2(1st) x10-3/M-1s-1 k2(2nd) x 10-3/M-1s-1 
       cPt 
      TU 
      DMTU 
      TMTU 
97.6 ± 0.4 
44.2 ± 0.2 
Too slow   
21.4 ± 0.06 
  8.6 ± 0.03 
 Too slow 
      cPtM 
        
      TU 
      DMTU 
      TMTU  
58.3 ± 0.2 
36.3 ± 0.1 
Too slow 
  8.2 ± 0.02 
  3.8 ± 0.01 
 Too slow 
      cPtR 
     
      TU 
      DMTU 
      TMTU 
2.8 ± 0.02 
1.9 ± 0.02 
Too slow 
  
 Too slow 
        
    
       tPt 
       
      TU 
      DMTU 
      TMTU 
 44.2 ± 0.03 
 22.9 ± 0.11 
   5.6 ± 0.01 
  
         - 
       tPtM 
       
      DMTU 
      TMTU 
 35.4 ± 0.11 
 18.2 ± 0.02   
   3.8 ± 0.03 
  
  
         - 
       tPtR 
      TU 
      DMTU 
      TMTU 
 19.0 ± 0.0016 
 10.3 ± 0.0001 
   2.2 ± 0.0065 
  
         -      
  
 
Besides, the electronic factors such as the electrophilicity of the metal centre favouring a greater 
reactivity of the trans-complexes over their corresponding cis-isomers, steric hindrances also play a 
prominent role. Steric hindrance is greater in the cis-complexes as compared to their trans-analogues 
[16]. The trans-configuration greatly minimises steric hindrance which enhances the axial approach 
of the entering nucleophile. The cis-geometry, on the other hand, amplifies steric hindrances which 
is anticipated to hinder the axial approach of the incoming nucleophile to the metal centre. This 
became more pronounced with the increasing bulkiness of the amine moieties. In the same vein, the 
steric effect, in the trans-complexes, increase as the amine ligands become bulkier. 
 
Furthermore, the increased steric hindrance in the cis-configured complexes is also enhanced through 
intramolecular hydrogen bonding. This is underpinned by the average interatomic distance between 
the hydrogen atoms on the nitrogen of the amine moiety and the oxygen atom of the aqua ligand as 
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well as the average interatomic distance between the hydrogen of the aqua ligand and the nitrogen 
atom of the amine ligands. These distances are shorter in the cis-complexes compared to their 
corresponding trans-counterparts. The increased possibility of intramolecular hydrogen bonding 
interactions in the cis-platinum(II) complexes forestalls the entering nucleophiles from reaching the 
platinum centre, thereby retarding the reactivity of the cis-complexes relative to those of their trans-
isomers. This observation has been previously reported [12, 35]. Intramolecular hydrogen bonding 
increases steric hindrances around the metal centre thereby retarding the activation of the substitution 
process in the cis-configured complexes. This possibility of steric hindrance due to intramolecular 
hydrogen bonding is remarkably minimised in the trans-configured complexes, hence, their increased 
reactivity. 
 
Another factor that contributed to the increased steric hindrance in the cis-complexes as compared to 
their corresponding trans-analogues, is the solvation of the hydrogen atoms on the nitrogen atom of 
the amine moieties. The solvated hydrogen atom increases steric crowdedness around the metal 
centre, thus, slowed down the attack of the nucleophile on the reaction site. This effect is also present 
in the trans-complexes. However, the remote distance between the -NH2R moiety and the leaving 
aqua ligand minimises the steric crowdedness around the metal centre, hence, the unhindered 
approach of the nucleophile. The proximity of aqua and amine moieties in the cis-complexes enhances 
crowdedness around the substitution sites. Generally, substitution of the aqua moieties from the 
studied cis and trans-platinum(II) complexes exhibits an apparent dependence on the steric hindrance 
of the entering nucleophiles. Hence, the reactivity of the thiourea nucleophiles with the complexes 
decreases with increase in steric demand in the following order: TU > DMTU > TMTU. 
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Table 3.4: Summary of the activation parameters for substitution of coordinated aqua moieties from the 
investigated analogous cis- and trans-platinum(II) complexes with thiourea nucleophiles in 
the temperature range 293–313 K. 
Complex Nu ∆Hⱡ1 (kJ/mol ∆Hⱡ2 (kJ/mol) ∆Sⱡ1 (J mol-1 K-1) ∆Sⱡ2 (J mol-1 K-1) 
cPt TU 
DMTU 
17 ± 0.03 
48 ± 0.08 
58 ± 0.08 
57 ± 0.09 
 
-189 ± 0.1 
-111 ± 0.3 
 
-84 ± 0.3 
-95 ± 0.3 
cPtM 
        
TU 
DMTU 
63 ± 7 
57 ± 1 
 
75 ± 6 
65 ± 1 
-57 ± 3 
-79 ± 6 
 
-34 ± 2 
-74 ± 4 
cPtR 
       
TU 
DMTU 
54 ± 5 
57 ± 5 
 
 
- 
-112 ± 16 
-108 ± 2 
 
- 
tPt 
       
TU 
DMTU 
TMTU 
63 ± 2 
55 ± 1 
68 ± 2 
 
- 
-29 ± 6 
-61 ± 4 
-27 ± 6 
 
- 
tPtM TU 
DMTU 
TMTU 
58 ± 3 
62 ± 1 
60 ± 2 
 
- 
-34 ± 10 
-43 ± 3 
-64 ± 7 
 
- 
tPtR TU 
DMTU 
TMTU 
58 ± 2 
54 ± 2 
57 ± 1 
 
- 
-51 ± 7 
-69 ± 5 
-72 ± 3 
 
- 
 
 
 
 
                 
0.00320 0.00325 0.00330 0.00335 0.00340
-8.0
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T
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Figure 3.6: Plot of ln(k2/T) against 1/T for the reaction of tPtR with the thiourea-based nucleophiles at 
various temperatures ranging from 293 to 313 K. 
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                                𝑙𝑛 (
𝑘2
𝑇
) =  −
∆𝐻#
𝑅𝑇
 +   (23.8 + 
∆𝑆#
𝑅
)                          (3.2)                        
 
The activation parameters ∆H# and ∆S# were calculated using the Eyring equation (equation 3.2) by 
measuring the rate constants for each of the substitution reactions of the investigated platinum(II) 
complexes with the thiourea-based nucleophiles as a function of temperature (Figure 3.6) and are 
summarized in Table 3.4. In general, ligand substitution for all the investigated complexes, regardless 
of their configurations, followed an associative mechanism and are characterized by negative intrinsic 
activation entropy values resulting from bond formation in the transition state [35-42]. The activation 
entropies for both the cis- and trans-configured complexes confirm the associative character for the 
substitution process with this character being generally more prominent in the cis-complexes 
compared to their trans-counterparts. This implies that bond-making in the transition state is more 
favoured in the cis-complexes than in the trans-complexes.  
  
3.7 Conclusion 
A series of analogues bifunctional dialkylamine cis- and trans-platinum(II) complexes were 
synthesised, characterised and investigated for comparative substitution reactions with thiourea-based 
nucleophiles. Substitution of the cis-complexes followed a concerted two-step process while those of 
the trans-complexes proceeded by a single step. The trans-complexes are ca. 103 more reactive than 
their cis-analogues. Electronic as well as steric effects controlled the overall reaction pattern. The 
negative entropy of activation values obtained for all the studied complexes affirmed an associative 
mode of substitution. The cis-complexes formed a different kinetic product as completely substituted 
and were confirmed by 195Pt NMR spectroscopy. The trans-complexes are thermodynamically more 
stable to complete substitution by the thiol-nucleophiles and hence, their use as alternative platinum-
based anticancer agents can be further explored.   
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Chapter Four 
A Kinetic Investigation of Mononuclear trans-Platinum(II) Complexes with Mixed Amine 
Ligands   
Abstract 
This study was aimed at investigating the substitution behaviour of mononuclear trans-
platinum(II) complexes with mixed amine ligands. The rate of substitution of the chloride moeities 
from the complexes trans-Pt(NH3)(NH2C2H5)Cl2 (tPt2), trans-Pt(NH3)(NH2C3H7)Cl2 (tPt3),  
trans-Pt(NH3)(NH2C4H9)Cl2 (tPt4) and trans-Pt(NH3)(NH2C5H11)Cl2 (tPt5), by three 
nucleophiles, viz. thiourea (TU), 1-methyl-2-thiourea (MTU) and 1,3-dimethyl-2-thiourea 
(DMTU), was studied under pseudo first-order conditions as a function of concentration and 
temperature by stopped-flow spectrophotometry. Substitution at each of the trans-platinum(II) 
complexes proceeds via a single-step and obeys first-order kinetics. The pseudo first-order rate 
constants, kobs obeyed the rate law: kobs = k2[nucleophile]. The reactivity of the complexes was 
largely dependent on the length of the alkyl chain of the alkylamine moiety of the complexes. 
Computational modelling using density functional theory (DFT) calculations showed that an 
increase in chain length by a methylene unit has no direct electronic consequence on the metal 
centre but did however, pose significant steric hindrance on the substitution sites due to the 
flexibility of the alkyl chains and thus governed the overall reaction pattern. The order of reactivity 
of the complexes is tPt2 > tPt3 > tPt4 > tPt5. The reactivity of the nucleophiles with the 
complexes decreases with increasing steric demand in the following order: TU > MTU > DMTU.  
195Pt NMR kinetic studies established that the mixed amine ligands remain coordinated to the metal 
centre in the final kinetic product. This implies that mononuclear trans-platinum(II) complexes are 
resistant to complete substitution of ligands by the incoming thiourea nucleophiles at the reaction 
sites. The low positive values of activation enthalpy and large negative values of activation entropy 
indicate an associative mechanism of substitution. 
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4.1 Introduction 
The flaws that are associated with cisplatin anticancer treatment such as severe side effects, lack 
of selectivity, inherent and acquired resistance, and transient retention in the bloodstream, have 
stimulated a great deal of research activity among synthetic inorganic chemists to the end that 
some more potent and veritably less toxic anticancer agents can be developed [1-6]. Platinum 
compounds with distinctively different DNA binding modes from cisplatin are some of the 
prospective anticancer agents that are currently under consideration [7, 8]. Top among those 
compounds are complexes in which the inert or spectator amine ligands are of trans 
stereochemistry [7, 9-14]. It has been well established that trans-diamminedichloroplatinum(II), 
i.e. transplatin, a trans isomer of cisplatin is biologically inert against cancer cell lines. Its dearth 
of activity has been suggested to have originated in part from kinetic instability thereby making it 
susceptible to deactivation.  
This was the genesis of the initial thinking amongst researchers in the field that platinum 
complexes with only the cis configuration are therapeutically useful as cytotoxic drugs. When one 
or both ammine ligands in transplatin are substituted by bulky ligands, the resulting compounds 
have been found  to be active with an increased toxicity [7]. It is believed that the bulky ligands 
might have restricted ligand substitution of the chloride ions, thus minimizing the formation of by-
products between platinum and cellular components thereby enhancing platinum interaction with 
DNA.  
These ideas have inspired the design and synthesis of novel platinum complexes with trans-
stereochemistry. Farrell et al. [7] and Navarro-Ranninger et al. [15, 16], have reported classes of 
biologically active trans-platinum compounds that have led to some researchers jettisoning the 
previously held structure-activity relationship that only cis-platinum complexes are equipped with 
antitumor potential. In fact, Navarro-Ranninger and co-workers disclosed some novel trans-
platinum(II) complexes with asymmetric aliphatic amines which showed cytotoxic properties 
against some cisplatin resistant cell lines. These compounds exhibited radically different 
pharmacodynamics from those already established for cisplatin. Consequently, the exigent need to 
further explore these alternative potential platinum-based anticancer agents cannot be over-
emphasized. Despite the burgeoning interest among medicinal inorganic chemists to develop more 
107 
 
effective trans-platinum complexes, the detailed mechanistic study of these compounds is still 
relatively non-existent when compared to the level of information available on their cis-
derivatives. Moreover, the dearth of understanding of the substitution behaviours and stability of 
these compounds have impeded the design possibilities and synthesis of new and more active 
platinum-based chemotherapeutic agents with low toxicities. A recent controversy on the 
interaction of transplatin with DNA has galvanised our interest to investigate ligand substitution 
kinetics of these complexes. 
Song et al. [17] have posited that transplatin is most probably transformed to the cis-isomer under 
UVA irradiation. Their speculations were hinged on the fact that transplatin, which is generally 
known to be non-toxic in the dark to all tumour cell lines, was found to be relatively of the same 
toxicity level with cisplatin under UVA irradiation. However, Brabec et al. [18] quashed that 
notion by employing three independent methods to show that transplatin does not isomerize to 
cisplatin in the presence of UVA light.  
Subsequently, in our previous study (Chapter 3), we had compared the substitution behaviour of 
the symmetrical trans-platinum(II) complexes with their corresponding cis-analogues. Our 
findings, among other things, showed that the trans complexes do not form the same kinetic 
product as the corresponding cis complexes. To our knowledge, we also provided for the first time 
detailed comparative mechanistic data between transplatin and cisplatin and their derivatives using 
spectrophotometric techniques. This present study is aimed at further extending the understanding 
of ligand substitution kinetics of trans-platinum(II) complexes. To this end, trans-platinum(II) 
complexes of mixed amine spectator ligands, as presented in Figure 4.1 below, were investigated. 
                                              
Figure 4.1: Structures of the mononuclear trans-platinum(II) complexes with mixed amine ligands 
selected for the current study. 
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4.2 Experimental 
4.2.1 Chemicals 
The ligands, ethylamine (70%), propylamine (99%), butylamine (99.5%), amylamine (99%),  
HCl (37%), cisplatin (99.9%), lithium trifluoromethanesulfonate, methanol, lithium chloride 
(99.0%), the nucleophiles: thiourea (99%), 1-methyl-2-thiourea (99%) and 1,3-dimethyl-2-
thiourea (99%), were all purchased from Sigma Aldrich and were used without further 
purifications. All other chemicals used are of the highest purity available commercially. Ultrapure 
water was used in the preparations of all aqueous solutions. 
4.2.2 General Synthetic Procedure for the Preparation of the Mixed trans-Platinum(II) 
Complexes 
The general synthetic procedure for the mixed trans-platinum(II) complexes has been reported by 
Wilson and Lippard [7]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL) and  
8 equivalents of the appropriate alkylamine ligand was added. The resulting mixture was heated 
at  
90 oC until the solution became colourless. After the solution was cooled to room temperature, it 
was then treated with 32% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at  
90 oC for 48 hours. The resulting yellow solution was placed in an iced bath to induce precipitation 
of the appropriate trans-platinum(II) complex which was recovered by filtration, washed 
intensively with water and diethyl ether, and air dried at room temperature. 
tPt2 yield: 49 mg (45%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 1.26 (t, 3H); 2.73 (sextet 2H); 
3.72 (s, 3H), 4.38 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), δ(ppm): -2165.7. TOF MS/ES+, m/z: 
(M + Na)+: 350.9 (C2H8NaN2PtCl2, species). Anal. Cal for C2H10N2PtCl2: N, 8.54; C, 7.32;  
H, 3.07. Found: N, 8.50; C, 7.00; H, 2.86.  
tPt3 yield: 91 mg (80%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 0.93 (t, 3H); 1.77 (sextet, 2H); 
2.65 (quintet, 2H), 3.74 (s, 3H), 4.36 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), δ(ppm): -2163. TOF 
MS/ES+, m/z: (M+): 340 (C3H10N2PtCl2, species). Anal. Cal for C3H12N2PtCl2: N, 8.19; C, 10.53; 
H, 3.54. Found: N, 8.12; C, 10.50; H, 3.27. 
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tPt4 yield: 89 mg (75%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 0.92 (t, 3H); 1.37 (sextet, 2H); 
1.74 (quintet, 1.74); 2.69 (quintet, 2H), 3.74 (s, 3H), 4.34 (s, 2H). 195Pt NMR (107 MHz, DMF-
d7), δ(ppm): -2163. TOF MS/ES+, m/z: (M + Na. CH3OH)+: 413 (C5H18N2NaOPtCl2, species). 
Anal. Cal for C4H14N2PtCl2: N, 7.87; C, 13.49; H, 3.96. Found: N, 7.84; C, 13.59; H, 3.91. 
tPt5 yield: 68 mg (55%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 0.90 (t, 3H); 1.32 (sextet, 2H); 
1.76 (quintets, 2H); 2.68 (quintet, 2H), 3.73 (s, 3H), 4.34 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), 
δ(ppm): -2162. TOF MS/ES+, m/z: (M + Na. CH3OH)+: 422 (C6H20N2NaOPtCl2, species). Anal. 
Cal for C5H16N2PtCl2: N, 7.57; C, 16.22; H, 4.36. Found: N, 7.50; C, 16.35; H, 4.57. 
 
4.3 Instrumentation and Physical Measurements 
A Waters Micro-mass LCT Premier spectrometer was used for mass determination of the trans-
platinum(II) complexes. Elemental analyses of the synthesised complexes were performed on a 
ThermoScientific Flash 2000. 1H and 195Pt NMR spectroscopic analyses were carried out on a 
Bruker Avance III 500MHz. This was also employed to monitor 195Pt-NMR of the substitution 
reactions of the trans-platinum(II) complex tPt3  with thiourea (TU). All 1H chemical shifts were 
referenced to Si(CH3)4 and 
195Pt NMR chemical shifts were externally referenced to K2[PtCl6][19]. 
For the determination of the coordination features at the platinum centre, 195Pt NMR is usually 
employed and this has been established as an effective technique because its chemical shifts are 
largely affected, among other things, by the nature of the coordinated donor atoms [20]. All kinetic 
measurements were carried out on an Applied Photophysics SX.20 stopped-flow analyser coupled 
to an online data acquisition system and kinetic traces were evaluated using the Origin 9.1®  
software [21]. The temperature of the instrument was kept within ± 0.05 oC for all the 
measurements. 
 
4.4 Computational Modelling 
Prefatory density functional theoretical (DFT) optimization modelling of the trans-platinum(II) 
complexes tPt2-tPt4 was performed at the DFT level B3LYP [22] with the LANL2DZ basis set 
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[23] using the Gaussian 09 programme suite (Table 4.1). B3LYP relates to the hybrid functional 
Becke’s three-parameter formulation, which has been proven to be superior to classical 
functionals. LANL2DZ is double-zeta basis set which comprises effective core potential (ECP) 
representations of electrons near the nuclei for transition metal complexes especially for platinum 
complexes [3, 24-28]. The theoretical calculations of the complexes were performed in methanol 
taking into account the effects of the solvent by employing conductor polarisable continuum model 
(CPCM) formalism [29, 30]. The complexes were optimized in their neutral form, and at singlet 
states because of the low electronic spin of platinum(II) complexes. 
  
Table 4.1: A summary of the DFT calculated data for the investigated trans-platinum(II) complexes at 
B3LYP/LANL2DZ level of theory. 
Parameters tPt2 tPt3 tPt4 tPt5 
Bond Length (Å)     
Pt—Cl 2.446 2.447 2.445 2.445 
NBO Charge     
Pt 0.099 0.090 0.092 0.090 
-NH2R –0.673 –0.685 –0.688 –0.698 
MO Energies (eV)     
HOMO –1.86 –1.86 –1.86 –1.85 
LUMO –6.22 –6.23 –6.23 –6.22 
ΔE 4.36 4.37 4.37 4.36 
Dipole Moment (D) 0.837 0.883 1.002 1.086 
 R = alkyl group 
 
4.5  Kinetic Measurements 
Substitution of the chloride moieties from each of the four trans-platinum(II) complexes (Figure 
4.1) by three different thiourea nucleophiles: thiourea (TU), 1-methyl-2-thiourea (MTU) and 1,3-
dimethyl-2-thiourea (DMTU) was investigated under pseudo first-order-conditions with at least a 
20-fold excess of the nucleophile. Spectral changes resulting from the mixing of the complex and 
the nucleophile solutions were observed over the wavelength range 200-800 nm to establish an 
appropriate wavelength at which the kinetic measurements could be performed on the stopped-
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flow spectrophotometer. The reactions were initiated by the mixing of equal volumes of a solution 
of the metal complex with a solution of the nucleophile directly in the stopped-flow machine. All 
reported rate constants represent an average value of at least seven independent kinetic runs for 
each experimental measurement. The temperature dependence of the rate constants was observed 
over a range of 20–40 oC at an interval of 5 oC. 
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Figure 4.2: Kinetic trace obtained on the stopped-flow spectrophotometer for the reaction of tPt2 and 
TU monitored at 335 nm in methanol, I = 0.09 M LiCF3SO3 and 10 mM LiCl at 298 K. 
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Figure 4.3: Dependence of kobs on the concentration of entering nucleophiles for the chloride 
substitution of tPt2 in methanol, I = 0.09 M LiCF3SO3 and 10 mM LiCl at 298 K. 
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Table 4.2: Second-order rate constants and activation parameters for the reactions of mononuclear  
trans-platinum(II) complexes with thiourea-based nucleophiles in 0.09 M LiCF3SO3 and              
10 mM LiCl methanolic solution. 
 
Complex Nucleophile k2 ×10−2 /M-1s-1 ∆H# /kJ mol-1 ∆S# /J K-1 mol-1 
 
tPt2 
TU 
MTU 
DMTU 
109.8 ± 0.9 
68.1 ± 0.6 
39.4 ± 1 
58 ± 2 
56 ± 1 
58 ± 2 
-73 ± 8 
-65 ± 4 
-118 ± 4 
 
tPt3 
TU 
MTU 
DMTU 
83.4 ± 0.4 
71.4 ± 0.3 
34.9 ± 0.6 
55 ± 3 
57 ± 0.6 
43 ± 2 
-64 ± 9 
-58 ± 2 
-108 ± 8 
 
tPt4 
TU 
MTU 
DMTU 
80.8 ± 1 
60.3 ± 0.3 
33.3 ± 0.1 
53 ± 0.8 
55 ± 4 
62 ± 0.7 
-128 ± 3 
-126 ± 13 
-105 ± 2 
 
tPt5 
TU 
MTU 
DMTU 
64.1 ± 1 
50.7 ± 0.3 
29.4 ± 0.2 
65 ± 2 
68 ± 0.8 
63 ± 2 
-91 ± 6 
-82 ± 3 
-104 ± 6 
 
4.6 Results and Discussion 
The substitution of the labile chloride ligands from each of the platinum(II) complexes (Figure 
4.1) by neutral thiourea-based nucleophiles viz: thiourea (TU), 1-methyl-2-thiourea (MTU) and 
1,3-dimethyl-2-thiourea (DMTU) was studied under pseudo first-order conditions and monitored 
on a stopped-flow spectrophotometer. The ionic strength of the reacting solution was maintained 
using lithium triflate because the triflate ion (CF3SO3
⁻) does not coordinate to platinum(II). Spectra 
changes resulting from mixing the complexes and the nucleophiles were recorded at an appropriate 
wavelength and a typical representative kinetic trace obtained on the stopped-flow 
spectrophotometer is shown in Figure 4.2. All kinetic traces for the substitution reactions gave an 
excellent fit to first-order exponential decay to generate the observed pseudo first-order rate 
constants, kobs. This indicates a single step process. These first-order rate constants were plotted 
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against the entering nucleophile concentration to elicit the second-order rate constants, k2, from 
the slopes (Figure 4.3) and it obeyed the rate expression described in equation 4.1 below. The 
plots gave straight line fits with zero intercepts for each of the entering nucleophiles indicating 
that the solvent cannot effectively displace the coordinated nucleophile [19, 31, 32]. All reactions 
for the displacement of the chloride ligands from the trans-platinum(II) complexes were 
investigated in the presence of a slight excess of chloride ions (10 mM)  in order to suppress 
spontaneous solvolysis reactions. The proposed mechanism for the reaction of the mononuclear 
trans-platinum(II) complexes with thiourea nucleophiles is given in Scheme 4.1. 
     𝑘obs = 𝑘2[Nu]                                          (4.1) 
  
  
                 
Scheme 4.1: Proposed pathway for the reaction of the trans-platinum(II) complexes with thiourea 
nucleophiles. 
 
The activation parameters, enthalpy of activation, ∆H# and entropy of activation, ∆S# were 
determined using the Eyring equation (equation 4.2) by measuring the rate constants for each of 
the substitution reactions of the investigated platinum(II) complexes with thiourea nucleophiles as 
a function of temperature is shown in Figure 4.4. The activation data from the plots are 
summarised in Table 4.2.  
𝑙𝑛 (
𝑘2
𝑇
) = − (
∆𝐻#
𝑅𝑇
) + (23.8 +
∆𝑆#
𝑅
)     (4.2) 
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Figure 4.4: Eyring plots for the determination of activation enthalpies and entropies for the reaction of 
tPt2 with TU, MTU and DMTU 
 
Comparing the second-order rate constants for the substitution of the chloride moieties from the 
trans-platinum(II) complexes, tPt2-tPt5 by the nucleophile TU, the reactivity trends follows: tPt2 
> tPt3 > tPt4 > tPt5 with tPt2 and tPt5 being the most and the least reactive respectively. A 
similar reactivity trend is observed for the remaining nucleophiles viz. MTU and DMTU as shown 
in Table 4.2. The observed reactivity of these trans-platinum(II) complexes can be rationalised in 
terms of electronic and steric effects. The notable difference in the second-order rate constant for 
the substitution of the chloride ligands from these complexes was largely controlled by the steric 
effect due to the chain length of the flexible alkyl amine ligands. The proposed mechanism of the 
substitution reactions of the trans-platinum(II) complexes with thiourea nucleophiles is described 
in Scheme 4.1. The simultaneous substitution of the chloride ligands from the trans-platinum(II) 
complexes were characterised by a single step and this was verified by 195Pt NMR, which has been 
known to be profoundly sensitive to the nature of the binding atoms or ligands on the platinum 
centre [33, 34]. The 195Pt NMR spectra for the chloride substitution of tPt3 by TU is presented in 
Figure 4.5.  
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t = 20 mins 
t = 0 mins 
Figure 4.5: 195Pt NMR spectra of the reaction mixture of tPt3 with six mole equivalents of TU, 
showing pure tPt3 (δ = -2169 ppm) before the reaction, and the final stable biadduct 
product (δ = -3256 ppm) ascribed to [trans-Pt (NH3){NH2(CH2)2CH3}(TU)2]2+. 
 
The initial peak of the pure tPt3 was at -2169 ppm and the final peak of the biadduct trans-Pt(II) 
product formed from the simultaneous substitution of the two chloride ligands by thiourea (TU) 
was obtained at -3256 ppm within twenty minutes of the reaction and remain at the same point 
after 24 hours. This is consistent with our previous studies (Chapter 3). The final peak observed 
for the biadduct product at around -3200 ppm agrees very well with previous reports in literature 
for the formation of [Pt(TU)2]
2+ [25, 35-38].    
Juxtaposing the summarised second-order rate constant values presented in Table 4.2 with the 
DFT-calculated parameters that is shown in Table 4.1, it can be seen that the electronic effect 
favours a higher reactivity of tPt2 compared to the rest of the trans-platinumt(II) complexes (tPt3-
tPt5).  From Table 4.1, it is obvious that the increase in the chain length by the addition of the 
methylene group results in veritably a negligible change in the HOMO-LUMO energy gap in all 
the complexes. The only parameter which increases moderately as the chain length of the alkyl 
group increases by the addition of the methylene unit is the dipole moment. The dipole moment is 
a measure of the charge separation within a molecule [39] and hence, an increase in the dipole 
moment is expected with the addition of the methylene unit in the alkyl chain length because the 
parameter correlates to the inductive negative charge in the complexes.  
There is increase in the inductive negative charge resulting from the increasing chain length of the 
alkyl group. This fact is underpinned by the successive increase in the DFT-calculated NBO charge 
on the nitrogen atom of the alkylamine ligand in the complexes. However, the inductive negative 
charge of the alkylamine ligand has very little or no influence on the platinum centre particularly 
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as the chain length increases from three to five carbon atoms. With the exception of tPt2, the DFT-
calculated NBO charge of the platinum centres for the remaining complexes is relatively the same. 
Complex tPt2 is more electrophilic than the other trans-platinum(II) complexes and this is 
reflected by its greater reactivity compared to the other complexes.  
However, the difference in reactivity of the complexes tPt3-tPt5 cannot be ascribed to the 
electronic effects because there are very small differences in the electronic properties of these 
complexes. Based on the electronic data from the DFT-calculations the second-order rate constant 
values for these complexes should have been relatively the same. It is reasonable to conclude that 
the electronic effect due to the increase in the chain length of the flexible alkylamine ligand bears 
small influence on the reactivity of the trans-platinum(II) complexes with mixed amine ligands 
[37, 40, 41]. However, the increasing chain length of the flexible alkylamine ligand creates steric 
interruption at the reaction sites resulting in the observed difference in the reactivity between the 
three other complexes tPt3, tPt4 and tPt5. The tendency for steric interference at the platinum 
centre increases as the chain length increases from three to five carbon atoms thereby causing a 
notable decrease in the substitution of the chloride ligands by the thiourea nucleophiles. The chain 
length in the complexes only blocks the approach of the entering nucleophiles to the substitution 
site, i.e. the platinum centre [25, 40, 41]. 
The reactivity of the nucleophiles follows the trend: TU > MTU > DMTU for all the trans-
platinum(II) complexes and this is consistent with the order of increasing steric hindrance due to 
the sizes of these nucleophiles. All available activation parameters, ∆H# and ∆ S# presented in 
Table 4.2 support the operation of an associative mechanism [3, 4, 42, 43]. In general, the 
substitution of reactions of square-planar platinum(II) complexes regardless of their 
stereochemistry proceed according to an associative mechanism [28, 44-50]. The remarkably 
negative values of entropy of activation and moderately positive values of enthalpy of activation 
presuppose that the activation process in the investigated trans-platinum(II) complexes are 
profoundly dominated by bond making [31, 32, 44, 51,].  
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4.7 Conclusion 
This study has demonstrated the kinetic behaviour and mechanistic data for the substitution 
reactions of mononuclear trans-platinum(II) complexes with asymmetric(mixed) amine ligands. 
The reaction of these complexes proceeds via a single step. The overall reaction pattern was largely 
dominated by steric effects. An increase in chain length of the alkylamine group by the addition 
of the methylene unit has veritably no significant influence on the electronic properties of these 
complexes. Besides tPt2 whose substitution reaction was driven by the electronic factor, the rest 
of the trans-platinum(II) complexes, tPt3, tPt4 and tPt5 were nearly the same electronically and 
hence, the notable difference in their reactivity was largely due to the tendency of the increasing 
carbon chain length of the alkylamine group in the complexes that interferes with the reaction site 
thereby shielding the entering nucleophiles from directly attacking the platinum centre for the 
substitution of the chloride ligands. All the studied complexes followed an associative mode of 
activation as indicated by the large negative intrinsic entropy values. 
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Chapter Five 
An Investigation of Comparative Substitution Behaviour of Bifunctional trans-Platinum(II) 
Complexes with Symmetric and Asymmetric Alkylamine Ligands 
 
Abstract 
This study was undertaken to investigate the comparative substitution behaviour of 
mononuclear trans-platinum(II) complexes with symmetric and asymmetric amine ligands. The 
rate of substitution of the aqua moeities from the complexes trans-[Pt(NH3)2(H2O)2](ClO4)2  
(tPt), trans-[Pt(NH3)(NH2C2H5)(H2O)2](ClO4)2, (tPt2H2O), trans-
[Pt(NH3)(NH2C3H7)(H2O)2](ClO4)2, (tPt3H2O), [trans-Pt(OH2)2(NH2CH3)2](ClO4)2 (tPtM) 
and [trans-Pt(OH2)2{NH2CH(CH3)2}2](ClO4)2 (tPtR), by three nucleophiles, viz. thiourea 
(TU), 1,3-dimethylthiourea (DMTU) and 1,1,3,3-tetramethylthiourea (TMTU) was studied 
under pseudo first-order conditions as a function of concentration and temperature by stopped-
flow spectrophotometry. All the substitution reactions of each of the trans-platinum(II) 
complexes proceeds by first-order kinetics in a single step. The pseudo first-order rate constants, 
kobs obeyed the rate law: kobss = k2[nucleophile]. The reactivity of the complexes was essentially 
governed by both steric and electronic factors. Comparing the second-order rate constants for 
the substitution reactions of the mononuclear diaqua trans-platinum(II) complexes with the 
thiourea-based nucleophiles, the observed trend follows: tPt ˃ tPt2H2O ˃ tPtM ˃ tPt3H2O ˃ 
tPtR. This reactivity trend is consistent with the pKa values obtained for the first deprotonation 
step. The reactivity of the nucleophiles with the complexes decreases with an increase in steric 
demand in the following order: TU > DMTU > TMTU.  The low positive values of enthalpy of 
activation and large negative values of entropy of activation indicate an associative mechanism 
of substitution in all the complexes. The computational modelling using density functional 
theory (DFT) calculations was employed to provide theoretical interpretation of kinetic data. 
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5.1 Introduction 
The development of new platinum-based anticancer agents that can circumvent some of the 
drawbacks, such as high toxicity in cancer patients [1-8], and can show improved activity 
towards cisplatin resistant cell lines, has been exhaustively focused on compounds with cis 
geometry [9]. This is largely because transplatin, the trans-isomer of cisplatin, is inactive. 
Research efforts to understand the dearth of the activity of transplatin reported two major 
findings [10-13]. Firstly, kinetic instability which bring about prompt deactivation of the 
complex and secondly, the formation of DNA adducts characterised by a regioselectivity and a 
stereochemistry that are radically different from those of cisplatin. These findings initially led 
to the general assumption among researchers that the presence of two leaving groups in cis 
positions is prerequisite for antitumour activity of platinum complexes and hence, most 
compounds reported were based on that structure-activity relationship [12-14]. Despite a large 
number of these cis-configured compounds reported every year, only a handful of them has 
made it to clinical trials [15, 16]. Moreover, even the clinical application of the successful ones 
has been compromised by flaws that are associated with cisplatin [17]. The urgent need to 
develop platinum-based complexes that can form DNA adducts that are qualitatively and 
quantitatively different from those already established for cisplatin and its analogues strongly 
supports the hypothesis that an active trans-platinum complex may have a different spectrum 
of activity. An attempt to develop trans-platinum with cytotoxic activity led Farrell et al. [13, 
18] to incorporate bulky amine ligands, such as aromatic N-donor and other heterocycles, into 
the structure of transplatin. The resulting series of trans-platinum(II) complexes not only 
showed phenomenal cytotoxicity better than cisplatin against certain cancer cell lines but also 
exhibited superior activity against cisplatin-resistant cell lines [9].  
Following the success of Farrell and his group, several other trans-platinum complexes with 
different aromatic, alicyclic and aliphatic bulky ligands have been synthesised [9], many of 
which have shown profound cytotoxicity even against cisplatin resistant cell lines. Navarro-
Ranninger et al. [19] reported some trans-platinum(II) complexes with bulky asymmetrical 
aliphatic amine ligands. These complexes were found to have comparable activity in cisplatin 
sensitive cells to that of cisplatin and significantly higher than that of cisplatin in several 
cisplatin resistant cancer cell lines. In a related study, Quiroga et al. [20] reported the reactivity 
and biological properties of a series of isomeric cis- and trans-platinum(II) complexes with 
symmetrical aliphatic amine and iodide ligands as the leaving groups. Although both sets of 
complexes were found to be cytotoxic, however, the trans isomers were observed to be 
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generally more effective than their cis counterparts when tested against a panel of human 
tumour cell lines.  
In general, the improved cytotoxic activity of the trans-platinum(II) complexes with sterically 
demanding ligands has been attributed to the reduction in the rate of displacement of leaving 
groups which, in most cases, are chloride ligands [9, 13, 21]. In chapter three, we reported the 
kinetic data and mechanisms of substitution of a series of isomeric cis- and trans-platinum(II) 
complexes with symmetrical dialkylamine and aqua leaving groups. These complexes are akin 
to those reported by Quiroga et al. [20]. Our findings, among other things, revealed that while 
all the investigated trans-platinum(II) complexes displayed similarity in their ligand 
substitution pattern and in their mechanisms, their rate of ligand substitution, however, 
decreases with an increase in a sterically demanding dialkylamine group (see Chapter Three).  
Furthermore, in chapter four, we reported the substitution behaviour of some mononuclear 
trans-platinum(II) complexes with mixed or asymmetrical amine ligands. In an effort to gain 
an in-depth understanding of the substitution behaviour of these mononuclear trans-
platinum(II) complexes, it is imperative to explore a comparative study of the substitution 
behaviour of some bifunctional mononuclear trans-platinum(II) complexes with symmetrical 
and asymmetrical alkylamine ligands. To this end, we will be investigating the substitution of 
diaqua moieties from some trans-platinum(II) complexes with alkylamine and dialkylamine 
ligands respectively in reference to aquated transplatin (Figure 5.1). 
 
 
 
                   
Figure 5.1: Structures and abbreviations of the investigated complexes. The charges and counterions 
of the complexes have been omitted for clarity. 
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5.2 Experimental 
5.2.1 Chemicals and Reagents 
Methylamine hydrochloride, isopropylamine (99.5%), ethylamine solution (70%), propylamine 
(99%), K2PtCl4 (98%), cis-[Pt(NH3)2Cl2] (99.9%), trans-[Pt(NH3)2Cl2] , KOH, AgClO4 (97%), 
NaClO4
.H2O (98%), HCl (32%) and HClO4 (70%) were purchased from Sigma Aldrich and 
were used without further purification. The nucleophiles: thiourea (TU, 99%)), 1,3-dimethyl-
2-thiourea (DMTU, 99%) and 1,1,3,3-tetramethyl-2-thiourea (TMTU, 98%) used for the kinetic 
determinations were obtained from Aldrich. All preparations of aqueous solutions were done 
using ultra-pure water. 
5.2.2 General Synthetic Procedure of the Mixed trans-Platinum(II) Complexes 
The general synthetic procedure of the mixed trans-platinum(II) complexes has been reported 
by Wilson and Lippard [13]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL) 
and 8 equivalents of appropriate alkylamine ligand was added. The resulting mixture was heated 
at 90 °C until the solution became colourless. After the solution was cooled to room 
temperature, it was treated with 32% (v/v) concentrated HCl (2.5 mL) followed by stirring and 
heating at 90 °C for 48 hours. The resulting yellow solution was placed in an iced bath to induce 
precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, 
washed intensively with water, diethyl ether and air dried at room temperature. 
tPt2H2O yield: 49 mg (45%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 1.26 (t, 3H); 2.73 (sextet 
2H); 3.72 (s, 3H), 4.38 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), δ(ppm): -2164.  
TOF MS/ES+, m/z: (M − Cl + Na.)+: 315 (C2H12N2PtCl, species). Anal. Cal for C2H10N2PtCl2: 
N, 8.54; C, 7.32; H, 3.07. Found: N, 8.50; C, 7.00; H, 2.86. 
tPt3H2O yield: 91 mg (80%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 0.93 (t, 3H); 1.77 (sextet, 
2H); 2.65 (quintet, 2H), 3.74 (s, 3H), 4.36 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), δ(ppm): -
2163. TOF MS/ES+, m/z: (M+): 340 (C3H10N2PtCl2, species). Anal. Cal for C3H12N2PtCl2: N, 
8.19; C, 10.53; H, 3.54. Found: N, 8.12; C, 10.50; H, 3.27. 
 
5.2.2.1  Synthesis of trans-[Pt(ma)2Cl2] (tPtM) 
trans-[Pt(ma)2Cl2] was obtained following the synthetic procedure outlined by                     
Messori et al. [20] with a few modifications.  The iodo derivative of cis-[Pt(ma)2Cl2] was first 
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prepared by slowly adding four equivalents of methylamine hydrochloride (4.8 mmol) to the 
dark brown solution of K2PtI4. The mixture was subsequently treated with four equivalents of 
KOH (269 mg, 4.8 mmol) in the dark at room temperature. After the addition was completed, 
the reaction mixture was stirred in the dark at room temperature for five hours to yield a yellow 
precipitate, cis-[Pt(ma)2I2]. The precipitate was obtained by filtration, washed thoroughly with 
warm water and diethyl ether, and air dried. 
Subsequently, a suspension of cis-[Pt(ma)2I2] (220 mg, 0.432 mmol) in water was treated with 
5 equivalents of methylamine hydrochloride (2.16 mmol). The resulting mixture was stirred at 
room temperature for 12 hours to give a colourless solution. The resulting solution was 
concentrated at 70 °C until a bright orange precipitate was detected and then left to stand 
overnight at 4 °C. The orange solid, trans-[Pt(ma)2I2] was filtered, washed with warm water 
and air dried.  
trans-[Pt(ma)2I2] (177 mg, 0.346 mmol) was suspended in 10 mL of water and treated with 1.9 
equivalents AgClO4. The mixture was stirred overnight in the dark. AgI was removed by 
filtration through a 0.45 µm nylon membrane and to the filtrate, four equivalents of KCl was 
added and stirred at 40 °C for six hours to give a yellow solution of trans-[Pt(ma)2Cl2]. The 
solution was left to stand overnight at 4 °C. The product was filtered, washed thoroughly with 
warm water and air dried.  
trans-[Pt(ma)2Cl2] (tPtM) yield: 12.8 mg (9%). 1H NMR (500 MHz, DMSO-d6), δ(ppm): 2.14 
(t, 6H); 4.25 (s, 4H). 195Pt NMR (107 MHz, DMSO-d6), δ(ppm): -2195. TOF MS/ES+, m/z: (M 
+ Na)+: 350.96 (C2H10N2NaPtCl2, species). Anal. Calc. for C2H10N2PtCl2: N, 8.54; C, 7.32; H, 
3.07. Found: N, 8.61; C, 6.97; H, 2.60. 
 
5.2.2.2  Synthesis of trans-[Pt(ipram)2Cl2] (tPtR) 
trans-[Pt(ipram)2Cl2] was synthesised following the method reported by Navarro-Ranninger et 
al. [19]. To a suspension of cis-[Pt(ipram)2Cl2 (200 mg, 0.521 mmol),  
4 equivalents of isopropylamine was added. The resulting mixture was heated at 70 °C and 
stirred until a colourless solution was obtained which was then heated at reflux for 30 minutes. 
The solution was left to cool to room temperature and concentrated HCl (0.364 mL) acid was 
added and subsequently heated at reflux for 8 hours. The yellow solution obtained was cooled 
in an ice bath and left to stand at 4 °C overnight. The product was obtained by filtration and 
was thoroughly washed with water and dried in air. 
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trans-[Pt(ipram)2Cl2] (tPtR) yield: 80 mg (40%). 1H NMR (500 MHz, DMSO-d6),     δ(ppm): 
1.18 (d, 12H); 3.02 (sept., 2H); 4.20 (s, 4H). 195Pt NMR (107 MHz, DMSO-d6), δ(ppm): -2205. 
TOF MS/ES+, m/z: (M + Na)+: 407 (C6H18N2PtCl2, species). Anal. Calc. for C6H18N2PtCl2: N, 
7.29; C, 18.76; H, 4.72. Found: N, 7.53; C, 18.51; H, 4.36. 
 
5.3 Instrumentation and Physical Measurements 
1H, 13C and 195Pt NMR spectroscopic analyses were carried out on a Bruker Avance III 
500MHz. All 1H and 13C NMR chemical shifts were referenced to Si(CH3)4 while 
195Pt NMR 
chemical shifts were externally referenced to K2[PtCl6]. A Waters Micro-mass LCT Premier 
spectrometer was employed for mass determination of the complexes. Elemental analyses of 
synthesised complexes were recorded on a Thermo Scientific Flash 2000. The pH of aqueous 
solutions of the complexes was recorded using a Jenway 4330 Conductivity/pH meter fitted 
with a Micro 4.5 diameter glass electrode which was calibrated at 25 °C using buffer solutions 
of pH 4.0, 7.0 and 10.0 purchased from Merck. A Varian Cary 100 Bio UV/Visible 
spectrophotometer thermostated by a Varian Peltier temperature controller was used to obtain 
the UV/Visible absorption spectra for the determination of pKa values and kinetic studies of 
slow reactions. Kinetic measurements of all reactions were monitored on an Applied 
Photophysics SX.20 stopped-flow analyser coupled to an online data acquisition system. The 
temperature of the instrument was kept within ±0.05 °C for all the measurements. Analyses of 
the pH and time-dependent kinetic spectral data were performed using Origin 9.1 [22]. 
 
5.4 Preparation of Platinum(II) Aqua Complexes and Determination of 
their pKa Values 
The aqueous solutions of the complexes tPt, tPt2H2O, tPt3H2O, tPtM, and tPtR were 
prepared following the literature procedure by adding a suitable amount of AgClO4 to each of 
the corresponding chloride complexes at a molar ratio of 1: 1.98 [23, 24]. Both the chloride 
complex and the AgClO4 were dissolved in 0.01M HClO4 and the mixture was vigorously 
stirred in the dark at 45 oC for 24 hours. The AgCl precipitate obtained was filtered off through 
a 0.45µm nylon membrane. The filtrate was diluted to 300 mL with 0.01 M HClO4. 
Spectrophotometric pH titrations were performed using NaOH as a base in the pH range of   1-
10 at 25 °C. To avoid absorbance corrections resulting from dilution, a large amount (300 mL) 
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of the complexes were used for the titrations. Adjustments in pH were made by stepwise 
additions of crushed NaOH pellets in the pH range 1-3, while a pasteur pipette was used for 
dropwise additions of NaOH solutions of different concentrations (1.0, 0.5, 0.1 and 0.01 M) or 
the same concentrations of HClO4 acid (for reversibility of the pH) were added to the solution 
in the pH range of 4-10 until the desired pH was attained prior to the withdrawal of a 1.0 mL 
aliquot from the solution for pH measurements and 2 mL aliquots for spectrophotometric 
monitoring. The 1 mL aliquot after each pH measurement was discarded to avoid in situ 
contamination of the complex solution by chloride ions leaching from the pH electrode. 
 
5.5 Kinetic Measurements 
Substitution of the aqua moieties from each of the five trans-platinum(II) complexes with 
symmetrical and asymmetrical amine ligands respectively (Figure 5.1) by three different 
thiourea nucleophiles: thiourea (TU),  1,3-dimethyl-2-thiourea (DMTU) and 1,1,3,3-
tetramethyl-2-thiourea (TMTU)  was investigated under pseudo-first-order conditions with at 
least a 20-fold excess of the nucleophile. Spectra changes resulting from the mixing of the 
complex and the nucleophile solutions were observed over the wavelength range 200-800 nm 
to establish an appropriate wavelength at which kinetic measurements could be performed on 
the stopped-flow spectrophotometer. The reactions were initiated by the mixing of equal 
volumes of a solution of the trans-platinum(II) complexes with a solution of the nucleophile 
directly in the stopped-flow machine. All reported rate constants represent an average value of 
at least seven independent kinetic runs for each experimental measurement. The temperature 
dependence of the rate constants was observed over a range of 20-40 °C at an interval of 5 °C. 
 
5.6 Results and Discussion 
5.6.1 Theoretical Aspects 
Density functional Theoretical (DFT) calculations of the complexes tPt, tPt2H2O, tPt3H2O, 
tPtM and tPtR were carried out at the DFT level B3LYP [25] with the LANL2DZ basis set 
[26] using the Gaussian 09 programme suite. B3LYP relates to the hybrid functional Becke’s 
three-parameter formulation, which has been proven to be superior to conventional functionals. 
LANL2DZ is a double-zeta basis set containing effective core potential (ECP) representations 
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of electrons near the nuclei for transition metal complexes [27]. The theoretical calculations of 
the complexes were executed in water taking into account the effects of the solvent by 
employing conductor polarisable continuum model (CPCM) formalism [28, 29]. The 
complexes were optimized in their aqua form as cations of +2 charge, and the singlet states 
were used because of low electronic spin of platinum(II) complexes. Table 5.1 shows the 
extracted data obtained from the DFT calculations. 
 
Table 5.1: An extract from the DFT calculated data for the investigated mononuclear trans-
platinum(II) complexes at B3LYP/LANL2DZ level of theory. 
where µ = electronic chemical potential, ω = electrophilicity index and η = chemical hardness 
 
A closer look at Table 5.1 reveals a corresponding decrease in the NBO charges on the 
platinum(II) ions as the amine moieties become bulkier in all the trans-platinum(II) complexes 
with symmetric amine ligands (tPt, tPtM and tPtR). For complexes tPt2H2O and tPt3H2O 
with asymmetric amine ligands, the NBO remains relatively the same. However, the gap 
energies in all the complexes are veritably constant. Although, there is a corresponding increase 
in the HOMO energy, through inductive electron donation, as the number of carbon atoms on 
Parameters tPt tPt2H2O tPt3H2O tPtM tPtR 
NBO Charge on Pt 
 
0.808 0.783 0.785 0.791 0.758 
Gap Energy (eV) 
 
     
LUMO -2.46 -2.42 -2.42 -2.40 -2.39 
HOMO -7.17 -7.12 -7.11 -7.08 -7.04 
∆E 4.71 4.70 4.69 4.68 4.68 
µ 4.82 4.77 4.77 4.74 4.72 
ω 4.92 4.84 4.84 4.80 4.76 
η 2.36 2.35 2.35 2.34 2.34 
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the amine moieties increases. However, the electron donation from the alkylamine has no 
significant contribution to the LUMO energy.  
Furthermore, on the basis of other DFT descriptors, such as chemical potential (µ), 
electrophilicity index (ω) and chemical hardness (η), which are sometimes used to predict the 
reactivity of inorganic and organic compounds [30, 31], one can observe an interesting trend. 
The electronic chemical potential, which is often described as the negative of electronegativity 
of a chemical species [32, 33], is obtained using equation 5.1. Essentially, it measures the 
escaping tendency of electrons from an equilibrium system [34-36]. The higher the electronic 
chemical potential, the more reactive the chemical species. Chemical hardness is defined by 
equation 5.2 and it relates to the stability and reactivity of a chemical compound. Generally, it 
determines the resistance to change in the electron distribution in a collection of nuclei and 
electrons [37, 38]. The chemical hardness for all the investigated trans-platinum(II) complexes 
are relatively the same. The electrophilicity index, which is a measure of the electrophilicity 
(tendency to accept electrons) of the chemical species [39-42], is obtained from equation 5.3. 
                                          µ =      
𝐸𝐻𝑜𝑚𝑜 + 𝐸𝐿𝑢𝑚𝑜
2
   (5.1) 
         η =      
𝐸𝐻𝑜𝑚𝑜 − 𝐸𝐿𝑢𝑚𝑜
2
   (5.2) 
         ω =      
𝜇2
2𝜂
     (5.3) 
Expectedly, the chemical potential and electrophilicity index of tPt is significantly higher than 
those of the other complexes, with tPtR having the lowest values. For trans-platinum(II) 
complexes with symmetric amine ligands, tPtM and tPtR, the trend of the theoretical data 
obtained is supported by the experimental data. However, for the complexes with asymmetric 
amine ligands, tPt2H2O and tPt3H2O, which have essentially the same electronic descriptor 
values, the experimental data obtained do not correlate with the theoretical data. Further details 
are provided in the Kinetic Analysis (vide infra). 
 
5.6.2 pKa Determination of the Diaqua Complexes 
To obtain information on the acidity of the bonded water ligands and the reactivity of all the 
aqua complexes, their pKa values were determined. To this end, a spectrophotometric pH 
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titration with NaOH as a base in the pH range 2–10 was carried out. The pH dependence of the 
aqua complex was observed by UV/Visible spectrophotometry. The pKa values of the 
coordinated aqua ligands were obtained by plotting absorbance at a specific wavelength as a 
function of pH. The typical spectral changes recorded during the pH titration with NaOH are 
presented in Figure 5.2 for the trans-aqua complexes tPt. The overall process can be presented 
by Schemes 5.1 and 5.2.   
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Figure 5.2: UV/Visible spectra of the diaqua tPt complex recorded as a function of pH in the range 
2-10 at 25 oC. Inset: Titration curve at 230 nm. 
 
 
 
Scheme 5.1: Proposed stepwise deprotonation for the pH dependence of the asymmetric trans-
platinum(II) complexes. 
 
Scheme 5.2: Proposed stepwise deprotonation for the pH dependence of the symmetric trans-
platinum(II) complexes. 
 
131 
 
The spectra data was analysed using the Origin 9.1®  [22] to obtain the resulting pKa values for 
the diaqua moieties by fitting the data to a double sigmoidal function which gave the best 
statistical fit and afforded two pKa values which indicates that there are three coloured species 
for each of the aqua complexes present in solution as a function of pH.  Table 5.2 is a summary 
of the data obtained for the deprotonation of the diaaqua moieties from the complexes. 
Table 5.2: Summary of pKa values from the diaqua trans-platinum(II) complexes. 
 
The pKa values obtained for the deprotonation of the first aqua ligand show that the acidity of 
the mononuclear trans-Pt(II) complexes followed the trend tPt (4.24) ˃  tPt2H2O (4.28) ˃  tPtM 
(4.56) ˃ tPt3H2O (4.80) ˃ tPtR (5.92). The acidity of the complexes decreases with increasing 
number of carbon atoms on the alkylamine and the dialkylamine moieties for the asymmetric 
and the symmetric trans-platinum(II) complexes respectively. Although, one would have 
expected tPt2H2O with an asymmetric amine ligand and tPtM with a symmetrical amine 
ligand, which have the same number of carbon atoms, to display the same level of acidity. 
However, tPt2H2O (pKa 4.28) is more acidic than tPtM (pKa 4.56). This experimental data 
contradicts the theoretical DFT calculation data in which the platinum(II) centre in tPt2H2O 
has an NBO charge that is about 0.08 unit less than that of  tPtM. However, the electrophilicity 
index (ω) of both complexes agrees with their respective pKa value. Essentially, the 
electrophilicity index is superior to the NBO charge in predicting electrophilicity and reactivity 
of a complex because the NBO charge indicates only the individual atomic charge, whereas the 
electrophilicity index describes the resulting charge of the entire complex [33, 43]. In general, 
pKa values are usually associated with the electrophilicity of the metal centre [44]. Moreover, 
on the basis of the DFT descriptors, such as NBO charges, electronic chemical potential, 
chemical hardness and electrophilicity index, one would expect the trans-platinum(II) 
complexes with asymmetric amines, tPt2H2O and tPt3H2O, to exhibit the same pKa values. 
However, the pKa value of tPt3H2O is 0.52 unit higher than that of tPt3H2O. This may be due 
to the steric factor resulting from the flexible alkylamine ligand. 
The second deprotonation step for the symmetric trans-platinum(II) complexes follows the 
expected trend as the first with the pKa2 value of tPt (6.91) being less than those of tPtM (7.05) 
     tPt  tPt2H2O  tPt3H2O    tPtM     tPtR 
pKa1 4.24 ± 0.05 4.28 ± 0.35 4.80 ± 0.24 4.56 ± 0.06 5.92 ± 0.07 
pKa2 6.91 ± 0.04 6.79 ± 0.1 7.74 ± 0.31 7.05 ± 0.03 7.28 ± 0.16 
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and tPtR (7.28). However, the second pKa values in the asymmetric trans-platinum(II) 
complexes is quite unexpected on the basis of their DFT obtained electronic descriptors with 
tPt2H2O (pKa2 6.79) being about a unity less than that of tPt3H2O (pKa2 7.74). Besides, the 
usual reduction in the overall charge from +2 to +1 at the platinum site following the first 
deprotonation step which makes the metal centre to be less electrophilic, this observation can 
also be attributed to the steric factor resulting from the increase in chain length of the flexible 
alkylamine. The overall trend for the second deprotonation step follows:  tPt2H2O (6.79) ˃ tPt 
(6.91) ˃ tPtM (7.05) ˃ tPtR (7.28) ˃ tPt3H2O (7.74). In general, for the first deprotonation 
step, the acidity of the mononuclear trans-platinum(II) complexes decreases with the increasing 
number of carbon atoms on the amine moieties. Nevertheless, the second deprotonation step 
did not show any consistent trend. 
 
5.6.3 Kinetic Analysis 
The substitution reactions of all the studied mononuclear trans-platinum(II) complexes 
followed a single reaction step. The reaction step in all the trans-platinum(II) complexes is 
dependent on the concentration of the nucleophiles. Kinetic traces for the trans-platinum(II) 
complexes fitted perfectly to a single exponential, typical for one-step reaction. The so-obtained 
pseudo-first-order rate constant, kobs for the trans-complexes, computed from the kinetic traces 
were plotted against the concentration of the entering nucleophiles (Figure 5.3). A linear 
dependence on the nucleophile concentration was observed for all the studied reactions without 
any intercept. The linear fits pass through the origin which indicates that there is no parallel or 
reverse reaction. The dependence of the observed pseudo-first-order rate constants on the 
concentration of the entering nucleophile obeyed the rate law presented in equation 5.4, where 
k2 represent the second-order rate constants for the substitution reactions of the mononuclear 
trans-platinum(II) complexes. Table 5.3 provides the summary of the second-order rate 
constants and the activation parameters for all the investigated mononuclear trans-platinum(II) 
complexes. 
   kobs = k2[nucleophile]     (5.4) 
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Table 5.3: Second-order rate constants and activation parameters for the reaction of the studied 
diaqua trans-platinum(II) complexes with thiourea nucleophiles at pH = 2.0 (0.9 M 
NaClO4 + 0.01 M HClO4) and 293-313 K. 
Complex Nucleophiles k2 /M-1s-1 ∆H# kJ/mol ∆S# J/mol/K 
tPt 
       
TU 
DMTU 
TMTU 
44.2 ± 0.03 
22.9 ± 0.11 
  5.6 ± 0.01 
63 ± 2 
55 ± 1 
68 ± 2 
-29 ± 6 
-61 ± 4 
-27 ± 6 
tPt2H2O TU 
DMTU 
TMTU 
38.5 ± 0.034 
19.6 ± 0.025 
  4.1 ± 0.002 
56 ± 1 
50 ± 0.9 
54 ± 2 
-26 ± 3 
-52 ± 3 
-51 ± 6 
tPt3H2O TU 
DMTU 
TMTU  
28.4 ± 0.02 
15.7 ± 0.04 
  3.0 ± 0.02 
57 ± 1 
49 ± 1 
57 ± 0.8 
-26 ± 3 
-55 ± 3 
-46 ± 3 
tPtM TU 
DMTU 
TMTU 
35.4 ± 0.11 
18.2 ± 0.02   
  3.8 ± 0.03 
58 ± 3 
62 ± 1 
60 ± 2 
-34 ± 10 
-43 ± 3 
-64 ± 7 
tPtR TU 
DMTU 
TMTU 
19.0 ± 0.0016 
10.3 ± 0.0001 
  2.2 ± 0.0065 
58 ± 2 
54 ± 2 
57 ± 1 
-51 ± 7 
-69 ± 5 
-72 ±3 
 
Comparing the second-order rate constants for the substitution reactions of the mononuclear 
diaqua trans-platinum(II) complexes with the thiourea-based nucleophiles, the observed trend 
follows: tPt ˃ tPt2H2O ˃ tPtM ˃ tPt3H2O ˃ tPtR. This reactivity trend is consistent with the 
pKa values obtained for the first deprotonation step. The high reactivity of tPt in relation to the 
rest of the complexes can be rationalised in terms of both electronic and steric effects. tPt is 
less sterically hindered, a feature which has been attributed not only to its geometry (see 
Chapter Three) but also because of the significantly less sterically demanding ammine ligands 
around it. Hence, the incoming nucleophiles, most especially the less sterically hindered 
thiourea (TU), can approach the complex easily for the substitution process.  
134 
 
A closer inspection of the second-order rate constants summarised in Table 5.3, reveals that 
tPt2H2O with the asymmetric amine ligands is slightly more reactive than the tPtM with 
symmetric amine ligands, although they have the same number of carbon atoms in the  
alkylamine ligand(s). This is in good agreement with the chemical potential and electrophilicity 
index obtained from the DFT calculations. However, this observed reactivity is not in line with 
the NBO charges on the platinum(II) centre with tPtM having a higher NBO charge than 
tPt2H2O. In relation to the reactivity of metal complexes, the electrophilicity index is a better 
electronic descriptor than NBO charge since it measures the overall charge of the complex 
rather than the charge on a single atom [45, 46]. One factor that can be responsible for the 
difference in their electrophilicity indices, and subsequently their pKa values and hence, their 
reactivity, is the charge separation in both complexes. The charges in tPtM are evenly 
distributed around the metal centre unlike in tPt2H2O. The asymmetric nature of the inert 
amine ligands around the platinum site in tPt2H2O results in a more electrophilic metal centre 
as supported by its electrophilicity index and its pKa value. 
In addition, when comparing the reactivity of tPt3H2O and tPtR, one would have expected the 
second-order rate constant of tPt3H2O to be significantly higher than that of tPtR, since its 
pKa1 value is about 1.12 units higher than that of tPtR. From an electronic factor viewpoint, 
one would expect the positive inductive donor effect of the diisopropylamine in tPtR as well 
as the electronic chemical potential and the electrophilicity index which are much higher in 
tPt3H2O, to make the reactivity of tPtR to be far less than that of tPt3H2O. It appears there is 
more steric hindrance in tPt3H2O as compared to tPtR. Even though tPtR has six carbon atoms 
which are evenly distributed around the platinum centre, the flexible nature of the alkylamine 
ligand in tPt3H2O tends to pose more steric hindrance on the substitution site than the relatively 
rigid dialkylamine ligands in tPtR resulting from its branched nature. The flexible nature of the 
amine ligand in tPt3H2O can interfere with the approach of the incoming nucleophiles from 
attacking the metal centre and thereby lowering its reactivity, otherwise, the second-rate 
constant of tPt3H2O should have been in the same range with those of tPt2H2O and tPtM.    
A similar trend is observed in the reactivity of tPt2H2O and tPt3H2O. Based on their electronic 
properties, both complexes with asymmetric alkylamine ligands should have shown the same 
substitution rate towards the thiourea-based nucleophiles. However, the longer chain length of 
the flexible alkylamine ligand in tPt3H2O creates a steric hindrance by preventing the 
approaching nucleophiles for easy substitution. In general, the second-order rate constants in 
all the mononuclear diaqua trans-platinum(II) complexes show a noticeable dependence on the 
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steric bulk of the thiourea-based nucleophiles. It is noted that thiourea, TU, in all the 
investigated complexes, is more reactive by nearly a factor of 2 than the more sterically 
hindered dimethylthiourea, DMTU. The most sterically hindered nucleophile, 1,1,3,3-
tetramethylthiourea, TMTU reacts significantly slower than the less hindered TU and DMTU 
in all the studied complexes (Figure 5.3).             
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Figure 5.3: Pseudo first-order rate constants plotted as a function of the concentration of the 
entering nucleophiles for the substitution reaction of the diaqua tPt complex by TU. 
DMTU, and TMTU at pH = 2.0 (0.09 M NaClO4 + 0.01 M HClO4) and 298 K. 
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Figure 5.4: Plot of ln(k2/T) against 1/T for the reaction of diaqua tPt with the thiourea nucleophiles 
at various temperatures ranging from 293 to 313 K 
     
Temperature dependence studies were carried out to gain more insight into the nature of the 
substitution mechanism from the activation parameters. The activation enthalpies, ∆H# and 
entropies, ∆S# were determined by measuring the rate constants of substitution at a fixed 
concentration of the nucleophiles as a function of temperature. The activation parameters were 
computed using the Eyring plots in equation 5.5. Figure 5.4 shows the Eyring plots for all the 
three nucleophiles and the results are summarised in Table 5.3. A moderately positive 
activation enthalpy in all the investigated complexes and a negative activation entropy favour 
an association mechanism which is ubiquitous in most d8 square planar complexes [47-52]. 
 
5.7 Conclusion 
In conclusion, this study has explored the comparative substitution behaviour of some 
mononuclear bifunctional diaqua trans-platinum(II) complexes with symmetric and 
asymmetric alkylamine ligands. The acidity of the complexes was found to decrease with 
increasing chain length in both the symmetric and asymmetric alkylamine ligand complexes. 
Diaqua transplatin, tPt is observed to be the most acidic and subsequently the most 
electrophilic, hence, the most reactive. The reactivity of the tPt is generally favoured by not 
only the electronic factors but also by the sterically less hindered inert ammine ligands. Even 
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though, the trans-platinum(II) complexes with asymmetric alkylamine ligands, tPt2H2O and 
tPt3H2O, exhibit similar electronic properties based on data obtained from the theoretical 
calculations, however, the experimental data contradicts this observation. The observed 
difference in their pKa values and in their substitution rates, is attributed to the steric factor. 
Although, tPt2H2O with asymmetric amine ligands and tPtM with symmetric dialkylamine 
ligands, have the same number of carbon atoms, the difference in their symmetry did not only 
influence their electronic properties but also their reactivity, with tPt2H2O being slightly more 
reactive than tPtM. The nature of the alkylamine ligands is also observed to influence the 
reaction rates, with the long flexible chain of the propylamine ligand in tPt3H2O posing more 
steric hindrance at the reaction site than the branched diisopropylamine in tPtR. All the trans-
platinum(II) complexes show similar substitution patterns and the overall reaction rates are 
driven by both electronic and steric factors. The proposed reaction scheme is the same for all 
the three thiourea-based nucleophiles employed in this study. However, the rate constants 
obtained are different as anticipated. The rate constants decrease in the order TU > DMTU > 
TMTU, which can be accounted for by the increase in steric hindrance. An associative mode of 
activation of substitution was observed for the reactions of all the trans-platinum(II) complexes 
with all the nucleophiles owing to the intrinsic negative entropies obtained.    
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Chapter Six 
Understanding the Role of Flexible Alkyl-α,ω-diamine Linkers on the Substitution Behaviour 
of Dinuclear trans-Platinum(II) Complexes: A Kinetic and Mechanistic Study 
 
Abstract 
In this study, we investigated the role of flexible alkyl-α,ω-diamine linkers on the substitution 
behaviour of dinuclear trans-platinum(II) complexes. The substitution reactions of four 
dinuclear trans-platinum(II) complexes viz. [PtNH3Cl2]2-µ-NH2(CH2)2NH2] (P12), 
[PtNH3Cl2]2-µ-NH2(CH2)3NH2] (P13), [PtNH3Cl2]2-µ-NH2(CH2)4NH2] (P14) and 
[PtNH3Cl2]2-µ-NH2(CH2)5NH2] (P15) with three neutral thiourea-based nucleophiles 
specifically: thiourea (TU), 1-methyl-2-thiourea (MTU) and 1,3-dimethyl-2-thiourea (DMTU) 
were studied quantitatively under pseudo first-order conditions as a function of concentration 
and temperature by conventional UV/Visible and stopped-flow spectrophotometers. Ligand 
substitutions for the complexes proceeded in three consecutive steps. Each step follows first-
order kinetics with the respective complex and nucleophile. The pseudo first-order rate 
constants, kobs(1/2/3), for sequential substitution of the chloride ligands and subsequent 
displacement of the linker obeyed the rate law: kobs(1/2/3) = k(1/2/3)[nucleophile]. The kobs(3) could 
not be monitored to completion because it was too slow.  Both electronic and steric effects drive 
the overall substitution pattern. However, our findings reveal that upon the substitution of the 
chloride moieties by the thiourea-based nucleophiles at the platinum centres, the σ-donor 
capacity via the inductive effect of these electron-rich nucleophiles overcompensate the steric 
strain imposed by the nucleophiles as well as by the alkanediamine linker on the substitution 
sites.  Consequently, electronic factors governed the overall reaction pattern of these 
complexes. 195Pt NMR results confirmed the simultaneous substitution of all the chloride 
leaving groups by thiourea-based nucleophiles, followed by the subsequent but successive 
displacement of the ammine groups and the flexible alkanediamine linker from the metal 
centres. The reactivity order of the complexes: P12 ˃ P13 ˃ P14 ˃ P15. The order of reactivity 
of the nucleophiles with the complexes decreases with the increase in steric bulk in the 
nucleophiles: TU > MTU > DMTU. The small positive enthalpy values and the large but 
negative entropy values confirm the associative mode of activation for all the studied 
complexes. The computational modelling using density functional theory (DFT) calculations 
was employed to rationalise the kinetic trend. 
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6.1 Introduction 
Platinum complexes have been extensively proficient not only for optoelectronic applications 
[1-4] but also in bioinorganic medicine most especially as anticancer drugs subsequent to the 
accidental discovery of the cytostatic activity of cisplatin by Barnett Rosenberg in 1969 [5-8]. 
Nearly five decades later, research efforts by medicinal inorganic chemists have led to the 
production of thousands of platinum-based compounds, some of which have been evaluated for 
anticancer activities but only a handful has made it to the clinical phase. Among the platinum 
complexes that have reached the clinical phase, carboplatin and oxaliplatin, which are 
derivatives of cisplatin, are the most successful, especially against testicular, cervical, 
colorectal, bladder and ovarian cancers [9, 10].  The success of these drugs has, however, been 
hampered by their severe side effects; lack of selectivity; short retention in the bloodstream; 
and inherent and acquired resistance [9-13]. Consequently, researchers have continued to seek 
the development of more effective anticancer agents with a radically different binding mode to 
the DNA and that can accommodate a wider spectrum of applications.  
 
Farrell and co-workers [14, 15] were the first to extend the frontier of development of novel 
anticancer agents which incorporated non-classical platinum complexes such as trans-platinum 
and polynuclear platinum complexes that have showed remarkable cytostatic potentials even 
against cisplatin resistant cell lines [16, 17]. Studies have shown that these polynuclear 
platinum(II) complexes display riveting biological activities, in vitro against lung, pancreatic 
and melanoma cancers [10, 16] as compared to cisplatin and its analogues. Unlike mononuclear 
platinum(II) compounds, polynuclear complexes interact with the DNA via their structure-
activity relationships (SARs). Their SARs have been reported to correlate with the length of the 
linker and the average distance between the platinum(II) centres [18-21].  
 
Moreover, several studies have revealed that the cytotoxicity and reactivity of these 
multinuclear platinum(II) complexes have been linked to the distance between the platinum 
centres and their reactivity are also influenced by the nature of the linker between the platinum 
centres [5, 10, 21-24]. Multinuclear complexes with flexible and hydrophilic linker have been 
reported to form interstrand and intrastrand DNA adducts that are very tough to repair by the 
cellular proteins. As a result, improve the overall cytotoxicity of these compounds [10, 18, 21].  
 
Furthermore, reports have shown that the reactivity of the first metal centre in some of dinuclear 
platinum(II) complexes, is independent of the other [24-26]. Nevertheless, in most cases, the 
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interaction between the two platinum(II) centres has been reported [5, 18, 24, 27-30]. Jaganyi 
et al. [18, 24, 27, 29, 31, 32], Van Eldik et al. [22, 30, 33] and Farrell et al. [16, 17] have all 
reported that the reactivity of dinuclear platinum(II) complexes with flexible alkyl-α,ω-diamine 
linkers is hinged on the average distance between the platinum centres and it diminishes as the 
length of the aliphatic chain increases. The geometry as well as the molecular symmetry 
assumed by these complexes, is also one of the prerequisites that determine the reactivity of the 
dinuclear platinum(II) centres [21, 29, 34].   
 
Recently, studies have shown that BBR3464, a triplatin tetranitrate complex ((trans-
PtCl(NH3)2)2(trans-Pt(NH3)2(NH2(CH2)6NH2)2))(NO3)4 and its analogues with monodentate 
amine ligands and with leaving groups which are trans to the alkyl-α,ω-diamine flexible linker 
on the two platinum centres were found to dechelate in vitro via the release of the flexible linker 
under the strong trans effect of coordinated thiols and nitrito nucleophiles [35]. Still in the same 
vein, Jaganyi et al. [31] reported that the dinuclear platinum(II) with alkyl-α,ω-diamine linker 
in which the leaving groups on each of the platinum centres are trans to the flexible linker is 
stable to dechelation upon coordination to thiourea-based nucleophiles. Dechelation, which 
normally leads to the deactivation of the platinum centre before the cytotoxic drug could reach 
its target molecule, has been reported to be mostly responsible for toxic behaviour in several 
cis-configured platinum complexes [36-40].  
 
However, our previous studies, Chapters 3 and 4, have shown that classical mononuclear trans-
configured platinum(II) complexes are stable to complete dechelation unlike their cis-
configured counterparts. The stability of the mononuclear trans-configured platinum(II) 
complexes has increased the potential to serve as a prospective anticancer drug with the 
possibility of low toxicity. Moreover, Ongoma and Jaganyi [18] have reported the stability of 
1,1/c,c dinuclear platinum(II) complexes to strong thiourea-based nucleophiles. Consequently, 
one of the important aspects to the extensive study of these phenomena will be to explore the 
substitution kinetics of the dinuclear trans-platinum(II) complexes with alkyl-α,ω-diamine 
flexible linkers in which the leaving groups are trans to each other on each of the platinum 
centres. In other words, the platinum centres in the dinuclear complexes are similar to the 
traditional mononuclear trans-platinum(II) complexes.  To this extent, the objective of this 
study is to understand the role of flexible alkyl-α,ω-diamine linkers on the substitution 
behaviour and stability of these dinuclear trans-platinum(II) complexes. The structures of the 
complexes to be studied are presented below in Figure 6.1: 
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Figure 6.1: Structures and abbreviations of the investigated dinuclear trans-platinum(II) complexes. 
 
6.2 Experimental 
6.2.1 Chemicals   
HCl (37%), dimethylformamide, cisplatin (99.9%), lithium trifluoromethanesulphonate, 
methanol (AR), lithium chloride (99%), the nucleophiles: thiourea (TU), 1-methyl-2-thiourea 
(MTU), 1,3-dimethyl-2-thiourea (DMTU) and the ligands: 1,2-diaminoethane (99%), 1,3-
diaminopropane (99%), 1,4-diaminobutane (99%) and 1,5-diaminopentane(95%) were all 
purchased from Sigma Aldrich. All the reagents were used without further purification. All 
other chemicals used are of the highest purity available commercially. Ultrapure water was used 
in the preparations of all aqueous solutions. 
 
6.2.2 General Synthetic Procedure of the Mixed trans-Platinum(II) Complexes 
 
6.2.2.1 Preparation of the Metal Precursor, NH4[Pt(NH3)Cl3] 
NH4[Pt(NH3)Cl3] was prepared according to synthetic procedure outlined by Oksanen and 
Leskela [41]. To a suspension of 1.00 g (3.33 mmol) of cisplatin in 20 mL of water, 10 mL of 
37% (v/v) conc. HCl was added and the resulting mixture was refluxed for 12 hours. The 
unreacted cisplatin was quickly removed by filtration and the filtrate was then carefully 
evaporated to dryness at temperature of 45 °C in the fume hood. Orange crystals of 
NH4[PtNH3Cl3] was obtained with 90% yield. The product was dried in air after it was washed 
with ethanol. 
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6.2.2.2 Synthesis of the Dinuclear trans-platinum(II) complexes  
The dinuclear trans-platinum(II) complexes were synthesised following a literature procedure 
by Farrell [15] with a slight modification. 200 mg (0.6 mmol) of NH4[PtNH3Cl3] was dissolved 
by stirring in 5 mL methanol at room temperature. A methanolic solution of the appropriate 
diaminoalkane bridging ligand (0.3 mmol in 5 mL methanol) was added dropwise to the 
dissolved solution of the metal. The resulting solution was vigorously stirred at room 
temperature for 24 hours. A yellow solid of the appropriate dinuclear trans-platinum(II) 
complex was obtained. The solid was washed with 5 mL of water, 10 mL of ethanol and 
subsequently left to dry in air. 
 
P12 yield: 103 mg (55%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 3.45 (s, 4H). 195Pt NMR (500 
MHz MHz, DMF-d7), δ(ppm): -2259.8. TOF MS/ES+, m/z: (M + Na)+: 368 (C2H11Cl2N3NaPt, 
species). Anal. Calc. for C2H10N2PtCl2: N, 8.54; C, 7.32; H, 3.07. Found: N, 8.50; C, 7.00; H, 
2.86 
P13 yield: 92 mg (48%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 1.90 (quintet, 4H); 2.94 (t, 
4H). 195Pt NMR (500 MHz, DMF-d7), δ(ppm): -2260.2. TOF MS/ES+, m/z: (M + Na)+: 383 
(C3H13N3NaPtCl2, species). Anal. Calc. for C3H12N2PtCl2: N, 8.19; C, 10.53; H, 3.54. Found: 
N, 8.12; C, 10.50; H, 3.27. 
P14 yield: 69 mg (35%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 2.10 (m, 4H); 3.34 (t, 4H) 
195Pt NMR (500 MHz MHz, DMF-d7), δ(ppm): -2262.8.  TOF MS/ES+, m/z: (M + Na)+: 397 
(C4H15N3NaPtCl2, species). Anal. Calc. for C4H14N2PtCl2: N, 7.87; C, 13.49; H, 3.96. Found: 
N, 7.84; C, 13.59; H, 3.91. 
P15 yield: 80 mg (40%). 1H NMR (500 MHz, DMF-d7), δ(ppm): 1.78 (quintet, 2H); 2.02 
(quintet, 4H), 3.25 (t, 4H).  195Pt NMR (500 MHz MHz, DMF-d7), δ(ppm): -2265.3. TOF 
MS/ES+, m/z: (M + Na)+: 411 (C5H17N3NaPtCl2, species). Anal. Calc. for C5H16N2PtCl2: N, 
7.57; C, 16.22; H, 4.36. Found: N, 7.50; C, 16.35; H, 4.57. 
 
6.2.3 Preparation of Complex and Nucleophile Solutions for Kinetic Measurement 
The chloride dinuclear trans-platinum(II) complexes of known concentration were prepared by 
dissolving a specified amount in 5 % DMF to enhance the solubility and topped up with 95 % 
of a methanolic solvent system which included 0.09 M lithium triflate (LiCF3SO3) for ionic 
strength adjusted by addition of 10 mM lithium chloride (LiCl) to prevent any solvolysis of the 
complexes. The nucleophile solutions were prepared shortly before use by dissolving 0.1 M 
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LiCF3SO3 solution in methanol. The ionic strength of the solution was maintained using lithium 
triflate because the triflate ion (CF3SO3
⁻) does not coordinate to platinum(II) [22, 27-29].  
 
6.3 Instrumentation and Physical Measurements 
1H and 195Pt NMR spectroscopic analyses were carried out on a Bruker Avance III 500MHz 
NMR. All 1H chemical shifts were referenced to Si(CH3)4 and 
195Pt NMR chemical shifts were 
externally referenced to K2[PtCl6] [42]. The Bruker Avance III 500MHz NMR was also used 
to monitor 195Pt-NMR of the substitution reactions of the dinuclear trans-platinum(II) complex, 
P13  with thiourea (TU). 195Pt NMR is usually employed for the determination of the 
coordination features at the platinum centre because its chemical shifts are largely affected, 
among other things, by the nature of the coordinated donor atoms [43]. A Waters Micro-mass 
LCT Premier spectrometer was used for the mass determination of the trans-platinum(II) 
complexes. Elemental analyses of the synthesised complexes were performed on a Thermo 
Scientific Flash 2000. All the kinetic measurements were carried out on an Applied 
Photophysics SX.20 stopped-flow analyser coupled to an online data acquisition system and 
kinetic traces were evaluated using the Origin 9.1®  software [44]. The temperature of the 
instrument was kept within ± 0.05 °C for all the measurements. 
 
6.4 Computational Modelling 
Density functional theoretical (DFT) optimization modelling of the trans-platinum(II) 
complexes P12-P15 was carried out at the DFT level B3LYP [45] with the LANL2DZ basis 
set [46] using the Gaussian 09 programme suite in the gas phase (Table 6.1). B3LYP relates to 
the hybrid functional Becke’s three-parameter formulation, which has been proven to be very 
efficient relative to the classical functionals. LANL2DZ is a double-zeta basis set which 
comprises effective core potential (ECP) representations of electrons near the nuclei for 
transition metal complexes especially for platinum complexes [24, 32, 47-50]. The complexes 
were optimised in their neutral form, and at singlet states because of the low electronic spin of 
platinum(II) complexes.  
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6.5 Kinetic Measurements 
The kinetics of substitution of the coordinated chloride ligands from the dinuclear trans-
platinum(II) complexes by three thiourea nucleophiles viz. thiourea (TU), N-methylthiourea 
(MTU) and N,N-dimethyl-2-thiourea (DMTU) were studied under pseudo first-order 
conditions on the stopped-flow and/or UV/Visible spectrophotometers. The nucleophile 
concentration was at least in a 40-fold excess compared to that of the dinuclear trans-
platinum(II) complexes in all reactions. This ensured at least a 10-fold of nucleophile 
concentration at the respective platinum centre and hence drive the reaction to completion. The 
reactions were advanced by mixing equal volumes of the solutions of the dinuclear platinum(II) 
complexes with the solutions of the respective thiourea nucleophile at suitable wavelengths. 
The kinetic data obtained were graphically analysed using Origin® 9.1 [44]. The temperature 
was controlled throughout all kinetic experiments within an accuracy of ±0.05 °C. The 
dependence of the rate constants on temperature was studied over a range of 20-40 °C at a 5 °C 
interval. The rate constants reported represent an average value of at least three to five 
independent kinetic runs for reactions performed on the stopped-flow spectrophotometer and 
of at least a duplicate run for those followed on the UV/Visible spectrophotometer. The kobs 
values were determined from nonlinear least-square fits by fitting the exponential function in 
equation 6.1 to the time dependent absorbance [51, 52]. 
                              𝐴 𝑡 =  𝐴∞  +  (𝐴0 ˗ 𝐴∞)𝑒𝑥𝑝
(−𝑘𝑜𝑏𝑠.𝑡)                     (6.1)  
where A0, At and A∞ represent the absorbance of the reaction mixture at the start of the reaction, 
at time t, and at the end of the reaction, respectively. Activation parameters (enthalpies and 
entropies) were determined from a linear least-squares analysis of ln(k2/T) versus 1/T using the 
Eyring plots as shown in equation 6.2. 
 
           
𝑙𝑛 (
𝑘2
𝑇
) = − (
∆𝐻#
𝑅𝑇
) + (23.8 +
∆𝑆#
𝑅
)          (6.2) 
 
6.6 Results and Discussion 
6.6.2 Computational Analysis 
In order to gain an in-depth insight into how the bridging flexible alkyl-α,ω-diamine linkers 
influence the reactivity and stability of the dinuclear trans-platinum(II) centres, it was 
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imperative to evaluate the molecular structures and electronic properties of the complexes under 
investigated. Minimum energy structures were calculated for each of the chloride-coordinated 
dinuclear trans-platinum(II) complexes (P12-P15) at the B3LYP/LANL2DZ level of theory in 
the gas phase. All the chloride complexes were optimised in their neutral form. An extract of 
the DFT-calculated data is presented in Table 6.1.  
 
Table 6.1: An extract of the DFT calculated data for the investigated dinuclear trans-platinum(II) 
complexes at B3LYP/LANL2DZ level of theory 
 
Parameter P12 P13 P14 P15 
NBO 
Charges 
Pt1/ Pt2 
-Namine 
 
0.035 
-
0.689 
 
0.031 
-
0.692 
 
0.028 
-
0.694 
 
0.023 
-
0.698 
MO 
energy 
HOMO/eV 
LUMO/eV 
∆E/eV 
 
 
1.895 
6.20 
 4.03 
 
- 
1.87 
-6.10 
 4.23 
 
- 
1.88 
-6.14 
 4.26 
 
- 
1.76 
-6.04 
 4.27 
Bond 
length (Å) 
Pt-Pt 
Pt-Namine 
Pt-Nammine 
 
 
7.039 
2.070 
2.073 
 
 
7.820 
2.069 
2.074 
 
 
8.813 
2.066 
2.077 
 
 
9.879 
2.066 
2.077 
 
A closer inspection of the extracted data in Table 6.1 reveals that there is a general increase in 
the energy gap, ∆E(HOMO-LUMO), of the frontier orbitals as the chain length of the flexible alkyl 
linker is increased. A similar trend has been reported by Jaganyi et al. [18, 31] in related studies. 
This observation is, however, contrary to what was obtained for their mononuclear counterparts 
in which the gradual increase in the alkyl chain length did not have any significant electronic 
contribution to the HOMO-LUMO energy gap (see Chapter 4).  It is also observed that the 
platinum centres in all the chloride-coordinated dinuclear trans-platinum(II) complexes carry 
symmetrical natural bond order (NBO) charges which indicate that the metal centres have the 
same electronic environment [18, 22, 28, 31]. The NBO charges on the platinum centres 
decrease as the chain length of the flexible alkyl linker increases. 
6.6.3 Ligand Substitutions 
The kinetics of the substitution of the coordinated chloride ligands in the dinuclear trans-
platinum(II) complexes with flexible alkyl linker were investigated spectrophotometrically by 
monitoring the changes in absorbance at suitable wavelengths as function of time on stopped-
flow and UV/Visible spectrophotometers. A typical kinetic trace obtained on the stopped-flow 
149 
 
is shown in Figure 6.2 whereas Figure 6.3 is a representation of the kinetic traces obtained on 
the conventional UV/Visible spectrophotometer. The proposed reaction pathways for the 
substitution process of the trans-platinum(II) complexes with neutral thiourea-based 
nucleophiles namely: TU, MTU and DMTU are presented in Schemes 6.1.  
 
 
Scheme 6.1:  Proposed mechanism of the chloride substitution from the studied complexes by a series 
of thiourea nucleophiles (Nu). 
 
All the kinetic traces fitted perfectly into single exponential functions. The pseudo first-order 
rate constants, kobs obtained were observed to have a linear dependence on the concentration of 
the thiourea-based nucleophiles. The second-order rate constant, k2 for the reaction of each 
complex with the nucleophiles were determined from the slopes of the plots of the pseudo first-
order rate constants, kobs against the concentration of the nucleophiles using the Origin 9.1
® 
[44].  
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Figure 6.2: A typical trace of the reaction of P13 and DMTU for the simultaneous substitution of 
the four chloride ligands from the stopped-flow measurement recorded at 351 nm, T = 
298 K, I = 0.1 M (0.09 M LiCF3SO3/10 mM LiCl). 
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Figure 6.3: A typical trace of the reaction of P13 and DMTU for the simultaneous substitution of 
the two ammine ligands from the UV/Visible measurement recorded at 351 nm, T = 
298 K, I = 0.1 M (0.09 M LiCF3SO3/10 mM LiCl). 
 
The summary of the second-order rate constants is shown in Table 6.2. Based on this 
observation, equation 6.3 represents the corresponding rate laws for the consecutive reaction 
steps 
kobs(1,2) = k-2 + k2[Nu]  ≈ k2[Nu]                      (6.3) 
where k-2 = rate constant for the solvent path; k2 = rate constant for the direct path, [Nu] = 
nucleophile concentration.  
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The contribution of the solvent through the solvolytic path (k-2) is negligible or veritably absent. 
The values of the second-order rate constants, k2 obtained from the linear regression analysis 
from equation 6.2 are summarized in Table 6.2. 
 
The substitution reactions of all the investigated dinuclear trans-platinum(II) complexes with 
thiourea-based nucleophiles proceeded by three separate steps. The first step, a moderately fast 
step followed on the stopped-flow, was assigned to the simultaneous substitution of the four 
chloro ligands from the two platinum centres. The second step, a slower step monitored on the 
UV/Visible spectrophotometer, was attributed to the simultaneous removal of the ammine 
(NH3) ligand, which is at cis-position to the incoming nucleophiles, from the two metal centres. 
The third step was ascribed to the release of the flexible bridging alkyl linker owing to the total 
displacement of all the ligands by the incoming nucleophiles at the platinum centres. This step, 
however, was extremely slow to be followed to completion on the UV/Visible 
spectrophotometer. 
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Table 6.2: Summary of second-order rate constants and activation parameters for the reaction of the dinuclear trans-platinum(II) 
complexes with thiourea-based nucleophiles in the temperature range of 293-33 K. 
Complex NU k2,1st ×10-3   
M-1s-1 
∆H# 1st 
kJmol-1 
∆S# 1st 
Jmol-1K-1 
k2, 2nd ×10-6   
M-1s-1 
∆H# 2nd 
kJmol-1 
∆S# 2nd 
Jmol-1K-1 
P12 TU 
MTU 
DMTU 
26.1 ± 0.047 
16.8 ± 0.001 
  5.8 ± 0.017 
50.3 ± 2 
53.8 ± 3 
46.6 ± 2 
-113.2 ± 2 
-103.7 ± 9 
-137.3 ± 7 
155.4 ± 0.01 
  96.4 ± 0.06  
  55.5 ± 0.06 
51.0 ± 0.6 
63.2 ± 2 
69.7 ± 0.8 
-152.7 ± 3 
-115.7 ± 5 
  -98.9 ± 3 
P13 TU 
MTU 
DMTU 
16.1 ± 0.028 
10.2 ± 0.024 
  4.2 ± 0.003 
45.7 ± 0.3 
49.0 ± 2 
61.6 ± 2 
-132.8 ± 0.9 
-124.9 ± 6 
  -89.6 ± 5 
106.3 ± 
0.001 
77.0 ± 0.004  
46.0 ± 0.027 
71.8 ± 0.3 
59.6 ± 1 
59.9 ± 0.7 
  -86.0 ± 1 
-129.6 ± 3 
-132.9 ± 2 
P14 TU 
MTU 
DMTU 
11.5 ± 0.004 
  8.4 ± 0.018 
  2.8 ± 0.003 
48.8 ± 3 
43.5 ± 1 
57.5 ± 1 
-124.6 ± 8 
-143.4 ± 4 
-106.7 ± 4 
78.0 ± 0.37 
54.4 ± 0.23  
40.1 ± 0.55 
43.7 ± 0.4 
34.4 ± 1 
53.4 ± 0.1 
-182.8 ± 1 
-178.7 ± 4 
-156.7 ± 0.3 
P15 TU 
MTU 
DMTU 
  6.2 ± 0.004 
  5.0 ± 0.009 
  2.1 ± 0.012 
47.1 ± 0.8 
49.8 ± 0.7 
62.7 ± 1 
-135.2 ± 3 
-127.9 ± 2 
  -92.5 ± 4 
73.2 ± 0.27 
45.6 ± 0.08  
34.8 ± 0.55 
43.1 ± 0.7 
41.9 ± 11 
41.8 ± 0.7 
-185.8 ± 2 
-151.8 ± 2 
-196.0 ± 2 
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6.6.4 NMR Studies 
To establish the stepwise mechanism proposed in Scheme 6.2, the reaction between P13 with 
twenty mole equivalents of TU in DMF was monitored by 195Pt NMR spectroscopy. The 195Pt 
NMR has been established to be an effective technique to determine coordination details at the 
platinum centre owing to the fact that its chemical shift is largely influenced by the number of 
coordinated donor atoms on the platinum(II) centre [53].  
 
 
(d)     t = 48 hrs  
(c)        t = 20 hrs 
 
(b)       t = 1 hr 
 (a)            t = 0 hr 
Figure 6.4: (a) 195Pt NMR spectra of the reaction mixture of P13 with twenty mole equivalents of 
TU, showing pure P13 (δ = -2261.2 ppm) before the reaction, (b) the first transient 
species obtained after one hour at -3044.7 ppm corresponding to [PtNH3TU2]2-µ-
NH2(CH2)3NH2]4+, (c) appearance of two additional peaks obtained after 20 hours at -
3396.3 ppm and -3886.6 ppm corresponding to [trans-{Pt(TU)3}2-µ-NH2(CH2)3NH2]4+ 
and [Pt(TU)4]2+ respectively and (d) the peak (δ = -3886.6 ppm) ascribed to the final 
degradation product [Pt(TU)4]2+,  persisted after 48 hours. 
 
The peak in (a) at -2261.2 ppm in Figure 6.4 corresponds to the unreacted starting complex 
P13. This peak disappeared after one hour and was replaced by a new peak in (b) obtained at   
-3044.7 ppm indicating the formation of a new species in the solution. This peak persisted until 
after twenty hours when two new additional peaks emerged at -3396.3 ppm and -3886.6 ppm 
respectively in (c). The peak at -3044.7 ppm is assigned to the species [trans-{PtNH3(TU)2}2-
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µ-NH2(CH2)3NH2]
4+ in which the two chloride moieties on the respective platinum centre have 
been substituted by thiourea. The peak at -3396.3 ppm is ascribed to the displacements of the 
ammine ligands by a third thiourea on both metal centres, [trans-{Pt(TU)3}2-µ-
NH2(CH2)3NH2]
4+ and the final peak in (d), which remained persistent after 48 hours, at -3886.6 
ppm is assigned to the final product in which the flexible alkanediamine linker has been released 
for the coordination of the fourth thiourea nucleophile on the platinum sites, [Pt(TU)4]
4+. The 
NMR results are consistent with what have been previously reported in literature [18, 62-65]. 
  
Hence, it is reasonable to conclude that the presence of strong labilising thiourea nucleophiles 
at the platinum centres facilitate the displacement of the ammine ligands and the cleavage of 
the flexible alkanediamine bridging ligand. This conclusion corroborates the earlier work 
reported by Ongoma and Jaganyi [18] in which the alkanediamine bridging ligand and the 
ammine group remained bonded to the metal centres in the presence of the strong labilising 
thiourea-based nucleophiles. However, the study did not rule the fact that a longer reaction time 
may be required to cause the cleavage of the ammine groups and of the flexible alkanediamine 
bridging ligand from the platinum centres. This present study further extends the earlier report 
and clearly establish that the presence of two strong labilising thiourea nucleophiles at the 
respective platinum centres in the dinuclear platinum(II) complexes with alkanediamine 
bridging ligands and a longer reaction time will cause the displacement of the ammine group 
and the cleavage of the linker from the metal centres. Therefore, based on our reports in 
Chapters 3 and 4, it is logical to assert that dinuclear trans-platinum(II) complexes with 
alkanediamine bridging ligands are not as stable as their mononuclear trans-platinum(II) 
counterparts in the presence of strong S-donor nucleophiles. 
 
Furthermore, comparing the substitution process of the dinuclear trans-platinum(II) complexes 
with that of their corresponding mononuclear analogue reveals that the dinuclear trans-
platinum(II) complexes have similar substitution patterns with their corresponding 
mononuclear isomers. In other words, there is a simultaneous substitution of chloride leaving 
groups by the thiourea nucleophiles in both sets of complexes. However, the substitution 
process is faster in the mononuclear trans-platinum(II) complexes as compared to their 
corresponding dinuclear counterparts. The mononuclear trans-platinum(II) complexes were 
found to be at least forty times more reactive than their corresponding dinuclear complexes.  
 
Although, one would expect that the coordination of the other end of the alkanediamine linker 
to the second metal centre would have minimised the steric hinderance posed by the flexible 
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alkylamine group on the substitution sites in the mononuclear trans-platinum(II) complexes. 
Nevertheless, the dinuclear trans-platinum(II) complexes appear to have experienced more 
steric restrictions than their corresponding mononuclear analogues because of the presence of 
the alkanediamine bridging linker as well as the incoming thiourea nucleophiles at the platinum 
sites. Moreover, in the case of the mononuclear trans-platinum(II) complexes, the flexible 
alkylamine group had little or no electronic communication with the platinum centre based on 
the DFT data obtained (see Chapter 4) as well as the experimental data obtained from the pKa 
values (see Chapter 5).  
 
However, the coordination of the other end of the flexible alkanediamine linker to the second 
metal centre not only enhances electronic communication between the linker and the platinum 
centre but also poses steric strain on the substitution process. A similar trend has been observed 
before by other researchers [21, 29]. Evidence of increased electronic communication between 
the platinum(II) centres and the alkanediamine bridging ligand can be seen from the significant 
reduction in the NBO charges when those of the dinuclear trans-platinum(II) complexes are 
compared to those of their corresponding mononuclear analogues (see Table 4.1 in Chapter 4). 
The electronic communication through the σ-donor ability (σ-inductive effect) of the 
alkanediamine linker to the platinum centre increases the electron density on the metal site and 
thus reduces its electrophilicity. Subsequently, there is a significant decrease in the reactivity 
of the dinuclear trans-platinum(II) complexes compared to their corresponding mononuclear 
analogues. 
 
Besides the electronic factor, steric effects resulting from the symmetry adopted by the 
dinuclear complexes due to the chain length, depending on the (even or odd) number of carbon 
atoms in the chain, has been reported by several researchers to be also responsible for the 
lowering in reactivity of the dinuclear complexes relative to their mononuclear counterparts 
[21, 29]. In the previous study in Chapter 3, we reported that the trans-configured platinum 
centre, in which the leaving groups are trans to each on the same metal centre, minimises steric 
hindrance as compared to the cis-configured complexes. However, the steric restraints resulting 
from the coordination of the bridging ligand to the two metal centres override the advantage 
due to the trans-configuration of the metal centre. Therefore, it is reasonable to conclude that 
the overall reaction pattern of the dinuclear trans-platinum(II) complexes is governed by both 
electronic and steric effects. 
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After a closer inspection of the second-order rate constants for the first kinetic step as presented 
in Table 6.2, it is quite evident that there is a gradual decrease in reactivity as the chain length 
increases. Comparing the second-order rate constants for the substitution reaction of the 
dinuclear trans-platinum(II) complexes with the thiourea (TU) nucleophile, the reactivity 
pattern is P12 ˃ P13 ˃ P14 ˃ P15. The first step is assigned to the simultaneous substitution of 
the four chloride moieties by the incoming thiourea-based nucleophiles. 
 
While one would have expected the symmetry adopted by the dinuclear complexes resulting 
from the number of carbon atoms (even or odd) in the chain length of the alkanediamine 
bridging ligand to have a remarkable effect on the reactivity pattern as previously reported from 
other studies [21, 29], the overall reaction rates were governed by the σ-inductive effect of the 
alkanediamine linker on the platinum centre as supported by the NBO charges. The NBO 
charges on the metal decreases gradually with each addition of the methylene (-CH2) unit. This 
observation contrasts with reports in previous studies in which the alkanediamine bridging 
ligand was believed to have no significant electronic contribution to the metal centre [21, 27, 
29]. Based on the kinetic results in the present study, the gradual increase in the σ-donor ability 
of the bridging ligand to the substitution sites resulting from the increase in chain length 
overrides its steric influence on the reactivity of the dinuclear complexes. 
 
A similar trend was observed for the second kinetic step which followed the reactivity order: 
P12 ˃ P13 ˃ P14 ˃ P15. This second step has been attributed to the slow displacement of the 
ammine ligand because of the strong labilising effect of the S-donor nucleophiles. However, in 
this study, we are reporting for the first time a third kinetic step which was too slow to be 
followed to completion on the UV/Visible spectrophotometer. The step is ascribed to the 
bonding of the fourth thiourea-based nucleophiles to, and the cleavage of the bridging ligand 
from, the metal centres. Until now, researchers have assumed that dinuclear trans-platinum(II) 
or structurally related complexes are stable to dechelation when compared to those in which the 
leaving groups adopt cis-configuration to each other or in trans position to the bridging 
alkanediamine linker [18, 31]. The cleavage of the bridging ligand was made possible because 
of the stronger labilising effect of the three thiourea-based nucleophiles on each of the 
platinum(II) centres.  
 
The DFT optimisation of the product of the first kinetic step in which all the chloride leaving 
groups have been replaced by thiourea evidently showed a considerable increase in the bond 
lengths between the ammine group and the platinum(II) ion on one hand, and between the 
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platinum(II) ion and the bridging alkanediamine linker on the other (Scheme 6.2). The 
elongation of these bond lengths is consequent upon the remarkable increase in the electron 
density at the metal centre because of the strong inductive effect of the S-donor nucleophiles. 
Despite the increase in the overall charge at the platinum centre, the inductive effect of the S-
donor nucleophiles coupled with that of the bridging alkanediamine linker counteract the impact 
of the surge in positive charge at the reaction sites resulting from the departure of the four chloro 
leaving groups. Based on the results from previous studies [18, 31], one would have expected 
that the steric strain imposed by the alkanediamine bridging ligand as well as the presence of 
the two thiourea nucleophiles already bonded to the platinum centres will prevent the 
coordination of the third and the fourth thiourea-based nucleophiles to the respective platinum 
centres due to the subsequent and successive removal of the ammine group and the bridging 
ligand from the platinum sites.  
                 (a)   
 
                (b)  
Scheme 6.2: (a) An optimised structure for the chloro complex P13 showing the bond 
lengths of the ammine ligand and the bridging alkanediamine ligand 
respectively from the platinum centre (b) An optimised structure for the 
complex P13 in which the chloro moieties have been replaced by TU indicating 
the bond lengths of the ammine ligand and the bridging alkanediamine ligand 
respectively from the platinum centre. 
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However, the electron donor capacity of the electron rich thiourea-based nucleophiles via sigma 
bonds to the platinum centre overrule the imposed steric effect by the entering nucleophiles as 
well as the flexible linker. In other words, the electronic effect clearly took precedence over the 
steric factor. The order of reactivity of the thiourea-based nucleophiles with dinuclear trans-
platinum(II) complexes decreases with increase in steric demand in the following order: TU ˃ 
MTU ˃ DMTU. The pseudo first-order rate constants, kobs 1st and kobs 2nd, obtained for the first 
and second steps in all the dinuclear trans-platinum(II) complexes from the kinetic traces were 
plotted against the concentration of the entering nucleophiles (Figures 6.5 and 6.6). 
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Figure 6.5: Pseudo first-order rate constants plotted as a function of the concentration of the 
entering nucleophiles for the substitution of the four chloride ligands in P13 complex 
by TU. MTU, and DMTU at 298 K, I = 0.1 M (0.09 M LiCF3SO3 + 0.01 M LiCl).  
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Figure 6.6: Pseudo first-order rate constants plotted as a function of the concentration of the 
entering nucleophiles for the substitution of the both ammine ligands in P13 by TU. 
MTU, and DMTU at 298 K, I = 0.1 M (0.09 M LiCF3SO3 + 0.01 M LiCl). 
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6.6.5 Activation Parameters 
The temperature dependence of the rate constant, k2, was investigated over the range 293-313 
K in increments of 5 degrees. The Eyring plots for the reaction of P13 with the thiourea-based 
nucleophiles for the first and second step respectively are outlined in Figures 6.7 and 6.8.  
0.00320 0.00325 0.00330 0.00335 0.00340 0.00345
-12.0
-11.4
-10.8
-10.2
-9.6
 TU
 MTU
 DMTU
In
(k
2
 (
1
s
t)
/T
)
[Nu] / M
 
Figure 6.7: Plots of ln(k2 (1st)/T) against 1/T for the reaction of P13 with the thiourea nucleophiles 
at various temperatures ranging from 293 to 313 K. 
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Figure 6.8: Plots of ln(k2 (2nd)/T) against 1/T for the reaction of P13 with the thiourea nucleophiles 
at various temperatures ranging from 293 to 313 K. 
 
The corresponding values for the activation parameters of enthalpy, ∆H#, and entropy, ∆S#, are 
summarized in Table 6.2. These results are temperature dependent and are consistent with an 
associative substitution mechanism for d8 square planar platinum(II) complexes owing to the 
negative activation entropy values as reported in the literature [9,10,55].  
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6.7 Conclusion 
This study explores the effect of a progressive increase in the chain length of alkanediamine 
bridging ligands on the substitution kinetics of some dinuclear trans-platinum(II) complexes. 
Our findings revealed that upon the substitution of the chloride moieties by the thiourea-based 
nucleophiles at the platinum centres, the σ-donor capacity via inductive effect of these electron-
rich nucleophiles over compensate the steric strain imposed by the nucleophiles as well as by 
the alkanediamine linker on the substitution sites.  Consequently, electronic factors governed 
the overall reaction pattern of these complexes. 195Pt NMR results confirmed the simultaneous 
substitution of all the chloro leaving group by thiourea-based nucleophiles within one hour of 
the start of the reaction followed by the subsequent but successive displacement of the ammine 
groups and the flexible alkanediamine linker from the metal centres after 20 hours. Contrary to 
reports from previous related studies [18, 31], our findings clearly proves that dinuclear trans-
platinum(II) complexes, in which the leaving groups are trans to each on the same metal centre, 
are just as unstable to the strong labilising effect of the S-donor nucleophile as their cis-
configured counterparts. Thus, these complexes are not as promising as their corresponding 
mononuclear trans-platinum(II) analogues in anticancer chemotherapy. The mononuclear 
trans-platinum(II) complexes have been well-established to show a high stability to strong S-
donor nucleophiles (see chapters three and four) [8, 66-68] which are known to play an 
important role in bioinorganic processes. However, the dinuclear trans-platinum(II) complexes 
showed a similar pattern as their corresponding mononuclear trans-platinum(II) isomers, for 
the substitution of the chloride moieties in the first step. The small positive enthalpy and the 
large but negative entropy confirm the associative mode of activation for all the studied 
complexes. This is an indication that the mechanistic reactions of these complexes are 
characterised by bond formation in the transition state as expected for all d8 square planar 
complexes [51, 54-61]. 
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Chapter Seven 
Summary and Future Research 
 
7.1 Summary 
This research project was undertaken to investigate the kinetic and mechanistic behaviour of 
some mononuclear and dinuclear trans-platinum complexes which are relevant in anticancer 
chemotherapy. This project is crucial because it will not only help to shed more light into the 
substitution behaviour, and hence the pharmacodynamics, of this promising class of platinum-
based compounds in anticancer research, but also provide useful information which can serve 
as the basis for the design and development of versatile and more efficient anticancer drugs 
with comparably low toxicity, improved cellular uptake and good retention time in the blood.  
The trans-platinum(II) complexes studied for their kinetic and mechanistic behaviour in this 
thesis are mainly those with aliphatic amine ligands. The ligand substitution reactions of these 
complexes, in their diaqua or dichloro form respectively, were carried out with a series of 
biologically relevant neutral thiourea-based nucleophiles, such as thiourea (TU), methyl-2-
thiourea (MTU), 1,3-dimethyl-2-thiourea (DMTU) and 1,1,3,3-tetramethyl-2-thiourea 
(TMTU). The results obtained are discussed and reported in Chapter Three to Chapter Six of 
this Thesis. Each of the preceding chapters are summarised below. 
 
Chapter One provides an insight into the involvement of metal complexes in the anticancer 
research through the accidental discovery of the biological activity of cisplatin by Barnet 
Rosenberg in the 1960’s. A detailed review of the successes of cisplatin: its mode of action and 
its interaction with its target molecule, the DNA of the cancer cell, and its failures: its 
mechanism of deactivation, were discussed in this chapter. Other platinum-based complexes, 
such as cis-configured platinum(II) and (IV) complexes, multinuclear platinum complexes, 
designed and synthesised with the hope to overcome the flaws that are associated with the 
continued clinical application of cisplatin, were also highlighted. The final aspect of chapter 
one considers the deliberate modification of the structure of transplatin with bulky groups to 
elicit a new class of platinum-based compounds which are quite promising in anticancer 
chemotherapy judging by the reported biological activity of these complexes, most especially 
against cisplatin-resistant cancer cell lines.  
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Chapter Two provides a highlight of the kinetic and mechanistic properties of the substitution 
reactions of d8 square planar complexes using platinum(II) complexes as a case study. 
Important theories usually employed to analyse kinetic data and contemporary methods which 
are engaged to collect kinetic data were also discussed in this chapter. The concluding aspect 
of the chapter gave a synopsis of the factors influencing the reactivity of d8 square planar 
complexes. 
 
Chapter Three reports a comparative study of the kinetic and mechanistic behaviour of 
bifunctional analogous cis and trans-dialkylamine diaquaplatinum(II) complexes of the general 
form, [PtX2L2]. The structures of the studied complexes are provided in Figure 7.1. 
 
     
           cPt                cPtM               cPtR 
    
             tPt                   tPtM                 tPtR 
 
Figure 7.1: Structures of the studied cis-platinum(II) complexes and their trans-analogues. The 
charges and counter ions on the complexes have been omitted for the sake of clarity. 
 
In this study, it was observed that the reaction of the cis-complexes proceeded in two concerted 
steps whereas those of the trans-complexes followed a single step. The trans-complexes were 
observed to be approximately 103 more reactive than their corresponding cis-analogues. The 
decrease in the rate of ligand substitution in the cis-platinum(II) complexes were found be 
largely influenced by the steric hindrance due to their structural pattern. The geometry of the 
cis-complexes enhance the intramolecular hydrogen bonding within their molecules and thus 
retard the approach of the incoming nucleophile for substitution purposes. The cis-geometry 
also facilitates steric crowdedness of the substitution sites due to the solvation of the nitrogen 
atoms of the alkylamine ligands. Whereas these steric effects were also manifested in their 
corresponding trans-isomers, the trans-geometry, however, helps to minimise these effects. 
The trans-complexes were found to be more acidic, and hence more electrophilic, than their 
corresponding cis-counterparts based on the pKa data obtained from the spectrophotometric 
titration and NBO charges on the platinum centre derived from the DFT calculations.  
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In a likely manner, the cis- and the trans-complexes were found to form different kinetic 
products. The cis-complexes were found to undergo complete substitution (dechelation) due to 
the presence of the strong labilising effects of the thiourea-based nucleophiles, unlike the trans-
complexes which were partially substituted by these nucleophiles. The complete substitution 
process in cisplatin and its cis-configured analogues has been reported to be responsible for 
their severe toxicities, whereas the comparably low toxicity in the trans-platinum(II) 
complexes has been attributed to their partial substitution with thiol molecules. 195Pt NMR 
spectroscopy was employed to demonstrate the stepwise substitution of the respective series of 
complexes with thiourea and to confirm their final kinetic products. 
 
In Chapter Four, a kinetic investigation of mononuclear trans-platinum(II) complexes with 
mixed amine ligands was reported. The study was carried out to further the understanding of 
the substitution behaviour of bifunctional mononuclear trans-platinum(II) complexes. The 
structures of the investigated complexes are summarized in Figure 7.2 below. 
 
                                              
Figure 7.2: Structures of the mononuclear trans-platinum(II) complexes with mixed amine ligands. 
 
The substitution reactions of each of the trans-platinum(II) complexes followed first-order 
kinetics in a single step. Expectedly, no dechelation step was observed in these complexes, this 
is consistent with the pattern found in the trans-complexes studied in Chapter Three. 195Pt 
NMR spectroscopy was employed to confirm their final kinetic products. The reactivity of 
these complexes was observed to be largely dependent on the length of the alkyl chain of the 
alkylamine moiety of the complexes. The computational modelling using density functional 
theory (DFT) calculations showed that an increase in chain length by a methylene unit has no 
direct electronic communication with the metal centre. However, the progressive increase in 
chain length posed a significant steric hindrance on the substitution sites due to the flexibility 
of the alkyl chains and thus governed the overall reaction pattern.  
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In Chapter Five, a comparative study of the substitution behaviour and mechanism of some 
bifunctional trans-platinum(II) complexes with symmetric and asymmetric alkylamine ligands 
was reported. The structures of the investigated complexes are presented below in Figure 7.3:  
               
 
Figure 7.3: Structures and abbreviations of the investigated complexes. The charges and counter 
ions th ofe complexes have been omitted for clarity. 
 
 
The classical diaqua transplatin complex, tPt was found to be more reactive than the other 
trans-platinum(II) complexes. The number of carbon atoms in the alkylamine chain length, for 
the asymmetric complexes, and in the dialkylamine chain length for symmetric complexes, 
generally influenced the electrophilicity as well as the reactivity of the complexes. From the 
theoretical data obtained using DFT, tPt2H2O and tPt3H2O exhibit similar electronic 
properties but the extra methylene group in tPt3H2O caused a considerable difference in the 
acidity and hence their reactivity. Although, tPt2H2O with asymmetric amine ligands and 
tPtM with symmetric dialkylamine ligands, have the same number of carbon atoms, the 
difference in their symmetry did not only influence their electronic properties but also their 
reactivity, with tPt2H2O being slightly more reactive than tPtM. The nature of the alkylamine 
ligands is also observed to influence the reaction rates, with the long flexible chain of the 
propylamine ligand in tPt3H2O posing more steric hindrance at the reaction site than the 
branched diisopropylamine in tPtR. All the trans-platinum(II) complexes showed similar 
substitution patterns and the overall reaction rates are driven by both electronic and steric 
factors. 
 
In Chapter Six, the kinetic and mechanistic investigation of dinuclear trans-platinum(II) 
complexes with flexible alkyl-α,ω-diamine linkers were presented. The chloride leaving group 
were trans to each other on each of the platinum centres. The central aim of the study was to 
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gain insight into the role that the flexible alkyl-α,ω-diamine linkers will play in the substitution 
kinetics and hence the stability to dechelation, of these dinuclear trans-platinum(II) complexes. 
The structures of the studied complexes are presented in Figure 7.4. 
 
                         
Figure 7.4: Structures and abbreviations of the investigated dinuclear trans-platinum(II) 
complexes 
 
Based on the DFT calculated NBO charges on the platinum centres, the electrophilicity of the 
dinuclear complexes decreases with progressive increase in the flexible linker chain length and 
thus controlled the overall reaction pattern. The dinuclear trans-platinum(II) complexes were 
observed to have a similar substitution pattern in the first step with their corresponding 
mononuclear analogues. However, unlike the mononuclear analogues, they are unstable to the 
strong labilising effect of the thiourea-based nucleophiles because they were found to undergo 
complete substitution. 195Pt NMR spectroscopy was employed to demonstrate the stepwise 
substitution of these complexes with thiourea and to confirm their final kinetic products which 
is tetrathiourea-substituted platinum centres, Pt(TU)4. This observation makes these dinuclear 
trans-platinum(II) complexes to be less promising than their corresponding mononuclear 
counterparts in anticancer chemotherapy 
In all the work presented in Chapters Three to Chapter six, the negative entropy of activation 
and the positive enthalpy of activation clearly affirmed an associative mode of activation for 
all the studied platinum complexes. In all the reported work, the reactivity of the complexes is 
generally sensitive to the steric bulk of the incoming nucleophiles. Essentially, the reactivity 
of the complexes decreases with attendant increase in the size of the nucleophiles. 
 
7.2 Ongoing work but not included in this Thesis 
In order to gain further understanding into the kinetic and mechanistic behaviour of the 
substitution reactions of the mono- and dinuclear trans-platinum complexes, as an extension 
of the work reported in this thesis, the following studies are currently being undertaken: 
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1. Tuning the substitution behaviour of the mononuclear trans-platinum(II) complexes 
through the influence of the planar π-acceptor ligands, such as pyridine. The effect of 
the systematic replacement of the ammine ligands around the transplatin structure with 
planar pyridine ligands will provide further insight into mechanism of these 
mononuclear trans-platinum(II) complexes. The structures of the complexes being 
investigated are presented in Figure 7.5. 
 
         
 
Figure 7.5: Structures of the diaqua mononuclear trans-platinum(II) complexes. The charges and 
counter ion have been omitted for clarity. 
 
 
tPtPy and tPt2Py are currently being synthesised. After full characterisation of the complexes, 
a spectrophotometric titration will be carried out to ascertain their pKa values to establish a 
suitable pH for their kinetic investigation. 
 
2. A kinetic investigation of the mononuclear trans-platinum(II) complexes and the effect 
of the substituents on the planar amine ligands on the mechanism. The structures of the 
complexes being investigated is shown in Figure 7.6. 
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Figure 7.6: Structures of trans-platinum(II) complexes with planar pyrazine derivatives. 
 
 
All the complexes have been synthesised and fully characterised and currently being 
investigated for their substitution behaviour. 
 
3. The role of substituted diazine linkers on the kinetics and mechanism of the dinuclear 
trans-platinum(II) complexes. This is being undertaken to ascertain the effect of the 
substituted diazine linker on the stability of these dinuclear trans-platinum(II) 
complexes. Figure 7.7 presents the structures of the complexes. 
              
Figure 7.7: Dinuclear trans-platinum(II) complexes with substituted diazine bridging ligands 
 
 
All the complexes involved in this study have been synthesised and are in the process of being 
investigated for their substitution behaviour. 
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4. The work on the dinuclear trans-platinum(II) complexes above can be further expanded 
by investigating the role of extended conjugation of the rigid bridging diazine ligand 
on the substitution kinetics and stability of the following dinuclear trans-platinum(II) 
complexes which are presented in Figure 7.8. 
 
              
Figure 7.8: Dinuclear trans-platinum(II) complexes with diazine bridging ligands with extended 
conjugation. 
 
 
The complexes are currently being synthesised, thereafter they will be fully characterised and 
subjected to DNA binding studies and their substitution kinetics will be investigated. 
 
5. The work mentioned above can be extended further to investigate the role of the 
internuclear distance between the platinum centres on the kinetics and mechanism of 
the dinuclear trans-platinum(II) complexes with the following complexes being 
considered (Figure 7.9). 
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Figure 7.9: Dinuclear trans-platinum(II) complexes with different internuclear distances between 
the platinum centres. 
 
These complexes have been synthesised and presently being characterised for DNA binding 
studies and kinetic investigate ions.  
 
The anticancer usefulness of the dinuclear trans-platinum(II) complexes presented in Figures 
7.7 to 7.9 will largely depend not only on their interaction with DNA but also their stability 
towards the strong labilising effect of the thiol-based nucleophiles, such as thiourea (TU), 
glutathione (GSH), guanosine 5’monophospahte (GMP) etc. 
 
7.3 Future Work 
In the proximate future, the stability of the dinuclear trans-platinum(II) complexes to 
degradation can be further tested by replacing the ammine (NH3) ligands in these complexes 
with sulfur containing molecules, such as dimethylsulfoxide, DMSO etc. other than any N-
donor ligands.  Also, planar bridging ligands with other homo- or hetero-atoms, such as carbon, 
sulfur, oxygen etc. can be considered as well.  
 
 
 
